

CURRICULUM VITAE

Name Prediman Krishan (P.K.) Shah, M.D., M.A.C.C.

Business Division of Cardiology
Cedars-Sinai Heart Institute and Cedars-Sinai Medical Center
127 S. San Vicente Boulevard, Suite A-3307
Los Angeles, CA 90048

EDUCATION

1962-1964	Premedical, S.P. College, Srinagar, Kashmir, India
1964-1969	Medical School, Medical College, Srinagar, Kashmir, India (M.D.)
1969-1970	Internship, S.M.H.S. Hospital of Medical College, Srinagar, Kashmir, India
1970-1971	Residency, All India Institute of Medical Sciences, New Delhi, India
1971-1972	Internship, Mount Sinai Hospital of University of Wisconsin, Milwaukee
1972-1973	Residency (Internal Medicine) Mount Sinai Hospital of University of Wisconsin, Milwaukee
1973-1974	Residency (Internal Medicine) Montefiore Hospital of Albert Einstein College of Medicine, Bronx, New York
1974-1976	Fellowship (Cardiology) Montefiore Hospital of Albert Einstein College of Medicine, Bronx, New York
1976-1977	Research Fellowship (Cardiology), Cedars-Sinai Medical Center, Los Angeles, California
1992-1993	Sabbatical and Visiting Associate Professor, Massachusetts General Hospital, Harvard Medical School

LICENSURE State of California A 031604
DEA AS7855224

BOARD CERTIFICATION

1975	Internal Medicine
1977	Cardiology

PROFESSIONAL EXPERIENCE

Cedars-Sinai Medical Center
1995-2013 Director, Division of Cardiology

1993-present Director, Oppenheimer Atherosclerosis Research Center
 2013-present Director, Atherosclerosis Prevention and Treatment Center
 2011-present Director, Steven S. Cohen Fellowship Program in Atherosclerosis Research
 2009-2011 Director, Preventive and Consultative Center of Excellence
 1990-present Shapell and Webb Family Endowed Chair in Cardiology
 1977-present Attending Cardiologist, Division of Cardiology
 1980-1996 Director, Inpatient Cardiology and Coronary Care Units
 1988-1999 Director, Cardiovascular Fellowship Training Program
 1981 Program Chairman, Cardiology Board Review Program
 1980-1996 Chairman, 4th year Student's Cardiology Training Program
 1979-1984 Director, Clinical Core of Specialized Center of Research (SCOR-NIH)
 1977-1986 Clinical Instructor, Critical Care and Cardiac Care Course for critical care nurses
 1977-1984 Director, Radionuclide Research, Coronary Care Unit

FACULTY APPOINTMENTS

UCLA School of Medicine

1978 Assistant Professor of Medicine in Residence
 1984 Associate Professor of Medicine in Residence
 1992 Professor of Medicine in Residence
 Professor of Medicine at Cedars-Sinai

MEMBERSHIP IN PROFESSIONAL SOCIETIES

- Fellow, American College of Cardiology (F.A.C.C.), 1980
- Fellow, American College of Physicians (F.A.C.P.), 1982
- Fellow, American College of Chest Physicians (F.C.C.P.), 1982
- Member, American Federation for Clinical Research, 1982
- Member, The Los Angeles Society of Internal Medicine, 1983
- Member, Alpha Omega Alpha, 1983
- Member, Council on Critical Care, American College of Chest Physicians, 1984
- Honorary Fellow, Argentina Society of Cardiology, 1989
- Honorary Fellow, Chilean Society of Cardiology, 1989
- Member, Emergency Cardiac Care Committee of American College of Cardiology, 1990-1993

- Councilor, California of American College of Cardiology, 1990-1993
- Member, Cardiac Care Committee, Council on Clinical Cardiology, American Heart Association, July 2002-June 2003
- Member, Scientific Program Committee, Clinical Council on Cardiology, American Heart Association, National Center (Dallas), 2003-2004
- Member, Board of Directors, Los Angeles Chapter of American Heart Association, 2000-2001
- President, Los Angeles Chapter of American Heart Association. 2001-2002
- Vice-President, Western States Affiliate, American Heart Association, 2005-2007
- Member, Board of Directors, Western States Affiliate of the American Heart Association, 2007-2009
- Member, Science Advisory Committee of the American Heart Association, 2004
- Member, Scientific Program Committee of the American College of Cardiology, 1992-present
- Member, Association of University Professors of Cardiology 2004
- Secretary, Western Regional Affiliate of AHA 2003-2004
- President, Western Regional Affiliate of AHA 2006-2008
- Member of ACCF/ACC/AHA Task Force 1 (Conflicts of interest) for Bethesda Consensus Conference on Professionalism and Ethics, 2003-2004
- NIH-NHLBI: Member of the Data Safety Monitoring Board for Cell and Gene Therapy Trials, 2007-present
- NIH-NHLBI Ad Hoc Panel Member on Safety of Drug Eluting Stents, February 2007
- NIH-NHLBI: Ad Hoc Reviewer of gene Therapy Grant, March 2007
- NIH-Recombinant DNA Advisory Committee(RAC): member 2007-2009
- Scientific Publications Committee of the American Heart Association: Member since 2010-2014
- NIH Special Emphasis Panel Member (Reviewer of K-Grants 2010)
- NIH-NHLBI: Member of the Data Safety Monitoring Board for Cardiothoracic Surgical Network (CTSN): 2011 till present
- Member, American College of Cardiology-Annual Scientific Program Task Force: 2012-2015
- Awards Committee of the American College of Cardiology: 2012-present
- Co-Chair of the Annual Scientific Program Committee of American College of Cardiology: 2014

- Program Director: Best of Am Coll of Cardiol 2014 Program Los Angeles (April 2014) and Chicago (May 2014)

PROFESSIONAL ACTIVITIES

- Member, Program Selection Committee, 50th Anniversary Annual Fall Symposium, Los Angeles American Heart Association (AHA), 1982
- Member, Program Selection Committee and Moderator of clinical section, Young Investigators Research program, Los Angeles AHA, 1982
- Reviewer, Research Fellowship Grant Awards, Los Angeles AHA, 1982
- Chairman, Scientific Session on Acute Myocardial Infarction, AHA annual meeting, 1984
- Chairman, Luncheon Panel and Member, Program Committee, Los Angeles AHA Annual Fall Symposium, 1985
- Program Co-Chairman, Scientific Session on Angioplasty, ACC annual meeting, 1986
- AHA Grant Site Visitor, Wadsworth VA Hospital, Los Angeles, 1986
- Member, Young Investigator Award Committee, AHA, 1987
- Member, Scientific Research Committee, AHA, 1987
- Moderator, Young Investigator Award Program, AHA, 1987
- Member, Research Committee, AHA, 1988
- Member, Research Fellowship Selection Committee, AHA, 1988
- Member, Research Committee of AHA, 1988
- Chairman, Scientific Program Committee, Los Angeles AHA Annual Fall Symposium, 1990
- Grant Reviewer, AHA National Center, 1992
- Member, Scientific Program Committee, AHA Council on Clinical Cardiology, 1995-1997
- Abstract Grader, annual scientific sessions, AHA, 1984, 1996 – present
- Abstract Grader, annual scientific sessions, ACC, 1985, 1996 – present
- Member, Special Emphasis Panel to Review Research Grants, National Institutes of Health, 1999
- Grant Reviewer, Wellcome Research Foundation, 1999
- Member, Los Angeles AHA Annual Fall Symposium Committee, 1999
- Member, Board of Directors, Western States Affiliate, AHA, 1999 – present
- Member, Scientific Program Committee, annual scientific sessions of the ACC for 2001,

- Coordinator, vascular biology section, annual scientific sessions of the ACC for 2001
- Co-Chair, Clinical Cardiology Highlights Session, annual scientific sessions of the ACC for 2001
- Chairman, Scientific Program Committee, Los Angeles AHA Annual Fall Symposium and Griffith Lectureship, 2000
- Member, Training Program Director's Committee, ACC, 2000
- Member, COCATS Committee, ACC, 2000
- Member, Task Force for Education, AHA, 2000
- Member, Scientific Advisory Committee for Save-A-Heart, 1992-2005
- Member, Scientific Advisory Board, Larry King Cardiac Foundation, 1995-present
- Chairman, Los Angeles Vascular Biology and Lipid Club
- President, Greater Los Angeles Affiliate, AHA, 2001-2002
- National Chairman, Scientific Advisory Board of the National Cardiovascular Research Initiative of the Entertainment Industry Foundation, 2001- onwards
- Member, Scientific Program Committee, annual scientific sessions of the ACC for 2002
- Co-Chair, Clinical Cardiology Highlights Session, annual scientific sessions of the ACC for 2002
- Co-Chair, Clinical Cardiology Highlights Session, annual scientific sessions of the ACC for 2003
- Member, Scientific Program Committee, annual scientific sessions of the ACC for 2003
- Member, Nominating Committee of the Council on Clinical Cardiology, American Heart Association (2002-2004)
- Member, European Academy of Sciences (elected 2002)
- Member, Association of University Professors of Cardiology
- Secretary, Western Regional Affiliate of AHA 2003-2004
- President, Western Regional Affiliate of AHA 2006-2008
- Member of ACCF/ACC/AHA Task Force 1 (Conflicts of interest) for Bethesda Consensus Conference on Professionalism and Ethics, 2003-2004
- Member of Academic Senate, UCLA School of Medicine
- Editorial Consultant for the SHAPE Initiative, 2005-present
- Reviewer for NIH Grants: Vascular Disease RFA 2005
- Member of Strategic Planning Advisory Committee of NHLBI 2006
- Chairman of Editorial Committee for the 1st National SHAPE Guideline for identification of subclinical atherosclerosis, 2005-present
- NIH-NHLBI Data Safety Monitoring Board member for Gene Therapy and Cell Therapy Trials 2007 till present

- NIH-NHLBI Ad Hoc Panel Member on Safety of Drug Eluting Stents, 2007
- NIH-Recombinant DNA Advisory Committee(RAC): member 2007-2009
- Scientific Publications Committee of the American Heart Association: Member since 2010-2014
- NIH Special Emphasis Panel Member (Reviewer of K-Grants 2010)
- NIH-NHLBI: Member of the Data Safety Monitoring Board for Cardiothoracic Surgical Network (CTSN): 2011 till present
- Member, American College of Cardiology-Annual Scientific Program Task Force: 2012-2015
- Awards Committee of the American College of Cardiology 2012-till present
- Co-Chair of the Annual Scientific Program Committee of American College of Cardiology 2014
- Program Director: Best of American College of Cardiology 2014 Program: Los Angeles (April 2014) and Chicago (May 2014)
- Co-Chair of LOLA (Lipidologists of Los Angeles) 2010-present

EDITORIAL SERVICES

Editor-in-Chief (Guest), Journal of American College of Cardiology appointed March 2014-present

AD HOC EDITORIAL SERVICES (1990-present)

- American Journal of Cardiology
- American Heart Journal
- Annals of Internal Medicine
- Circulation
- Cardiology (Israel)
- Chest
- Journal of Electrocardiography
- Mt. Sinai Journal of Medicine
- Heart and Vessels (Japan)
- The New England Journal of Medicine
- British Heart Journal
- Archives of Internal Medicine
- Arteriosclerosis, Thrombosis and Vascular Biology
- Journal of Applied Physiology
- Nature Medicine
- Circulation Research
- Journal of Clinical Investigation
- American Journal of Pathology
- Journal of American College of Cardiology
- Proceedings of the National Academy of Sciences

- American Journal of Physiology
- British Medical Journal
- Future Lipidology

MEMBER OF EDITORIAL BOARDS

- American Journal of Cardiology (1992-present)
- Journal of the American College of Cardiology (1992-1998)
- Journal of the American College of Cardiology (July 2005-present)
- Circulation (1992-present)
- Indian Heart Journal (1992-present)
- Journal of Cardiovascular Pharmacology and Therapeutics (2007-present)
- Journal of Heart Failure (2006-present)
- Current Cardiology Reports (2006-present)
- Reviews in Cardiovascular Medicine (2004-present)
- Men's Health (1998-present)
- Information and Education Resource (PIER) module on Myocarditis (2010-2012)
- ATVB current

HONORS AND SPECIAL AWARDS

1962	Best outgoing student of the High School, Awarded Gold Medal
1969	Best medical graduate of the Medical School, Awarded Chief Ministers Gold Medal
1969	M.D. with honors in Medicine, Surgery, OB-GYN, Anatomy and Physiology
1964-1969	Fifteen Silver Medals and Certificates of Distinction for Academic Achievement in Medical School
1971-1972	Mount Sinai Alumni Association Plaque for Outstanding Intern of the Year
1981	Golden Apple and Kaiser award for excellence in teaching by the UCLA students Alumni Association
1982	Golden Apple and Kaiser award for excellence in teaching by the UCLA students Alumni Association
1989	Fulbright Visiting Professor, Argentina
1989	Fulbright Visiting Professor, Chile
1989	Shapell and Webb Family Endowed Chair in Clinical Cardiology
1991	UCLA Dean's Faculty Award for Excellence in Teaching

- 1992-1993 Visiting Associate Professor, Harvard Medical School and Cardiovascular Biology Research Laboratory at Massachusetts General Hospital
- 1992 Annual Honoree, Save-A-Heart Foundation
- 1992 Fulbright Visiting Professor, Japan
- 1992 Fulbright Visiting Professor, Taiwan
- 1995 Annual Honoree, United Hostesses' Charities
- 1986-1997 Best Doctors in America: Pacific Region, Woodward and White, Inc.
- 1996 Best Doctors in America, American Health
- 1996 Best Doctors in Los Angeles, Los Angeles Magazine
- 1996-2015 America's Top Doctors
- 2001 Annual George C. Griffith Lecture (American Heart Association)
- 2002 Lifetime Achievement Award: American Heart Association (GLAA)
- 2002 Elected to the European Academy of Sciences
- 2003 Gifted Teacher Award from the American College of Cardiology
- 2003 Lifetime Achievement Award from the Association for Eradication of Heart Attacks and Vulnerable Plaque
- 2003 Member, Association of University Professors of Cardiology
- 2007 Pioneer in Medicine Award, Cedars-Sinai Medical Center (Highest Award Given by Medical Staff at the Medical Center)
- 2008 Annual Excellence in Teaching Award from Cardiology Fellows of Cedars-Sinai Medical Center
- 2008 James B Herrick Award from the American Heart Association: (Presented at the Annual Scientific Sessions of AHA, New Orleans, November 2008)
- 2008 Laennec Society Lectureship Award from the American Heart Association: (Presented at the Annual Scientific Sessions of AHA, New Orleans, November 2008)
- 2008-2015 Who's Who in Medicine/Cardiology
- 2012 Distinguished Scientific Achievement Award (Basic Science) from the American College of Cardiology (March-2012)
- 2012 Steven S Cohen Humanitarian Award from The Heart Foundation
- 2014 Inaugural Docey and Kanu Chatterjee Lecturer at the 63rd American College of Cardiology Annual Scientific Sessions, Washington DC, March 31, 2014
- 2014 Arthur Agatston Lifetime Achievement Award by the Society of Cardiac CT, July 2014, San Diego

- 2014 Deputy Editor, Journal of Am Coll of Cardiol (JACC)
Editor-in-Chief (Guest) JACC
- 2014 Eliot Rapaport Cardiologist of the Year Awarded by
the Am Coll of Cardiology in Nov- 2014 in San Diego
- 2015 Master of the Am Coll of Cardiology(MACC),
conferred in March 2015 at the Annual Scientific
Sessions of the Am Coll Cardiol, San Diego, CA

RESEARCH GRANTS AND AWARDS

- 1979-1984 NIH-SCOR grant for application of radionuclides in
the evaluation of acute myocardial infarction; principal
investigator; \$150,000 per year
- 1980 Award from Factor Family Foundation; \$70,000
- 1982-1983 Marion Laboratories: Double-blind placebo controlled
trial of oral diltiazem in prevention of recurrent
infarction; principal investigator; \$90,000
- 1982-1983 Merrell-Dow Pharmaceuticals: Evaluation of
hemodynamic, myocardial, metabolic and clinical
efficacy of MDL-17,043 a new inotropic drug, in
chronic heart failure; principal investigator; \$90,000
- 1984-1985 Merck-Sharpe and Dohme Pharmaceuticals:
Evaluation of oral Lisinopril, a long-acting ACE
inhibitor, in the therapy of chronic heart failure;
principal investigator; \$95,000
- 1985 Gerald and Maxine Dunitz: Establishment of
Research Fellowship in Cardiology; \$150,000
- 1988 Beecham Laboratories: Study of intravenous APSAC
in acute myocardial infarction; principal investigator;
\$80,000
- 1989-1992 NIH-RO1 grant for CORSAGE–hybrid expert artificial
intelligence system for myocardial infarction; co-
principal investigator; \$220,000 per year
- 1989-1991 Beecham Laboratories: Randomized double blind
comparison of intravenous APSAC and t-PA in acute
myocardial infarction; principal investigator; \$168,000
- 1991-1992 TIMI-Study Research Group (TIMI-4): A randomized
trial comparing t-PA, APSAC and t-PA plus APSAC;
principal investigator; \$100,000
- 1991-1992 Sterling-Winthrop: Milrinone in postinfarction heart
failure; principal investigator; \$50,000
- 1992-1993 Merck: Efficacy and safety of IIb/IIIa, a platelet-
receptor antagonist (MK 852) in unstable angina;
principal investigator; \$80,000

- 1993-1996 TIMI-Study Research Group (TIMI-9): Role of hirudin vs. heparin with thrombolysis; principal investigator; \$50,000
- 1994-1998 Pharmacia Lab: Apo A-1 Milano and intimal thickening in rabbits; principal investigator; \$450,000
- 1994-1996 Merck: Platelet receptor antagonism with MK 383 (tirofibrin) vs heparin in unstable angina; principal investigator; \$98,000
- 1995 Walter and Helga Oppenheimer: Establishment of the Atherosclerosis Research Center; \$1,000,000
- 1995 Award from Grand Foundation; \$250,000
- 1995 Award from Mrs. Dora B. Herbert; \$25,000
- 1995 Award from Western Heart Foundation; \$80,000
- 1995 Award from United Hostesses Charities; \$25,000
- 1996-2001 Ornest Foundation: Research Fellowship in Atherosclerosis; \$62,500 per year (PI: P.K. Shah)
- 1997 Award from Henry J. Wheeler; \$100,000
- 1997-1999 Parson's Foundation: Genetics of atherosclerosis; \$150,000 for 1997, \$100,000 each for 1998 and 1999
- 1997 Award from Western Heart Foundation; \$75,000
- 1997-2001 Steinberg Foundation: Gene therapy for atherosclerosis; \$50,000 per year (PI: P.K. Shah; 5% effort)
- 1997-2002 Award from Wasserman Foundation; \$200,000 per year (PI: P.K. Shah; 5% effort)
- 1997: Award from Steven B. Cohen Heart Fund; \$150,000
- 1997-2000 Award from Richard Weisman; \$25,000 per year
- 1997: California Community Foundation (Solomon Baker): Vascular biology program; \$50,000
- 1997 Grand Foundation: Gene therapy for atherosclerosis; \$125,000
- 1997 United Hostesses: Gene therapy for atherosclerosis; \$17,500
- 1998 Marjorie Sanders Foundation: Genetics of atherosclerosis and vein-graft occlusion; \$130,000
- 1998-1999 Genentech: rVEGF for therapeutic angiogenesis; \$160,000
- 1999-2005 NIH-Program Project Grant (PPG): Gene therapy of atherosclerosis using adeno-associated virus vector (Total direct cost: \$2.0 million; PI (project 2 of 3): P.K. Shah; 10% effort)
- 1999- 2004 Mitchell Foundation: Gene therapy; \$50,000 per year (PI: P.K. Shah; 5% effort)
- 2000-2005 Eisner Foundation six atherosclerosis-related research projects; \$4.2 million (Overall PI: P. K. Shah; 10% effort)

- 1996-present: The Heart Foundation Approx \$500,000/yr
(PI: P.K. Shah; 1% effort)
- 2005-2008: Cardiovox: Immunomodulation of Atherosclerosis:
\$650,000 (PI: P.K. Shah; 1%)
- 2006-2007: Bio-Invent: Passive immunization using p45
monoclonal antibody in rabbit atherosclerosis model.
\$110,000 (PI: P.K. Shah; 1%)
- 2006-2009: Savacor (PI: P.K. Shah; 1%) \$22,000/patient;
Hemodynamically guided home self-therapy in severe
congestive heart failure patients (Homeostasis-2)
- 2006-2011: NIH-RO1: Omega 3 Fatty Acids for Treatment of
Major Depression (PI: M. Rappaport; Co-Inv: P.K.
Shah; 2.5%); (Total Direct Cost: \$1,250,000)
- 2007-2014: Steven Spielberg Foundation Grant \$1 million /year
for 7 years for Atherosclerosis Research (PI: P.K.
Shah, 1%)
- 2008-2009 SemBiosys (PI: P.K. Shah; 5%) \$236,000; Effect of
Plant Derived recombinant Apo A-1 milano on
atherosclerotic plaque phenotype and plaque
regression in ApoE null mice.
- 2008-2009: BioLine RX (PI: P.K. Shah; 5%) \$134,225; Effect of
Paraoxonase-1(PON) enriched Apo A-I on murine
atherosclerosis
- 2008-2009: Cardium (PI: P.K. Shah; 1%) \$15,556/patient;
Angiogenesis in women with angina pectoris who are
not candidates for revascularization
- 2008-2013: 1R0 NIH/NHLBI – 1HL085800-01A2 (VLADUTIU)
\$255,240 (Co-Inv: P.K. Shah; 1%) Genetic
Susceptibility to Lipid-Lowering Drug-Induced
Myopathies
- 2007-2011: NIH-RO1 (1R01-HL050566-09A2): The Role of
Tenascin in Neointimal Formation (PI: P.K. Shah,
20%) (Direct Cost: \$1,250,000)
- 2008-2013: NIH-RO1 (1R01-HL090653-01A1): Directed
Vascular Graft Regeneration in the Mouse Peritoneal
Cavity (PI: P.K. Shah; 20%) (Direct Cost:
\$1,000,000)
- 2011-2015: NIH-RO1 (1R01-HL104068-01A1): Pleiotrophin
Function in Intimal Thickening (PI: P.K. Shah; 15%)
(Direct Cost: \$1,000,000)
- 2017-2021: NIH-RO1 (1R01 HL136350-01) The Role of myeloid-
specific GATA3 in Atherosclerosis: (PI: P.K. Shah;

Additional Research Awards/Grants:

Sanofi US Services Inc. Shah, PK (PI) “ODYSSEY OLE”	9/17/2014-9/16/2017 \$14,172 per subject	1%
Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 & LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia		
The objective of the study is to assess the long-term safety of alirocumab when added to currently available lipid-modifying drug therapy in patients diagnosed with heterozygous familial hypercholesterolemia who have complete one of the four parent studies.		
Amgen, Inc. (PI: Shah, PK)	5/8/2014-5/7/2017 \$27,411 per subject	1%
A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects with Severe Familial Hypercholesterolemia: TAUSSIG – Trial Assessing Long term Use of PCSK9 Inhibition in Subjects with Genetic LDL Disorders (Protocol 20110271)		
The purpose of this study is to characterize the safety and tolerability of long-term administration of AMG 145 among subjects with severe familial hypercholesterolemia. Role: PI		
Amgen, Inc. (PI: Shah, PK)	6/27/2014-6/26/2017 \$21,560	3%
A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase inhibitor Due to Muscle Related Side Effect GAUSS-3 Goal Achievement after Utilizing an anti-PCSK antibody in Statin Intolerant Subjects (Protocol 20120332)		
The purpose of the study is to evaluate safety and efficacy of AMG 145 compared with Ezetimibe in subject unable to tolerate effective statin dosing due to muscle related side effect.		
Aegerion Pharmaceuticals (PI: Shah, PK)	12/4/2014-12/3/2017 \$9,630 per subject	3%
LOWER: Lomitapide observational Worldwide Evaluation Registry: The Effects of Lomitapide on Carotid and Aortic Atherosclerosis in Patients Treated with Lomitapide in Usual Care		
The goal of this registry study is to collect information from clinical practice to establish the long-term safety profile of Lomitapide and characterize its effectiveness and patterns of practice, while also assessing risk minimization intervention in place for Lomitapide which received FDA approved on 12/31/12. Role: PI		
Amgen, Inc. (PI: Shah, PK)	12/18/2014-12/17/2018 \$10,710 per subject	1.5%
A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG145 (OSLER2-Open Label Study of Long Term Evaluation Against LDL-C Trial) (Protocol 20120138)		
The purpose of this study is to characterize the safety and tolerability of long-term administration of AMG 14 as assessed by low density lipoprotein cholesterol (LDL-C) in subjects with primary hyperlipidemia and subjects with mixed dyslipidemia.		
Regeneron Pharmaceuticals (PI: Shah, PK)	7/14/2015-7/13/2018	1%

\$20,320 per subject

An open-label, single-arm, proof of-concept study to evaluate the safety and efficacy of single and multiple doses of REGN1500 in patients with homozygous familial hypercholesterolemia

The purpose of the study is to determine the efficacy of REGN1500 in lowering LDL-C; study different dose regimen effects on other cholesterol markers; evaluate safety and tolerability; assess drug concentration over time, and determine immune system response to study drug.

Scientist Development Award (PI: Fan, Zhaoyang) 7/1/2015-6/30/2019

American Heart Association, Western States Affiliate **\$70,000/year**

Carotid Atherosclerosis Disease: 3D MRI Characterization of Vulnerable Plaque Features without Contrast Media

The project will develop an MRI technique to provide spatially co-registered multicontrast images for carotid plaque characterization with a single fast scan.

Role: Co-investigator; 1%

2R01HL096119-05 (PI Li, Debiao)

7/1/2015-6/30/2020

NIH

\$867,428

3D MRI Characterization of High-Risk Carotid Artery Plaques without Contrast Media

The objective of the study is to improve the prognosis of patients with carotid atherosclerosis, by developing and validating a fast & non contract agent enhanced 3D MRI technique to identify carotid atherosclerotic plaques that have a high probability of causing neurovascular events. **Role: Co-investigator; 2%**

1K23HL127262-01A1 (Shufelt)

9/1/16-8/31/2021

NIH

\$183,370

Premenopausal Hypoestrogenemia: Effects of Immune-mediated Mechanisms of Cardiovascular Disease

The goal of this K23 is to provide inter-disciplinary patient-oriented research training for the applicant Chrisandra Shufelt MD, MS, to test the effects of transdermal estradiol and estradiol plus progesterone on vascular endothelial function, arterial stiffness and immune-mediated inflammation vs. placebo in premenopausal hypoestrogenemia.

Role: Mentor; 2%

Post-Graduate/Post-Doctoral Research Fellows trained:

Max Pichler, MD (1977-1979)
 Mark Nathan, MD (1984)
 Alnoor Abdullah, MD (approximately 1985-1986)
 Brian Griffin, MD (1991)
 Devendra Amin, MD (1991-1993)
 Doron Zahger, MD (1995-1996)
 Jatin Amin, MD (1995-1996)
 Jan Regnstrom, MD, PhD (1995-1997)
 Ann Sticko, MD, PhD (1995-1996)
 Stephan Jovinge, MD, PhD (1998-2000)
 Kuang-Yuh Chyu, MD, PhD (1999-2003)
 Simcha Meisel, MD (1999-2002)

Shlomo Matetsky, MD (2002-2003)
 Jose Faria-Neto, MD, PhD (2002-2004)
 Fernando Cesena, MD, PhD (2005-2007)
 Fang Tian, MD, PhD (2005-2011)
 Alexander Schiopus, MD, PhD (2006-2007)
 Tomoyoki Honjo ,MD, PhD (2010-2013)
 Xiaoning Zhao, PhD (2000-present)

PATENTS AWARDED

Inventors: Sharifi, Behrooz G; **Shah, Prediman K.**

Patent#: 6,124,260

Title: Inhibition of smooth muscle cell migration by Tenascin-C peptides

Date: September 26, 2000

Peptides capable of interacting with smooth muscle cells are provided. Peptides are derived from Tenascin-C protein, particularly from the Fbg-L domain of Tenascin-C protein. Peptides of the present invention are useful in inhibiting smooth muscle cell migration

Inventors: Kaul, Sanjay; **Shah, Prediman K.**

Patent#: 6,692,772

Title: Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium

Date: February 17, 2004

Treatment with magnesium produces an inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.

Inventors: Kaul, Sanjay; **Shah, Prediman K.**

Patent#: 7,279,183

Title: Method of reducing thrombosis and complications after arterial angioplasty using stent coated with magnesium-based compound

Date: October 9, 2007

Treatment with magnesium produces an inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.

Inventors: Kaul, Sanjay; **Shah, Prediman K.**

Patent#: 7,452,373

Title: Stent coated with magnesium-based compound for reducing thrombosis

Date: November 18, 2008

Treatment with magnesium produces an inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.

Inventors: Nilsson, Jan; **Shah, Prediman K.**

Patent#: 7528225

Title: Peptide epitopes of apolipoprotein B

Date: May 5, 2009

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**
Patent#: 7527795
Title: Peptide epitopes of apolipoprotein B
Date: May 5, 2009

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**
Patent#: 7537758
Title: Antibodies against a peptide epitope of apolipoprotein B
Date: May 26, 2009

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**
Patent#: 7544360
Title: Peptide epitopes of apolipoprotein B
Date: June 9, 2009

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**
Patent#: 7556811
Title: Peptide epitopes of apolipoprotein B
Date: July 7, 2009

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**
Title: Antibodies against a peptide epitope of apolipoprotein B
Patent#: 7704499
Date: April 27, 2010

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of such antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**

Title: Antibodies against a peptide epitope of apolipoprotein B -

Patent#: 7785589

Date: August 31, 2010

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of such antibodies.

Inventors: Kaul, Sanjay **Shah, Prediman K.**

Patent#: EP1406697 and FR1406697

Title: Use of magnesium for preventing in-stent thrombosis and complications after arterial angioplasty with stent placement

Date: 9/8/2010

Treatment with magnesium produces an inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.

Inventors: Arditi, Moshe; Rajavashisth, Tripathi; **Shah; Prediman K.**

Title: Methods for treating vascular disease

Patent#: 7,959,918

Date: June 14, 2011

Compositions and methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic activity of the toll-like receptor 4 (TLR4) and/or myeloid differentiation factor 88 (MyD88).

Inventors: Nilsson, Jan; **Shah, Prediman K.**

Title: Antibodies against a peptide epitope of apolipoprotein B

Patent #: 8,025,876

Date: September 27, 2011

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of the antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**

Patent#: 8,034,336

Title: Antibodies against a peptide epitope of apolipoprotein B

Date: October 22, 2011

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**
Patent#: 8,029,786
Title: Peptide epitopes of apolipoprotein B
Date: October 4, 2011

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**
Patent#: 8,647,628
Title: Peptide epitopes of apolipoprotein B
Date: October 4, 2011

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**
Patent#: 8,642,726
Title: Peptide epitopes of apolipoprotein B
Date: October 4, 2011

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**
Patent#: 8,642,043
Title: Peptide epitopes of apolipoprotein B
Date: October 4, 2011

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Nilsson, Jan; **Shah, Prediman K.**
Patent#: 8,470,768
Title: Peptide epitopes of apolipoprotein B
Date: October 4, 2011

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Bisgaier Charles; **Shah, Prediman K.**; Kaul, Sanjay;

Patent#: 8,119,590

Title: Prevention and treatment of restenosis by local administration of drug

Date: February 21, 2012

Use of local delivery through catheter, and stent, of apo Ai milano for inhibition of post-PTCA and post-stent restenosis

Inventors: Nilsson, Jan; **Shah, Prediman K.**

Patent#: RE43,581

Title: Peptide epitopes of apolipoprotein B

Date: August 14, 2012

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Inventors: Sharifi, Behrooz G.; Wang, Lai; **Shah, Prediman K.**

Patent#: 8,465,976

Title: Methods for isolating and using hematopoietic and embryonic stem cells of the peritoneal cavity

Date: June 18, 2013

Isolation and use of hematopoietic and embryonic stem cells in the peritoneal cavity as a new source of hematopoietic progenitor stem cells and methods of regenerating bioengineered tissues and/or reconstituting a hematopoietic system.

Inventors: **Shah, Prediman K.**, Chatterjee, Saswati; Wang, Jr, Kamehameha Kay-Min

Patent#: 8,926,958

Title: Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano

Date: January 6, 2015

Gene therapeutic approach to the prevention and treatment of vascular disease and coronary heart disease for prevention and treatment of atherosclerosis, as well as any disease or physiological condition in which atherosclerosis plays a role.

Inventors: Chyu, Kuang-Yuh; **Shah, Prediman K.**

Patent#: 9,125,850

Title: Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis

Date: September 8, 2015
 Immunomodulatory agents, T cell, compositions, methods and systems for treating and/or preventing hypertension and/or a condition associated thereto in an individual.

Inventors: Sharifi, Behrooz G.; **Shah, Prediman K.**
Patent#: 9,133,479
Title: Effective vector platform for gene transfer and gene therapy
Date: September 15, 2015

A method of improving efficiency of gene transfer and/or gene therapy to a cell by inhibiting phosphorylation of one or more serine residues of a virus capsid protein

Inventors: **Shah, Prediman K.**, Chyu, Kuang-Yuh; Honjo, Tomoyuki
Patent#: 9,205,139
Title: Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
Date: December 8, 2015
 Immunomodulatory agents, T cell, compositions, methods and systems for treating and/or preventing an aneurysm and/or a condition associated thereto in an individual.

Inventors: Chyu, Kuang-Yuh; **Shah, Prediman K.**
Patent#: 9,205,141
Title: Immunomodulatory methods and systems for treatment and/or prevention of hypertension
Date: December 8, 2015
 Immunomodulatory agents, T cell, compositions, methods and systems for treating and/or preventing hypertension and/or a condition associated thereto in an individual.

Inventors: Chyu, Kuang-Yuh; **Shah, Prediman K.**; Dimayuga, Paul
Patent#: 9,221,876
Title: Methods for treating kidney disease with fragments of ApoB-100
Date: December 29, 2015
 Compositions comprising immunogenic fragments of ApoB-100 for eliciting an immune response in a subject or vaccinating a subject, so as to treat, prevent, 5 inhibit and/or reduce symptoms of kidney diseases in the subject. The compositions include immunogenic fragments of ApoB-100, CD8+ T cells activated with immunogenic fragments of ApoB-100 or a combination thereof.

PATENTS SUBMITTED

1. Intrapericardial delivery of apo A-I Milano for prevention of vascular response to injury (Sanjay Kaul and Prediman K. Shah)
2. New Genes that predispose to and protect arteries from atherosclerosis (Behrooz Sharifi and P.K. Shah)
3. Novel mouse model of plaque rupture and thrombosis (Behrooz Sharif, Lai Wang and PK Shah)
4. Novel treatment of Alzheimer's disease (PK Shah)

5. A Novel Biomarker of atherosclerosis (Sharifi. Wang, Shah)

LECTURES AND PRESENTATIONS

“Cardiogenic shock,” San Gabriel Community Hospital, San Gabriel, 1977

“Role of hemodynamic monitoring in critically ill patients,” Los Angeles Chapter of the American Heart Association Fall Symposium, Los Angeles, 1978

[Visiting Professor] “Hemodynamic monitoring in acute myocardial infarction,” Fresno VA Hospital, Fresno, 1978

“Radionuclide assessment in acute myocardial infarction,” American College of Cardiology Minicourse, Anaheim, 1978

“Hemodynamic monitoring in acute myocardial infarction,” Southwest Clinical Society Fall Symposium, Kansas City, 1979

[Visiting Professor] “Intra-aortic balloon counterpulsation: role and medications,” St. Mary’s Hospital, Kansas City, 1979

“Value of radionuclide ventriculography in predicting prognosis in acute myocardial infarction,” Los Angeles Chapter of the American Heart Association Fall Symposium, Los Angeles, 1979

“Hemodynamic profiles in selected clinical disorders,” Cedars-Sinai Medical Center, Annual Critical Care Course, Los Angeles, 1979

“Recent advances in the medical management of angina pectoris,” Baylor College of Medicine Symposium, Houston, 1980

“Radionuclide assessment in acute myocardial infarction,” Center Foundation of Los Angeles Symposium: *Recent Advances in Cardiology*, Los Angeles, 1980

“Invasive and noninvasive methods of assessment of cardiac function,” Southwest Clinical Society of Kansas City Fall Symposium: *A Clinician’s Retreat*, Rancho Santa Fe, 1980

“Recent advances in the management of angina pectoris: role of calcium channel blockers,” Parkwood Community Hospital Second Annual Fall Symposium, Studio City, 1980

“Vasodilators: indications and role in cardiovascular disorders,” California Association of Hospital Pharmacists Annual Symposium, Sacramento and Orange, 1980

“Role of vasodilators in congestive heart failure,” Methodist Hospital of Southern California Fall Symposium, Arcadia, 1980

“Early prediction of prognosis in acute myocardial infarction,” Live satellite television program: *Clinics in Cardiology*, Los Angeles, 1981

“Clinical applications of bedside hemodynamic monitoring” and “Ambulatory electrocardiography,” Cardiopulmonary Seminar, Canton and Beijing (Peoples Republic of China), 1981

“Non-surgical reperfusion in acute myocardial infarction,” American College of Cardiology Seminar, San Francisco, March 1981

“Radionuclide predictors of prognosis in acute myocardial infarction,” Luncheon Panel: *What's New In Acute Myocardial Infarction*, Los Angeles Chapter of the American Heart Association Fall Symposium, Los Angeles, 1981

“Clinical applications of radionuclides in the coronary care unit,” Desert Hospital Cardiology Symposium Palm Springs, 1981

“Calcium antagonists,” Golita Community Hospital, Santa Barbara, October 1981

“Calcium antagonists,” Kaiser-Sunset Foundation Hospital, Los Angeles, November 1981

“Clinical update on calcium channel inhibitors,” Valley Presbyterian Hospital Cardiology Symposium, Van Nuys, November 1981

“The multipurpose pacing Swan-Ganz catheter” and “Interpretation of hemodynamic data,” *3rd Annual Symposium on High-Risk Patients*, Cedars-Sinai Medical Center, Los Angeles, January 1982

“The role of calcium channel blockers in coronary artery disease,” Methodist Hospital of Southern California, Arcadia, February 1982

“Streptokinase in acute MI and slow calcium channel blockers in coronary spasm,” *Cardiology and Cardiac Surgery - New Frontiers*, St. Mary's Hospital and Medical Center, San Francisco, February 1982

“Radionuclides in acute myocardial infarction,” [Moderator] *Recent Advances in Noninvasive Cardiac Imaging*, American College of Cardiology Extramural Program, Los Angeles, February 1982

“Calcium (Ca⁺⁺) channel blockers,” Good Samaritan Hospital, Los Angeles, March 1982

“Calcium (Ca⁺⁺) channel blockers,” Ross-Loos Medical Center, San Diego, March 1982

“Calcium (Ca⁺⁺) channel blockers,” Marina Mercy Hospital, March 1982

[Program co-chairman/speaker] "Calcium (Ca⁺⁺) channel blockers," Symposium: *Ca⁺⁺ Blockers*, co-sponsored by Tulane University and Cedars-Sinai Medical Center, Los Angeles, March 1982

"Calcium (Ca⁺⁺) channel blockers," Pacoima Memorial Hospital, Pacoima, March 1982

"Calcium (Ca⁺⁺) channel blockers," St. Vincent Medical Center, Los Angeles, March 1982

"Calcium (Ca⁺⁺) channel blockers," Baldwin Park Community Hospital, Los Angeles, April 1982

"Calcium (Ca⁺⁺) channel blockers," Kaiser Foundation Hospital, Los Angeles, April 1982

"Calcium (Ca⁺⁺) channel blockers," Serra Memorial Hospital. Sun Valley, April 1982

"Calcium (Ca⁺⁺) channel blockers," St. Lukes Hospital. Pasadena, April 1982

"Calcium (Ca⁺⁺) channel blockers," Marian Hospital. Santa Maria, April 1982

"Calcium (Ca⁺⁺) channel blockers," Lancaster Community Hospital. Lancaster, April 1982

"Calcium (Ca⁺⁺) channel blockers," Maxicare Medical Center. Los Angeles, April 1982

"Calcium (Ca⁺⁺) channel blockers," French Hospital. Los Angeles, April 1982

"Calcium (Ca⁺⁺) channel blockers," Hollywood Presbyterian Hospital. Los Angeles, April 1982

"Calcium (Ca⁺⁺) channel blockers," Los Angeles County Society of Anesthesiology. Los Angeles, May 1982

"Detection and prognostic assessment of patients with acute myocardial infarction: Comparative strengths and usefulness of various radionuclide methods," and "Comparative utility of scintigraphic echocardiographic and digital radiographic techniques in assessing patients with acute myocardial infarction," American College of Cardiology, Nuclear Cardiology Symposium, Heart House, Bethesda, June 1982

"Hemodynamic changes and treatment of septic shock," First Annual Conference on Critical Care Medicine: *Septic Shock*, Santa Barbara, June 1982

"Intracoronary streptokinase and angioplasty," Society of Nuclear Medicine, Miami Beach, June 1982

“Calcium (Ca⁺⁺) channel blockers,” 93rd Annual Continuing Education Meeting of the Washington State Pharmacist Association, Seattle, June 1982

“Calcium (Ca⁺⁺) channel blockers,” Kaiser-Permanente, West Los Angeles, July 1982

“Calcium (Ca⁺⁺) channel blockers,” Huntington Memorial Hospital, Pasadena, July 1982

“Digital angiography,” “Calcium blockers” and “Percutaneous transluminal coronary angiography,” *New Frontiers in Cardiovascular Nursing*, Cedars-Sinai Medical Center, Los Angeles, August 1982

“Clinical application of intraaortic balloon pump” and “Syndrome of predominant right ventricular dysfunction in acute myocardial infarction,” Unicorn Symposium, Sao Paulo (Brazil), August 1982

“Role of predischarge evaluation of post-MI patients” and “Intracoronary thrombolysis in acute myocardial infarction,” 13th Biennial Congress of Southern Africa Cardiac Society, Cape Town (South Africa), September 1982

[Moderator] *Surgery Is Indicated with Patients with Acute Myocardial Infarctions*;
[Chairman] *Beta Blockade after Myocardial Infarction - Which One, Why, How Long?*
American Heart Association Greater Los Angeles Affiliate 50th Annual Fall Symposium, Los Angeles, September 1982

[Program chair] *Current Trends in Cardiovascular Therapy* Symposium, Cedars-Sinai Medical Center, Palm Springs, October 1982

“Clinical applications of bedside hemodynamic monitoring using the Swan-Ganz catheter,” American Physiological Society Annual Fall Meeting: *Recent Advances in Physiological Monitoring*, San Diego, October 1982

“Intracoronary thrombolysis in acute myocardial infarction,” USC School of Medicine 4th Annual Symposium for Critical Care Nurses: *Developing Proficiency in Bedside Skills and Practice*, Anaheim, October 1982

“Calcium (Ca⁺⁺) channel blockers,” American Academy of Family Physicians National Meeting, San Francisco, October 1982

“Calcium (Ca⁺⁺) channel blockers,” The California Society of Hospital Pharmacists - Seminar '82, Los Angeles, October 1982

“Calcium (Ca⁺⁺) channel blockers,” Midway Hospital, Los Angeles, October 1982

“Calcium (Ca⁺⁺) channel blockers,” California Society of the Hospital Pharmacists Annual Meeting, Los Angeles, November 1982

“Pulmonary artery waveform analysis” and “Misadventures in the CCU and OR,” *The High Risk Patient - Fourth Annual Symposium*, Cedars-Sinai Medical Center, Las Vegas, January 1983

“Ca⁺⁺ channel inhibitors,” Annual Clinical Conference in Pediatric Anesthesiology, Los Angeles, February 1983

“Newer application of beta-blockers in the post myocardial infarction patient” and “Clinical application of calcium channel blockers,” *Cardiology Update* 1983, Honolulu, February 1983

“Angina: Start to finish,” Rancho Los Amigos Hospital, Downey, April 1983

“Calcium antagonists,” St. John’s Medical Center, Oxnard, April 1983

“Treatment of congestive heart failure with Captopril,” Montana Heart Association, Great Falls, May 1983

“Detection and prognostic assessment of patients with acute myocardial infarction: Comparative strengths and usefulness of various radionuclide methods,” American College of Cardiology Heart House, Bethesda, May 1983

“Current concepts of thrombolytic therapy in evolving acute myocardial infarction,” Centinela Hospital, Los Angeles, May 1983

“Clinical application of calcium blockers: Applied therapy in critical care medicine,” Good Samaritan Hospital, Los Angeles, June 1983

“Calcium Blockers,” *Acute Myocardial Infarction Symposium*, Santa Barbara, June 1983

“Congestive heart failure - New drugs in cardiovascular drug therapy,” West Los Angeles Kaiser Permanente Medical Center, Los Angeles, September 1983

“Clinical applications of nitrates,” Good Samaritan Hospital Los Angeles, October 1983

“Calcium antagonists: An update on therapy,” Salinas Valley Memorial Hospital, Salinas, November 1983

[Member, Program Committee] *The First Annual Cedars-Sinai Cardiology Update: Newest Concepts and Techniques in the Care of the Patient with Ischemic Heart Disease*, Los Angeles, November 1983

“Nuclear medicine techniques in the critically ill patient,” Southern California Chapter Society of Nuclear Medicine and the Cancer Foundation of Santa Barbara, *Cardiovascular Nuclear Medicine Symposium*, Santa Barbara, December 1983

“Calcium antagonist in treatment of angina,” Seaton Medical Center. Daly City, January 1984

“Refractory heart failure” VA Sepulveda Hospital, Sepulveda, California, February 1984

“Heart failure – current therapy,” Century City Hospital, Los Angeles, February 1984

“Pulmonary hypertension,” Huntington Memorial Hospital, Pasadena, California. February 1984

“Current concepts in the management of angina,” Marian Medical Center, Santa Maria, March 1984

“New concepts and developments in the management of CHF,” American Heart Association Physicians Symposium: *Current Concepts in Ischemic Heart Disease*, Westlake Village, April 1984

“Detection and prognostic assessment of patients with acute myocardial infarction: Comparative strengths and usefulness of the various radionuclide methods,” and “Comparative roles of scintigraphic, echocardiographic and hemodynamic techniques in assessing patients with acute myocardial infarction,” American College of Cardiology Heart House. Bethesda, May 1984

“Use of streptokinase for reperfusion of patients with acute MI,” Washington Hospital Medical Grand Rounds, Washington, D.C. May 1984

“Systemic thrombolysis in acute myocardial infarction,” “Nuclear Cardiology in the critically ill adult,” and “New therapeutic options for refractory heart failure,” The 11th Annual 1984 Cardiology Conference. Toronto, May 1984

“Nuclear imaging assessment of myocardial heart disease, pericardial heart disease and cardiac masses,” *Cardiac Morphology: Echocardiographic, Nuclear Imaging and Necropsy Correlations*, American College of Cardiology and Indiana University School of Medicine, Indianapolis, and Lake Tahoe, May 1984

“Experimental data on the protective effect of calcium entry blockers-clinical studies,” Calcium Entry Blockers, Update '84, Alberta (Canada), September 1984

“Beta blockers in hypertension and coronary disease,” 50th American Heart Association Fall Symposium, Los Angeles, September 1984

“Different types of beta blocking agents and their individual practical value in the treatment of ischemic heart disease,” 14th Annual Cardiology Symposium at Borgess Medical Center, Kalamazoo, September 1984

“Medical management,” University of Vienna Symposium: *Pathophysiology and Management of Heart Failure*, Vienna, Austria, October 1984

“Thrombolytic therapy in acute MI,” and “Current status of laser angioplasty,” Third Annual Unicolor Symposium, Sao Paulo (Brazil), July 1984

[Course Chairman] *Interventions In Acute Myocardial Infarction*, UCLA Extension and the UCLA School of Medicine, Los Angeles, April 1985

“Non-invasive assessment of acute myocardial infarction,” American Heart Association, Ventura County Chapter, Annual Physicians’ Symposium: *Ischemic Heart Disease-1985*, Westlake Village, May 1985

[Visiting Professor] “Thrombolytic therapy in acute myocardial infarction,” Northwick Park Hospital, Middlesex (England), May 1985

[Visiting Professor] Government Medical College and SMHS Hospital, Srinagar, Kashmir, India, May-June 1985

[Visiting Professor] Seri-Kashmir Institute of Medical Sciences, Soura, Kashmir, India, May-June 1985

“Non-invasive assessment of patients admitted with chest pain,” Inter-Community Medical Center, Covina, October 1985

“Approaches to myocardial salvage in evolving myocardial infarction,” and “New concepts in cardiogenic shock and cardiogenic pulmonary edema,” American College of Emergency Physicians, Las Vegas, September 1985

“Angioscopy identifies coronary thrombus in unstable angina,” International workshop on coronary thrombosis sponsored by the University of Munich (West Germany), January 1986

“Dynamic nature of myocardial infarction,” Annual Conference of International School of Cardiology, Palermo (Italy), April 1986

“Limited effectiveness of pharmacological approaches for infarct size limitation,” Annual Conference of the International School of Cardiology, Palermo (Italy), April 1986

[Visiting Professor] “Pathophysiology of acute myocardial infarction,” Catholic University, Rome, (Italy), April 1986

[Visiting Professor] “Pathogenesis of acute ischemic syndromes,” University of Rome Policlinic, Rome (Italy), April 1986

[Visiting Professor], Grand Rounds: “Clinical implications of right ventricular involvement in acute myocardial infarction”; Research seminar: “New insights into pathogenesis of unstable angina and role of coronary angioscopy,” University of Virginia, Charlottesville; April 22, 1986

“Pathophysiology of Unstable Angina,” 8th Annual Symposium, Hollywood Community Hospital, Los Angeles, June 1986

[Plenary speaker] “Acute heart failure: Pathophysiology,” and “New developments in hemodynamic monitoring,” European Congress of Intensive Care Medicine, Hamburg (Germany), June 1986

[Program Chairman] “Calcium channel blockers,” *Calcium Channel Blocker Update for the Practicing Physician*, Monterey, August 1986

“Thrombolytic therapy in acute infarction,” UCLA and Wadsworth Veterans Administration Hospital, September 1986

“Right ventricular infarction,” University of Southern California, October 1986

“Cardiopulmonary actions of Ca⁺⁺ channel blockers,” Annual Meeting of the California Society of Hospital Pharmacists, Los Angeles, October 1986

[Program Chairman] Symposium: *Angiotensin-Converting Enzyme Inhibitors*, Cedars-Sinai Medical Center, Los Angeles, October 1986

“Applications of Nuclear Cardiology in Acute Myocardial Infarction,” American College of Cardiology extramural program *Nuclear Cardiology Review with Experts*, Los Angeles, January 31, 1987

[Visiting Professor] “Clinical implications of right ventricular involvement in acute myocardial infarction,” Georgetown University, Washington, D.C., February 3, 1987

“Angina and silent myocardial ischemia and infarction,” Riverside Community Hospital, February 1987

[Program Director] *Acute Ischemic Syndromes*, American College of Cardiology, Heart House, Bethesda, February 5-6, 1987

“Mental stress and the heart,” Los Angeles County Medical Association, April 1987
Acute Myocardial Infarction, American College of Physicians Annual Scientific Session, New Orleans, March 31, 1987

“Clinical diseases in the post-infarct patient,” Huntington Memorial and Verdugo Hills Hospitals, April 1987

“Calcium channel blockers,” University of Southern California School of Medicine Symposium on *Cardiovascular Drug Therapy*. Los Angeles, April 1987

“Pathophysiology of unstable angina,” St. Paul Medical Center Annual Symposium, Dallas, May 1987

“Silent ischemia,” Humana Hospital, Phoenix, May 1987

“Angioplasty in acute myocardial infarction,” and “Clinical decisions in the post-infarct patient,” Straub Clinic Annual Cardiology Symposium, Hawaii; May 1987

“Pathophysiology of unstable angina,” Borgess Medical Center. 17th Annual Cardiology Symposium: *Advances in the Field of Interventional Cardiology and Medical Treatment of Organic Heart Disease*, Kalamazoo, October 1987

“New concepts of pathophysiology of acute coronary syndromes (unstable angina),” Nassau County Medical Ctr Eighth Annual Lectures in Continuing Medical Education. East Meadow, NY, October 1987

“ACE inhibitors and Ca⁺⁺ channel blockers,” Valley Hospital Medical Center, Van Nuys, October 1987

“Thrombolytic therapy,” McLeod Family Medicine Center Heart Symposium. Florence, SC, November 1987

“Angina and silent myocardial ischemia and infarction: The role of calcium antagonists,” Western Medical Center, Santa Ana, CA; November 1987

Interactive Satellite Videoconference: *Fibrinolytic Therapy with t-PA in Acute Myocardial Infarction*, December 1987

[Chairman] *Acute Coronary Syndrome: Therapeutic Trends in the Management of Post-MI Patient*,” Laguna Niguel, December 1987

[Visiting Professor] “New pathophysiologic concepts of unstable angina and coronary syndromes,” and “In-vivo angioscopy and its clinical applications,” All India Institute of Medical Sciences, Mool Chand Hospital and Sir Ganga Ram Hospital, New Delhi (India), January 1988

“Role of radionuclide techniques in the early and pre-discharge assessment of patients with acute myocardial infarction,” American College of Cardiology Extramural Program *Nuclear Cardiology*, Los Angeles, January 1988

“Thrombolytic therapy in acute myocardial infarction,” Emergency Medicine Grand Rounds, UCLA School of Medicine, Los Angeles, February 1988

“Current concepts of pathophysiology of acute ischemic syndromes,” Medical Grand Rounds, UCLA School of Medicine, Los Angeles, February 1988

“New pathophysiologic concepts of unstable angina,” UCLA-sponsored Symposium: *Perspectives in Ischemic Heart Disease*, San Diego, March 1988

[Visiting Professor] “Vascular angioscopy: Current status and future role,” Loma Linda University, March 1988

“Pitfalls of hemodynamic monitoring,” and “Role of intraaortic balloon counterpulsation,” [Chairman] *Thrombolysis*, European Society of Intensive Care Annual Symposium, Brussels (Belgium), March 22-25, 1988

“The management of post-infarction angina,” Rush-Presbyterian-St. Luke’s Medical Center Videoconference: *Calcium Channel Blockers Update for the Practicing Physicians*, Chicago, March 1988

“Thrombolytic therapy: practical consideration for the emergency physicians,” Good Samaritan Hospital Conference: *Activase(R) (T.P.A) in the Emergency Department, an Essential Therapeutic Intervention*, April 1988

[Moderator/lecturer] “New concepts of pathophysiology of acute coronary syndrome,” Cardiology Symposium for Inter-Community Medical Center, Covina, April 1988

[Chairman] *Hypertension and Heart Failure Symposium*, Cedars-Sinai Medical Center, Los Angeles, April 1988

“Management of the post-MI patient,” Scottsdale, May 1988

“Aortic dissection,” Symposium: *Vascular Disease for Primary Care Physician*, Cedars-Sinai Medical Center, Los Angeles, May 1988

“Angina and silent myocardial ischemia and infarction: The role of calcium antagonists,” University Medical Center of South Nevada and Valley Hospital Medical Center, Las Vegas, May 1988

“Calcium channel blockers,” Hospital of Good Samaritan, Los Angeles, June 1988

“Practical aspects of thrombolytic therapy,” Glendale Memorial Hospital, Glendale, June 1988

“Angina and silent myocardial ischemia and infarction: The role of calcium antagonists,” AMI Tarzana Regional Medical Center, Tarzana, July 1988

“Thrombolytic Therapy in Acute MI,” Wadsworth VA Hospital Grand Rounds, West Los Angeles, July 1988

“Interventions in Acute MI,” VA Medical Center Grand Rounds, Sepulveda, July 1988

USC Symposium: *Pathophysiology of Unstable Angina*, Los Angeles, July 1988

“Current therapeutic approaches in chronic heart failure,” “A new look at old drugs Digitalis and Nitrates,” “New concepts in pathophysiology in acute coronary syndromes,” and “Current status of interventions in acute myocardial infarction,” USC 31st Annual Postgraduate Refresher Course, Kawai, August 1988

“Pathophysiology of acute ischemic syndrome,” Midway Hospital, Los Angeles, September 1988

“Current and Future Roles of Inotropic Agents in the Treatment of Chronic Heart Failure,” Luncheon panel: *Congestive Heart Failure*, 56th Fall Symposium of the American Heart Association - Greater Los Angeles Affiliate, Los Angeles, September 1988

[Visiting Professor] “Acute coronary syndrome and coronary angiography,” San Antonio Chapter of American Heart Association Cardiology Society, San Antonio, October 1988

“Angina and silent myocardial ischemia and infarction: The role of calcium antagonists,” Kaiser Foundation – Sunset, Los Angeles, October 1988

“Prognostic and therapeutic implications in the management of post MI patient,” Rush-Presbyterian-St. Lukes Hospital *Advances in the Management of Cardiovascular Disease*, Chicago, December 1988

“Angina and silent myocardial ischemia and infarction: The role of calcium antagonists,” St. Mary’s Hospital, Long Beach, December 1988

“Update on interventions in acute evolving myocardial infarctions,” UCLA Emergency Medicine Center Grand Rounds, Los Angeles, January 1989

“Radionuclide techniques in the early and pre-discharge assessment of patients with acute myocardial infarction,” The American College of Cardiology and Cedars-Sinai Medical Center Clinical Nuclear Cardiology Case Review with the Experts, Los Angeles, January 1989

“Thrombolytic therapy in evolving myocardial infarction,” The Twenty-Seventh Annual Scientific Seminar, Brotman Medical Staff Foundation, Los Angeles, January 1989

[Visiting Professor] “Treatment of the post-myocardial infarction patient,” Los Angeles County Medical Association and Lancaster Community Hospital, Lancaster, February 1989

[Visiting Professor] “Contemporary management of the post-MI patient,” Desert Hospital, Palm Springs, February 1989

“Silent myocardial ischemia,” Good Samaritan Hospital Cardiology Grand Rounds, Los Angeles, February 1989

“Angina and silent myocardial ischemia and infarction: The role of calcium antagonists,” Family Heart Program at Fountain Valley Hospital, Long Beach, April 1989

“New pathophysiologic insights into the mechanism of acute coronary syndromes,” and “New insights into the EKG in evolving myocardial infarction gained during the thrombolytic era,” *Clinical Perspective in the Management of Post MI Patients*, World Health Communications, Inc. & Marion Laboratories. Phoenix, May 1989

“Treatment of heart failure in acute myocardial infarction,” “Restrictive cardiomyopathy: Pathology and pathophysiology,” “Beta -blockers in dilated cardiomyopathy: When are they indicated?” and “Atrial natriuretic peptide II,” First International Symposium on Heart Failure, Jerusalem (Israel), May 1989

[Program Chairman] *New Concepts of Pathogenesis and Management of Acute Ischemic Syndromes; Unstable Angina and Acute Myocardial Infarction*, American College of Cardiology Heart House, Bethesda, June 1989

“Past, present and future of the coronary care units in your health system,” Spanish Society of Cardiology Symposium: *Treatment of Acute Phase of Cardiologist Patients*, Madrid (Spain); June 1989

“New insights into the electrocardiogram in acute MI: Lessons learned from the thrombolytic era,” *Clinical Perspectives in the Management of Post-MI Patients*, Fort Lauderdale, June 1989

“Recent developments in thrombolytic therapy and PTCA,” Inter-Community Medical Center, Covina, July 1989

“Pitfalls in hemodynamic monitoring,” American College of Cardiology Critical Care Cardiology, San Francisco, August 1989

“Pathophysiology of ischemic syndromes,” City of Hope National Medical Center, Duarte, September 1989

Luncheon panel: Is Catheterization Mandatory for Patients with Coronary Artery Disease and MI: Pre-Discharge Risk Assessment, 57th Fall Symposium of the American Heart Association - Greater Los Angeles Affiliate, Los Angeles, September 1989

Fulbright Visiting Professor, Argentina and Chile: Reperfusion Injury? Does it exist?” and “New insights into the electrocardiogram in AMI. Lessons learned from the thrombolytic error,” Argentina Congress of Cardiology, October 1989

“Saving lives post MI,” King Drew Medical Center, Los Angeles, October 1989

“Unstable angina: Mechanisms and logic for therapy,” Los Angeles County-USC Medical Center Morbidity & Mortality Program, Los Angeles, October 1989

“Current status of thrombolytic therapy and angioplasty in acute myocardial infarction,” Philippine Medical Society of Southern California, Los Angeles, November 1989

“Thrombolysis and angioplasty in AMI - Current status,” Los Angeles Kaiser Hospital, Los Angeles, November 1989

“Radionuclide techniques in the early and pre-discharge assessment of patients with acute myocardial infarction,” Clinical Nuclear Cardiology Case Review with the Experts, American College of Cardiology and Cedars-Sinai Medical Center, Los Angeles, January 1990

“Angioscopy,” Desert Hospital Symposium, Palm Springs, February 1990

“Saving lives post MI,” Phoenix Baptist Hospital, Phoenix, February 1990

“New concepts in the pathophysiology of acute coronary syndrome,” St. Joseph Hospital, Burbank, February 1990

“Saving lives post MI,” University Hospital, Seattle, February 1990

“Thrombolytic therapy,” San Diego Heart Institute, San Diego, March 1990

“Thrombolytic therapy,” St. Francis Hospital, Lynwood, May 1990

“Thrombolytic therapy,” Little Company of Mary Hospital, Torrance, May 1990

“Aortic dissection,” Vascular Disease for Primary Care Physicians. Recent Advances and Controversial Issues, Los Angeles, June 1990

“Thrombolytic update in acute MI,” Mercy Heart Institute, Sacramento, June 1990

“Thrombolytic therapy,” Long Beach Community Hospital, Long Beach, June 1990

“Thrombolytic therapy,” Western Medical Center, Anaheim, California; July 1990

“Thrombolytic therapy,” University Medical Center Southern Nevada. Medical Grand Rounds, Topic:” Las Vegas, Nevada; July 1990.

[Chairman] Los Angeles American Heart Association 58th Annual Fall Symposium, “Heart Failure and New Vascular Interventions.” Beverly Hills, September 1990

“Recent advances in thrombolysis,” Critical Care Medicine Symposium. September 1990

“Outpatient treatment of congestive heart failure,” Cardiovascular Disease - Current Issues, Los Angeles, October 1990

“Current status of reperfusion therapy in acute myocardial infarction,” Memorial Medical Center, Long Beach, October 1990

“Pathogenesis of acute coronary syndromes,” University of Texas Health Science Center at San Antonio, Newer Concepts in the Diagnosis and Treatment of Cardiac Disease: An Update for the Visiting Professor, Ft. Lauderdale, October 1990

“Angioscopic perspectives of coronary artery disease,” Fifth National Meeting of the Council on Myocardial Ischemia & Infarction, Aventura, FL; December 1990

“Thrombolytic therapy in acute myocardial infarction: Unresolved issues,” Symposium: Unstable Angina: Mechanisms of Ischemia and Injury, Carlsbad, December 1990

“Thrombolytic therapy,” Fairfield, CA, January 1991

“Unstable angina,” Cardiology Symposium, Newport, CA; January 1991

“Radionuclide techniques in the early and pre-discharge assessment of patients with acute myocardial infarction,” American College of Cardiology and Cedars-Sinai Medical Center Nuclear Cardiology: Case Review with the Experts, Los Angeles, January 31 - February 2, 1991

“Thrombolytic therapy,” Santa Rosa, February 1991: “The spectrum of ischemia: Risk stratification of the coronary -prone patient,” Annual Meeting of the California Academy of Family Physicians, Palm Springs, February 1991

“Basic anatomy and physiology,” “Pathology and pathophysiology of the cardiovascular system” and “The cardiac emergency: How to recognize it and what to do,” Nuclear Cardiology for the Technologist, American College of Cardiology, Los Angeles, February 1991

“Coronary thrombosis: Angioscopic features and perspectives,” Symposium: Treatment Strategies for Coronary Artery Disease, Buckhead, GA, March 1991.

“Future of thrombolytics,” Daniel Freeman Memorial Hospital, Inglewood, March 1991

“Basic anatomy and physiology,” “Pathology & pathophysiology of the cardiovascular system,” and “The cardiac emergency: How to recognize it and what to do,” Nuclear Cardiology for the Technologist, American College of Cardiology, Bethesda, April 1991

“The treatment of acute myocardial infarction,” and “New pathogenetic issues,” International Symposium: Advances in Cardiology and Cardiac Surgery, Tuscany (Italy) May 1991

[Chairman] First H.J.C. Swan, M.D. Lectureship in Cardiology Visiting Professorship, Cedars-Sinai Medical Center, Los Angeles, June 5-6, 1991

[Co-chairman] "Thrombolysis: Where do we go from here?" New Frontiers in Vascular Interventions, Sponsors: American College of Cardiology, The California Chapter, American College of Cardiology and Cedars-Sinai Medical Center, Los Angeles, June 6-7, 1991

"Classification and treatment of heart failure," Update in Cardiology, co-sponsored by Central California Heart Institute and Bakersfield Memorial Hospital, Bakersfield, June 1991

"Pathogenesis of thrombosis," Therapeutic Advances in Coronary Care, Colorado Springs, August 1991

"Pathogenesis of acute coronary syndromes," New concepts in Cardiovascular Medicine: An Educational Update for the Cardiology Fellow, September 1991

[Panelist] "Who is at high risk for sudden death?" AHA 59th Annual Fall Symposium: Impact of Therapeutic Interventions and Clinical Trials on Mortality. Los Angeles, September 1991

"Pathogenesis of acute coronary syndromes," New Concepts in Cardiovascular Medicine: An Educational Update for the Cardiology Fellow, Tucson, October 1991

"ISIS III (International Studies of Infarct Survival)," 2nd Annual Cardiology Hawaii, The Queen's Medical Center Heart Institute, Honolulu, October 1991

"Thrombolysis: Where do we go from here?" Desert Hospital, Palm Springs, January 1992

"Current management of acute myocardial infarction," Valley Hospital Medical Center, Van Nuys, January 1992

"A Clinician's approach to noninvasive testing in patients with acute ischemic syndromes," Nuclear Cardiology Symposium, American College of Cardiology and Cedars-Sinai Medical Center. Los Angeles, January 1992

"Cardiac anatomy, physiology, pathology, pathophysiology" and "Emergencies," Nuclear Cardiology for the Technologist, American College of Cardiology, Los Angeles, February 1992

"New insights into coronary pathology revealed by angiography (fiberoptic and ultrasound)," "Limitations of thrombolytic therapy and directions for the future," and "Controversies in thrombolysis: Non-angiographic diagnosis of reperfusion," Acute Ischemic syndromes: Pathophysiology and new therapeutic approaches - Drugs, catheters, devices, surgery. American College of Cardiology Heart House, Bethesda, February 1992

[Chairman] Minicourse: Risk stratification and management of myocardial infarction following thrombolysis"; [Chairman] Fireside Panel: New insights into the EKG of acute myocardial infarction; ACCEL tape for ACC: EKG in Acute MI: Insights during thrombolytic era, American College of Cardiology Annual Scientific Session, Dallas, April 1992

"The Treatment of AMI - Where Do We Go From Here?" Annenberg Center at Eisenhower, Rancho Mirage, April 1992

[Fulbright Visiting Professor, Japan] "Thrombolytic therapy: present achievements, limitations and future direction," and "Role of review PTCA after thrombolysis failure," sponsored by American College of Cardiology and the United States Information Agency, May 1992

[Fulbright visiting Professor, Taiwan] "New directions in the management of CHF," and "New pathophysiology insights into the mechanism of acute coronary syndromes," sponsored by American College of Cardiology and the United States Information Agency, May 1992

"Recent advances in CV therapeutics," American College of Cardiology and Tufts University School of Medicine, Boston, June 1992

"Silent myocardial ischemia," University of Nevada, Las Vegas, July 1992
Extramural Course: Management of Cardiogenic Shock, University of California, San Francisco and American College of Cardiology, San Francisco, August 1992

"Adjunctive therapy with thrombolysis" and "New insights into EKG in AMI" American Heart Association, Maine Chapter, Annual Scientific Session, January 1993

[Visiting Professor] "Pathophysiology of Acute Coronary Syndromes," University of Texas, San Antonio, February 1993

[Visiting Professor] "New insights into the EKG of AMI gained during the thrombolytic era," Harvard Medical School and Massachusetts General Hospital, Boston, April 1993

[Program Chairman] Session on Thrombolysis and Session On Monocytes-Vessel Wall Interaction [Speaker] "Cardiac rupture," Symposium: Cardiogenic Shock, American College of Cardiology: Annual Scientific Session, Anaheim, March 1993

[Moderator]: Porcine model of PTCA restenosis Controversies in Cardiology, Massachusetts General Hospital, 1993

[Visiting Professor] "Plaque-rupture: Causes and consequences," Montefiore Hospital of Albert Einstein College of Medicine, Bronx, August 1993

[Visiting Professor] "New insights into the pathophysiology of acute ischemic syndromes," and "Current status of thrombolytic therapy in AMI," University of Pittsburgh, Johnstown, PA, August 1993

"Dyslipidemia and restenosis" and "Mechanisms of plaque rupture," Tenth Santa Fe Colloquium on Cardiovascular Therapy, Santa Fe, October 1993

"Thrombolytic therapy - The GUSTO Trial," Antelope Valley physicians, Lancaster, October 1993

"New insights into pathophysiology of plaque rupture and its consequence," St. Joseph Mercy Hospital, Pontiac, MI, October 1993

"Noninvasive diagnosis or reperfusion, post thrombolysis," "Unstable angina," and "Shock in acute myocardial infarction," Simposio: 25 Anos de Unidad Coronaria, Instituto del Corazon and El Hospital Italiano, Buenos Aires (Argentina), November 1993

[Visiting Professor] "Role of HDL-like molecule in intimal hyperplasia in hypercholesterolemic rabbits" and "New insights into the mechanisms and consequences of plaque rupture," University of Virginia, Charlottesville, February 1994

[Visiting Professor] "Insights into the mechanisms and consequences of plaque rupture," Medical College of Virginia, Richmond, February 1994

[Program Director] Thrombolysis: Current achievements and future directions, American College of Cardiology Extramural Course, Los Angeles, February 1994

"New insights into mechanisms and consequences of plaque rupture," University of Texas, San Antonio and American College of Cardiology, extramural course, San Antonio, February 1994

"Plaque rupture and its consequence: New insights from cell biology," University of Southern California, Los Angeles, February 1994

[Visiting Professor] "Matrix Metalloproteinases and plaque rupture," Karolinska Institute, Stockholm (Sweden), April 1994

"Cardiac rupture: Mechanisms, diagnosis and management," Critical Care Symposium, San Francisco, August 1994

"The acute ischemic syndromes: Pathophysiology and treatment," and "The acute MI: What to do in order to save your patient's life?" Cardiology for the Internist and Family Physician, San Diego, August 1994

[Visiting Professor] "New insights into pathophysiology of unstable coronary plaque," "Roll of primary PTCA in acute MI," and "Identification of viability of myocardium

following acute MI," Catholic University of Chile and University of Chile, Santiago (Chile), August 1994

[Visiting Professor] "Direct vascular protective effects of HDL," and "New insights into pathophysiology of plaque-rupture," Emory University, Atlanta, November 1994

"Pathology of vulnerable plaque," American Heart Association Annual Scientific Session, Atlanta, November 1994

[Meet the Experts] Plaque-Rupture and Plaque Stabilization, [Luncheon Panel] Management of Acute Myocardial Infarction," [Program Chairman] Abnormalities of Lipoprotein Metabolism, American College of Cardiology Annual Scientific Session, March 1995

"New insights into the pathophysiology of plaque rupture and its consequences," University of California, Irvine, 1995

[Visiting Professor] "Vascular protective effects of HDL," and "New insights into pathophysiology of plaque rupture and its consequences," University of Iowa, 1995

[Visiting Professor] "New concepts of pathophysiology of acute coronary syndromes," Nippon Medical School and University of Osaka, Tokyo and Osaka (Japan), 1995

[Visiting Professor] "Ventricular remodeling post acute myocardial infarction," "Prognostic value and ventricular remodeling," and "Prognostic value of late patency: Clinical strategies after 12 hours in the high risk group patients," XXII Argentine Congress of Cardiology Buenos Aires, Buenos Aires (Argentina), September 1995

[Visiting Professor] "Inflammation: Its role in plaque rupture and atherogenesis," "New antithrombotic drugs," and "Non-invasive detection of reperfusion in AMI," Symposium: Reperfusion in Acute Ischemic Syndromes, Hospital Italiano, Buenos Aires (Argentina), September 1995

[Visiting Professor] International Symposium on Apolipoprotein A-I: Structure, Function and Therapeutic Potential, Limone sul Garda (Italy), October 1995

"The atherosclerotic plaque: Why does it rupture?" and "Vascular protective effects of HDL: The Limone-Milano-Los Angeles Story," Twelfth Annual Santa Fe Colloquium on Cardiovascular Therapy, sponsored by the American College of Cardiology, Santa Fe, October 1995

[Visiting Professor] "Management of acute myocardial infarction," Wadsworth VA Hospital, Los Angeles, November 1995

University of Southern California Course for Primary Care Physicians: Pharmacological Management of Acute Myocardial Infarction. Los Angeles, December 1995

“Plaque stabilization: A new paradigm in atherosclerosis,” LAC-Harbor UCLA Medical Center: Los Angeles, January 1996

“Prevention of atherosclerosis with Apo A-1 Milano,” American College of Cardiology Annual Scientific Sessions, Orlando, March 1996

“Plaque Stabilization: A new paradigm in atherosclerosis prevention,” Medical Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, 1996

“Pathophysiology of acute ischemic syndromes,” and “Plaque stabilization: A new paradigm in atherosclerosis prevention thrombolysis in acute myocardial infarction, 1996 and beyond,” Mayo Clinic and University of Vienna Cardiology Update, Vienna (Austria) April 1996

“Pathophysiology of unstable angina,” Danish Society of Thrombosis and Hemostasis, Aarhus (Denmark), April 1996

“Novel Antiatherogenic Strategies: Role of Apo A-I Milano,” Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, 1996

[Simon Dack Visiting Professor] “Novel strategies against atherosclerosis: from apolipoproteins to nitric oxide donors,” and “Thrombolysis versus PTCA in acute myocardial infarction,” Cardiovascular Institute, Mount Sinai School of Medicine and Medical Center, New York, 1996

“New concepts in atherosclerotic plaque rupture,” and “Atherosclerosis prevention with Apo A-I Milano,” Cardiology Grand Rounds, Sharp Memorial Medical Center, San Diego, 1996

“Unstable angina acute myocardial infarction,” Cardiology for the Primary Care Physician, San Diego, 1996

[Moderator] Management of Acute Myocardial Infarction Management of Chronic Heart Failure American College of Physicians and UCLA School of Medicine-sponsored Annual Internal Medicine Board Review Course, Los Angeles, 1996

[Visiting Professor] “Novel antiatherogenic strategies: Focus on HDL and apolipoprotein A-I Milano,” Cleveland Clinic, Cleveland, 1996

“The Plaque II - Why Does It Rupture?” 13th Annual Santa Fe Colloquium on Cardiovascular Therapy: Therapy of Acute and Chronic Myocardial Ischemia, Santa Fe, October 1996

[Visiting Professor], “Role of HDL and apolipoprotein A-I Milano in atherosclerosis,” UCSD, La Jolla, 1996

“Pathophysiology and risk stratification in unstable angina,” Symposium: Unstable Angina, Annual Scientific Session of AHA, New Orleans, November 1996

“Role of matrix metalloproteinases in coronary plaque disruption,” Council on Myocardial Ischemia, New Orleans, November 1996

“Management of unstable angina,” Chest Pain 2000, West Palm Beach, 1996

[Plenary Speaker] “The Story of the Milano Gene,” Annual Session of the Society for Minimally Invasive Surgery, Lake Como (Italy), 1996

“New insights into the pathophysiology of acute ischemic syndromes,” American College of Cardiology Clinical Nuclear Cardiology: Case Review with the Experts, Los Angeles, January 1997

“Role of inflammation in complications of atherosclerosis from plaque rupture to coronary thrombosis,” Department of Medicine Grand Rounds, UCLA School of Medicine, Los Angeles, February 1997

“The pathogenesis of atherosclerosis,” Effective Lipid Management in High Risk Patients, sponsored by the University of North Carolina at Chapel Hill School of Medicine, Philadelphia, PA, March 1997

[Visiting Professor] “Role of inflammation in plaque disruption,” and “HDL: A novel antiatherogenic strategy,” Texas Heart Institute and the University of Texas, Houston, 1997

“Pathophysiology of acute coronary syndromes,” Albert Einstein Hospital, New York, April 1997

“Novel antiatherogenic strategies: Focus on HDL,” and “Apolipoprotein AI,” Medical Grand Rounds, Columbia-Presbyterian Medical Center, New York, April 1997

“Coronary plaque disruption and thrombosis: Role of inflammation,” Good Samaritan Hospital, New York, April 1997

“Novel antiatherogenic strategies: Focus on HDL and apolipoprotein AI,” Montefiore Medical Center, New York, April 1997

“Why do plaques rupture?” National Lipid Consultant’s Meeting, Palm Springs, 1997

[Visiting Professor] “New anti-atherosclerosis treatment: Focus on HDL,” University of California San Francisco Medical Center, San Francisco, June 1997

1997 Lipid Master’s Conference, Oahu, July 1997

“The acute ischemic syndromes: Pathophysiology and treatment of unstable angina and what to do in order to save your patient’s life?” Cardiology in Primary Care, CMEA/San Diego State University, San Diego, August 1997

“Role of inflammation in complications of atherosclerosis: from plaque rupture to coronary thrombosis,” Los Angeles, August 1997

“Atherogenesis,” “Acute myocardial infarction and aortic aneurysms and aortic dissection,” [Course Director] West Coast Cardiovascular Review Course for Cardiology Boards and Recertification, Los Angeles, October 1997

“New antiatherogenic strategy: Focus on HDL,” USC – Cardiology Grand Rounds, Los Angeles, October 1997

“Acute coronary syndromes: new drugs and devices” and “Lipid lowering for prevention of MI: Does it work?” Cardiology symposium sponsored by USC, 1997

“Role of New and Emerging Risk Factors for Coronary Artery Disease Lipid Lowering: Does It Work and for Whom?” and “Novel Antiatherogenic Strategies: From Gene Therapy to ‘NO’ Donors,” Annual Scientific Meeting of Cardiological Society of India, Calcutta (India), November 1997

“The stabilization of the atherosclerotic plaque,” Cardiology at Big Sky, co-sponsored by Henry Ford Hospital Heart and Vascular Institute and Council of Clinical Cardiology, American Heart Association, Big Sky, February 1998

[Visiting Professor] “Novel anti-atherogenic strategies,” and “A look into the future: Pathophysiology of acute coronary syndromes,” Mayo Clinic, Rochester, March 1998

[Visiting Professor] “An update on our current understanding of the pathophysiology of atherosclerosis,” Mount Carmel Medical Center, Columbus, April 1998

“Novel antiatherogenic strategies: From immunization to gene therapy – A look into the future,” Cardiology '98 Mayo and Vienna, Vienna (Austria), May 1998

“The pathophysiology of acute coronary syndromes,” Revamping Our Approach to Acute Coronary Syndromes: A New, Comprehensive Perspective on Pathophysiology, Diagnosis, and Treatment, Pasadena, July 1998

“Acute coronary syndromes: pathophysiology,” Acute Coronary Syndromes: A Revolution in Practice, Portland, OR, September 1998

“Novel anti-atherogenic strategies: A look down the road,” University of New Mexico, Albuquerque, Division of Cardiology, Cardiology Grand Rounds, Albuquerque, September 1998

“Treatment of unstable angina,” ACEP CME Satellite Symposium: Cooling down the Unstable Angina Patient: Platelet-targeted strategies for the Emergency Department, San Diego, October 1998

“Novel anti-atherogenic strategies,” 2nd International Congress on Coronary Artery Disease – Prevention to Intervention, Florence (Italy), October 1998

“Role of inflammation and infection in coronary artery disease,” Annual meeting of the California Chapter of the American College of Cardiology: Cardiology and Beyond – Entering the New Millennium, Santa Monica, October 1998

“Plaque disruption: A unifying concept in acute coronary syndromes,” Management of Acute Coronary Syndromes, UCLA, Los Angeles, November 1998

[Grollman Visiting Professor], University of Virginia, Charlottesville, 1999

“Role of inflammation and infection in atherothrombosis: an emerging new paradigm,” Cedars-Sinai Medical Center Medicine Grand Rounds, Los Angeles, 1999

“Novel antiatherogenic strategies: a look into the future,” Cedars-Sinai Medical Center Cardiology Grand Rounds, Los Angeles, 1999

“Pathogenesis and management of ACS,” “The effect of lipid lowering on vascular structure and function,” and “Novel antiatherogenic strategies for the new millennium,” American College of Cardiology and Mayo Clinic - Cardiology at Cancun 1999, Cancun (Mexico), February 1999

“Pathophysiology of plaque disruption and thrombosis: role of inflammation and infection,” European Society of Cardiology: 13th International Postgraduate Course On Myocardial Infarction And Angina Pectoris, Davos (Switzerland), February 1999

“Gene therapy for CAD: The role of cholesterol modification,” Seventh Annual Cardiology Fiesta: Update on Cardiac Diagnostic and Therapeutic Techniques, American College of Cardiology, San Antonio, April 1999

“Lipid lowering for risk reduction,” Western Working Group, Deer Valley, April 1999

“Novel antiatherogenic strategies: A look into the future,” Symposium in honor of James Scheuer, M.D., Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, May 1999

UCLA Family Practice Symposium: Pathogenesis of Atherosclerosis, Los Angeles, 1999

“Pathophysiology of acute coronary syndrome,” Acute Coronary Symposium, UCLA, Los Angeles, June 1999

Young Presidents Organization, Hawaii, July 1999

[Visiting Professor] "Role of inflammation in plaque disruption," William Beaumont Hospital, Michigan, October 1999

"Mechanisms of plaque rupture," American College of Cardiology Extramural Course, Santa Fe, October 1999

"Novel antiatherogenic strategies: A look into the future," Los Angeles AHA Fall Symposium, October 1999

"Inflammation in atherosclerosis: An emerging new paradigm," Symposium: Pathogenesis of Unstable Coronary Syndromes, Hoag Heart Institute, Newport Beach, November 1999

"Role of inflammation in athero-thrombosis," Cardiological Society of India, December 1999

"Pathophysiology of unstable angina," Symposium on Unstable Angina, Annual Scientific Sessions of the American College of Cardiology, Anaheim, March 2000

[Keynote speaker/session co-chair] "Do statins change plaque composition," and "Role of inflammation in athero-thrombosis," Japanese Circulation Society Meeting Year 2000, Osaka, Japan, April 2000

[Visiting Professor] "Role of IIb/IIIa receptor antagonists in acute coronary syndromes," Columbia University, New York Presbyterian Hospital, New York, April 2000

[Visiting Professor] "Novel anti-atherogenic strategies for the new millennium," Columbia University, St Lukes Roosevelt Hospital, New York, April 2000

[Invited Speaker and Program Chairman] "Unstable Angina," Annual Scientific Session of the American College of Physicians and American Society of Internal Medicine, Philadelphia, April 2000

"Role of HDL in atherosclerosis," Update on Cardiovascular Therapeutics, Hotel Bel Air, Los Angeles, April 2000

[Visiting Professor] "Role of inflammation and infection in atherothrombosis," Division of Cardiology, City of Hope, Duarte, May 2000

"Biology of the Unstable Plaque," Annual American Diabetes Association Scientific Meeting, San Antonio, June 2000

[Visiting Professor] "Role of inflammation and Infection in athero-thrombosis" and "Novel Anti-atherogenic strategies for the new millennium," University of Utah, Salt Lake City, July 2000

[Plenary Speaker] "Novel antiatherogenic strategies for the new millennium: Focus on Apo A-I Milano," XIth International Vascular Biology Society Meeting, Geneva, Switzerland, September, 2000

[Program Director and Speaker] "Gene Therapy for Cardiovascular Diseases: Opportunities and Challenges," Cardiovascular Gene Therapy 2000, Western Affiliates of the American Heart Association and LA Vascular Biology Club, Los Angeles, September 2000

"Gene-based therapy of atherosclerosis," for the Board of Directors of American Heart Association, Los Angeles, September 2000

"Good plaque-bad plaque" and "Infection and atherosclerosis: Are we ready to treat?" Annual American College of Cardiology Santa Fe Colloquia, Santa Fe, October 2000

"Inflammation in Atherosclerosis," Institute of Medical Education, Santa Monica, October 2000

"Secondary prevention after acute coronary syndromes," Fibrinolysis Symposium, Vienna, Austria, October 2000

"Gene therapy of heart disease," program organized by members of the Hillcrest Country Club, Los Angeles, October 2000

"HDL-based therapy of vascular disease: New developments," Cardiology Grand Rounds, UCLA School of Medicine, Los Angeles, October 2000

"Role of low molecular weight heparin in acute coronary syndromes" and "Role of HDL in coronary artery disease," symposium sponsored by the American College of Cardiology and U. C. San Francisco, December 15, 2000

"Role of Plaque Rupture in Deaths from CHF," symposium on chronic heart failure sponsored by the University of Southern California, Pasadena, January 27, 2001

"Angiogenesis in Vaso-occlusive Disease," Medical Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, February 2001

"Recent Progress in HDL Biology", Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, February 2001

"Bedside Diagnosis of Reperfusion," Meet the Experts, [Session Co-Chair] Whose Diet is Best, [Speaker] "Role of inflammation in pathophysiology of athero-thrombosis," [Program Chair and Speaker] "Pathophysiology of acute coronary syndromes," Clinical Cardiology Spotlight, Annual Scientific Sessions, American College of Cardiology, Orlando, March 2001

"Role of Inflammation in Plaque Disruption and Thrombosis," "Secondary Prevention after Acute Coronary Syndromes," "Cardiovascular Gene Therapy" Annual Scientific Session, Hong Kong Academy of Cardiology; Bedside Rounds, Rutonjee Hospital, Hong Kong, April 20-23, 2001

"Cardiovascular Gene Therapy," Medical Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, April 2001

[Visiting Professor] "Role of Inflammation and Infection in Atherothrombosis," New Jersey School of Medicine, Newark, April 2001

"Modulation of Plaque Phenotype by Statins and Recombinant HDL," scientific symposium on "Plaque Stabilization," Johns Hopkins University School of Medicine, Baltimore, May 5, 2001

"Role of Inflammation in Vascular Response to Injury". Scientific session chairman and speaker at the 2nd Annual International Cardiology Meeting, July 21-23, 2001, Washington DC

34th Annual George C Griffith Lecture of the American Heart Association: "Inflammation: Role in atherothrombosis and vascular response to injury", September 15, 2001, Los Angeles

Annual Kettering Institute Cardiovascular Colloquium, Dayton, Ohio: "New Insights into Pathophysiology of Athero-thrombosis", February 27, 2002

Annual Scientific Session of the American College of Cardiology: Co-Chair of ClinCard Spotlight session, March 2002

Annual Scientific Session of the American College of Cardiology: Invited Speaker at a Core-curriculum Session on Acute Coronary Syndromes" Pathophysiology and therapeutic targets", Atlanta, March 2002

Annual Scientific Session of the American College of Cardiology: Invited Speaker at a Luncheon Panel Session on" Vascular Benefits of Aggressive Lipid-lowering Therapy", Atlanta, March 2002

3rd Annual Vulnerable Plaque Symposium: Invited Speaker: "Apo A-I milano for Plaque Stabilization", Atlanta, March 2002

Acromegaly Symposium: Invited Speaker: "Inflammatory Paradigm of Atherosclerosis". Versailles, France, April 2002

Cardiovascular Symposium: Infection and Atherosclerosis: Invited Speaker: "Inflammation and Atherosclerosis: An overview), Washington DC, April 2002

Cardiovascular Symposium: Infection and Atherosclerosis: Invited Speaker:” AZACS Trial Results), Washington DC, April 2002

14th World Congress of Cardiology. Invited Speaker: “Inflammation and Infection as risk factors for atherosclerosis”, Sydney Australia May 2002

14th World Congress of Cardiology. Invited Speaker: “Therapeutic implications of Inflammation and Infection as risk factors for atherosclerosis”, Sydney Australia May 2002

Cardiology Grand Rounds, University of California, San Diego: “The inflammatory paradigm of athero-thrombosis”, May 29, 2002.

The American College of Cardiology and UCSF Critical Care Update Symposium, San Francisco, August 2002: “Role of inflammation in acute coronary syndromes” and “New lipid targets for atherosclerosis prevention and treatment”

George Herrmann Visiting Professor, University of Texas Medical Branch at Galveston, Texas, August 2002:” The inflammatory paradigm of atherothrombosis” and “New targets for atherosclerosis prevention and treatment”.

The American College of Cardiology and the University of New Mexico Extramural Program (Santa Fe Colloquium): “The inflammatory paradigm of athero-thrombosis”, Santa Fe, October 2-4, 2002

The American College of Cardiology and the University of New Mexico Extramural Program (Santa Fe Colloquium): “HDL: Player or Bystander”, Santa Fe, October 2-4, 2002

American Heart Association-Annual Fall Symposium: “Assessment and Management of Patients after Myocardial Infarction”, Los Angeles, October 12, 2002

American Heart Association –The Samson Symposium: “Plaque Vulnerability: Pathophysiology and Assessment”. San Francisco, October 25, 2002

Western Working Group-Round Table:” New Targets for Lipid Modification in Atherosclerosis”, Carlsbad, California, October 26, 2002

4th Annual Vulnerable Plaque Symposium, AHA scientific sessions “Role of immunotherapy in atherosclerosis”, Chicago, November 16, 2002

“Novel non-statin therapies for atherosclerosis”, Nippon Medical College, Tokyo, December 12, 2002

16th Annual Japanese Coronary Association Meeting:” The Inflammatory Paradigm of Athero-thrombosis”, Osaka, December 13, 2002

16th Annual Japanese Coronary Association Meeting: “Effect of statins on plaque phenotype”, Osaka, December 13, 2002

16th Annual Japanese Coronary Association Meeting: “Evolution of Reperfusion Therapy in Acute MI”, Osaka, December 14, 2002

Grand Rounds at UCLA, Division of Endocrinology: “Novel targets for inhibition of atherosclerosis: Concept of Immunotherapy”, March 2003

Annual Scientific sessions of the American College of Cardiology, March 29-April 2, 2003 Chicago: invited speaker at Symposium on Acute Coronary Syndromes “Vulnerable plaque and pathophysiology of acute coronary syndromes”.

5th Annual Vulnerable Plaque Symposium at the Annual Scientific sessions of the American College of Cardiology, March 29-April 2, 2003 Chicago: Invited speaker: “Immunotherapy and Reverse Cholesterol Transport Therapy with HDL for Plaque Stabilization”

Transcatheter Therapeutics (TCT-2003), Washington, DC: Invited Talks

- Inflammatory genes and vascular response to injury (Plenary session)
- Gene therapy with apo A-I-milano
- Plaque Vulnerability: Molecular mechanisms

Association of University Professors of Cardiology, Annual Meeting (January 2004, Florida): Invited speaker: “Immunomodulation of Atherosclerosis: An Emerging New Paradigm”

NIH-NHLBI and CIMIT Workshop on “Vulnerable Plaque: Opportunities and Challenges”: Chairman of Session on “Molecular Determinants of Plaque Rupture and Thrombosis”, Bethesda, Maryland, January 25-26, 2004

Annual Scientific Sessions of the American College of Cardiology (ACC) 2004: New Orleans (March 7-10)

- ACC-ACCEL Tape interview with James Cheesbro, MD: How low should we go with LDL
- Session Chairman, Luncheon Panel: Vulnerable Plaque: How do we detect it
- Program participant Breakfast Panel: How low should we go with LDL
- Symposium Speaker: Novel Risk Factors for Atherosclerosis: Hemostatic Factors
- Medical Crossfire Speaker Panel Participant
- Invited Speaker at Symposium on Inflammatory Markers: Inflammatory paradigm of athero-thrombosis

Annual Scientific Sessions of the Japanese Circulation Society, Tokyo, Japan, Marc-Apr 2004

- Keynote Speaker and Special Lecture: Immunomodulation of Atherosclerosis
- Special Lecture: Statins and Atherosclerosis

University of New Mexico Symposium on Diabetes and Metabolic Syndrome, Santa Fe, April 1 2004

- Invited Speaker: Progress in Atherosclerosis Pathophysiology 3rd Annual Berdie Justice Memorial Lecture, CSMC, May 5, 2004
- Gene based therapy and Vaccine for Atherosclerosis

Annual Scientific Session of Cardiovascular Research and Therapy Organization, May 6, 2004, Washington DC: Invited Speaker: Regulatory Genes in Vulnerable Plaque

Esperion Therapeutics, Ann Arbor, May 7 2004: Invited Speaker: The Gene from Limone: The Italian Connection

5th Conference on Apolipoprotein A-I milano, Limone sul Garda, Italy, May 29, 2004: Invited Speaker: HDL and the Vulnerable plaque

North-Shore University Hospital Visiting Professor (June 9-10, 2004): Annual Whitney Lecture (Dept of Medicine Grand Rounds): HDL based Therapy of Atherosclerosis: Cardiology Grand Rounds: Inflammatory paradigm of Athero-thrombosis

Long Island Jewish Hospital (June 11, 2004): Cardiology Grand Rounds: Immunomodulation of Atherosclerosis

Annual Scientific Sessions of the American Society of Echocardiography, San Diego (June 27, 2004): Moderator and Speaker: Vascular Structure and Function Assessment

UCLA-Medical Center, Grand Rounds in Department of Medicine: "Novel therapeutic strategies for Atherosclerosis", July 16, 2004

Nevada Cardiology Symposium: Emerging Paradigms in Athero-thrombosis", August 31, 2004. Las Vegas Nevada

Annual Fall Symposium of the LA-AHA: "Update on the Management of Acute Myocardial Infarction". Los Angeles, CA, October 2, 2004

American College of Cardiology-Annual Santa Fe Colloquium, October 2004, Santa Fe

- Invited speaker: Progress in Atherothrombosis
- Invited Speaker: Novel Anti-atherogenic Strategies: HDL and Immune-modulation

UCSF-Cardiology for the Practitioner-Yosemite, October 2004: Invited Speaker:
Emerging paradigms in Athero-thrombosis

Los Angeles-AHA: Women's Heart Symposium, October, 2004: Invited speaker:
Pathophysiology of atherothrombosis

UC Irvine-Cardiology /Medicine Grand Rounds, October 2004: Inflammatory paradigm
of atherothrombosis

AHA –annual Scientific Sessions, Nov 2004(New Orleans):

- Invited Speaker: “Vulnerable Plaque”, November 7, 2004
- Invited Speaker: Treatment of Vulnerable Plaque: Reverse Cholesterol Transport, Inflammation or both, November 7, 2004

AHA-Indian –Asian Symposium-Arizona Heart Institute, November 2004, New Orleans:
New Paradigms in Atherothrombosis

AHA-Association for Eradication for Heart Attack Annual Symposium, New Orleans,
Nov 2004: Invited Speaker: What have we learned from President Clinton's Heart
Illness: New Paradigm in Atherosclerosis Screening

AHA-First Annual Vaccine Symposium, New Orleans, Nov 2004: Invited Speaker:
Immune Modulation of Atherosclerosis with a Peptide Vaccine

University of Southern California-Cardiology Grand Rounds, Los Angeles, November
2004: Emerging paradigms in Athero-thrombosis

Annual Goodenow memorial Lecture, November 2004, Los Angeles: HDL based
therapies for atherosclerosis

American College of Cardiology and the New York Cardiovascular Symposium, Dec 10-
12, 2004, New York: The Henry Russek Lecture: Immunomodulation of Atherosclerosis
with a Vaccine

Loma Linda University Symposium, (March 2005): Emerging paradigms in
atherosclerosis pathophysiology and management

American Heart Association-leadership retreat symposium (March 4, 2005, Los
Angeles): Obesity and Metabolic Syndrome

American College of Cardiology (Orlando, March 4-9, 2005)

- Invited Speaker: New Paradigm for Atherosclerosis Detection
- Chairman: Vulnerable Plaque Symposium

UCSD Visiting Professor Grand Rounds (San Diego, May 4, 2005): Atherosclerosis: New Paradigms in Pathophysiology

Cleveland Clinic- Visiting Professor (May 27, 2005): Emerging Paradigms in Pathogenesis and Management of Athero-thrombosis

3rd Vulnerable Plaque Symposium (Capri, Italy, June 2005): A New Murine Model of Plaque Hemorrhage

Annual Einstein Lecture (Kern Medical Center and UCLA, Bakersfield, California, June 2005): Emerging New Paradigms in Athero-thrombosis

Annual Kern-Aspen Lipid Conference on HDL, University of Colorado (Aspen, Colorado, August 2005): HDL based therapy of atherosclerosis

Institute de Cardiologia, Mexico City (September 22, 2005): Emerging paradigms in atherosclerosis pathophysiology and management

Annual TCT Meeting, October 2005, Washington DC:

- Visionary approaches to atherosclerosis regression and plaque stabilization
- HDL-based therapy for primary and secondary prevention
- Atherosclerosis-pathophysiology (Satellite Symposium)

American College of Cardiology and New York Cardiologic Society Annual Symposium, Oct 29-2005: Emerging new paradigms in athero-thrombosis

American Heart Association Annual Scientific Program, Dallas, Nov 2005:

- Invited Speaker at the SHAPE Symposium: A New Paradigm for Atherosclerosis Detection
- Immunomodulation of Atherosclerosis using apo B peptides

University of California, San Francisco: Visiting Professor: January 2006: Emerging New Paradigms in Athero-thrombosis

The Gladstone Foundation Cardiovascular Institute-CVRI/UCSF: Visiting Professor, San Francisco, April 2006: Emerging New Paradigms in Athero-thrombosis

Annual CRT Symposium, Washington DC 2006:

- Immune modulation of Plaque Vulnerability
- HDL therapy of Atherosclerosis

The 53rd Annual Scientific Meeting of the Israel Heart Society, Tel Aviv, April 2006:
The Henry Neufeld Memorial Lecture: HDL-based therapy of Atherosclerosis; the next frontier

Euro-PCR, Paris France May 2006: Molecular Mechanisms of Plaque Vulnerability
X1Vth International Atherosclerosis Society Scientific Meeting, Rome, Italy. June, 2006:

- Molecular Determinants of Plaque Vulnerability
- Co-Chairman, Session on Vulnerable Plaque

6th Annual SIS (Science, Innovation, Synergy) Conference, Seattle, July 2006:
Molecular mechanisms of atherosclerosis and novel antiathero-genic strategies

Ipsen Foundation Symposium on Inflammation in atherosclerosis, Oct 2006 (Paris): -
Novel molecular mechanisms of plaque Vulnerability

Transcatheter Therapeutics Meeting, October 2006 (Washington DC):
Immunomodulation of atherosclerosis with active and passive immunization

Annual Scientific Sessions of the American Heart Association, Chicago, November 2006:

- Invited Speaker (Cardiovascular Symposium: Innate and adaptive immunity): Humoral immunity in Atherosclerosis
- Invited Speaker (Cardiovascular Symposium: Imaging of Vulnerable Plaque): Management of Vulnerable Plaque
- Invited Moderator (Cardiovascular symposium: Progress in Atherosclerosis)
- Invited Speaker (National Lipid Association's HDL Summit): Synthetic HDL: Focus on Apo A-I Milano

USC- CHF Symposium: What is New in Anti-lipid Therapy of Atherosclerosis
Biltmore Hotel, January 2007

UCLA- Borun Visiting Professor: March 2007: Emerging Paradigms in Atherosclerosis
Pathophysiology and management

56th Annual Scientific sessions of the American College of Cardiology 2007

- Invited speaker: HDL-Based Therapy of Atherosclerosis – A new Paradigm
- Invited speaker: Biological HDL based Therapy of Atherosclerosis

Annual Scientific Session of the American College of Physicians (ACP), San Diego, April 21-2007: Meet the Professor invited Lecture: Acute Coronary Syndromes
Simon Dack Visiting Professor, Mount Sinai Cardiovascular Institute, New York
April 23, 2007: HDL Based Therapy of Atherosclerosis

Beverly Hospital 18th Annual Cardiovascular Symposium, April 27, 2007

- Vaccine for Atherosclerosis
- Lipid Management of CAD

Los Robles Hospital, Annual symposium, April 28, 2007: Lipid Management of Atherosclerosis

American Heart Association: 4th Annual symposium on the burden of athero-thrombotic disease: diagnosis and therapy June 2007, New York:

- Invited speaker: Immune mechanisms in atherosclerosis
- HDL based therapy of atherosclerosis

6th Annual Desert Heart Institute Symposium, Las Vegas, August 2007: Emerging therapies for atherosclerosis

Asian Heart Symposium, San Jose, California, Sept 2007: HDL and Reverse Cholesterol Transport

Karolinska Institute: Inflammation and Atherosclerosis, Stockholm, October 2007: Vaccine for Atherosclerosis

American College of Cardiology, West Coast Forum, San Francisco, October 2007: HDL: An Odd Molecule

St. Lukes –Roosevelt Hospital, New York, Cardiology Grand Rounds- January 2008: Emerging Paradigms in Athero-thrombosis

Loma Linda University Hospital Symposium, February 2008:

- Lipid management of athero-thrombosis
- Vaccine for atherosclerosis

Indian Medical Association-Annual Lecture, Los Angeles, March 2008: Current approaches to atherosclerosis management

Department of Medicine Grand Rounds, Cedars-Sinai Medical Center, March 2008: The HDL Conundrum: where do we go from here?

American College of Cardiology, Annual Scientific Sessions, Chicago, March 2008: Moderator of SHAPE Symposium

Annual Symposium of Beverly Hospital, Los Angeles, April 2008: Vaccine for Atherosclerosis

Los Robles Heart Symposium, April 2008, Sherwood Country Club: Management of Acute Myocardial Infarction

Annual Cardiovascular Symposium, Beverly Hospital, April 2008: Vaccine for Atherosclerosis

Annual European Atherosclerosis Society Meeting, Istanbul, April 2008:

- Co-Chair: Immuno-modulation
- Apo B Peptide related vaccines for atherosclerosis

Annual Scientific Sessions of the American College of Physicians, Washington DC, May 2008

- Lunch with the Professor: What is new in ACS?
- Meet the Professor: Management of ACS

Annual Mayo Clinic Symposium, August 2008, Sedona:

- New Paradigms in Atherothrombosis
- HDL Conundrum

Annual Controversies in Cardiology and Cardiac Surgery, Los Angeles, September 2008:

- Time to move beyond LDL
- Vaccine for Atherosclerosis

Visiting Professor, Oregon Health Sciences University, Portland, Oregon, October 2008:

- Emerging new paradigms in atherosclerosis
- The role of immune system in atherosclerosis

Annual Herrick Award Lecture, Council on Clinical Cardiology of the American Heart Association, AHA annual Scientific Sessions, New Orleans, Nov 11, 2008: Vaccine for atherosclerosis: chasing the holy grail

Annual Laennec Clinician Educator Award Lecture, Council on Clinical Cardiology of the American Heart Association, AHA annual Scientific Sessions, New Orleans, Nov 11, 2008: Gene from Limone: Is it Golden?

Annual John Goodnow Lecture, Los Robles Hospital, Westlake Village, California, Dec 2, 2008: Vaccine for Atherosclerosis

University of Southern California Annual Heart Failure Symposium, February 2009: LDL Lowering after the ENHANCE Trial

Baptist Health Care System, Annual Scientific Meeting, Coral Gables, Florida February 2009: Key Note Speaker

- Emerging New Paradigms in Athero-thrombosis
- Immunomodulation of Atherosclerosis with a Vaccine

- Is HDL Still a Legitimate Target for Atherosclerosis

American College of Cardiology Annuals Scientific Sessions, Orlando, March 2009
(Invited Speaker):

- ACC Symposium: HDL-present and future
- ACC Symposium: Inflammation and Pathophysiology of Rupture Prone Plaque
- ACC Symposium: Novel strategies to increase HDL
- ACC ClinCard (Master Clinician Session): Panelist

Hong Kong Public Hospital Cardiologists Association (HKPHCA) Annual Scientific Meeting, 2009: Key Note Speaker

- Atherosclerosis: Emerging Paradigms in Pathophysiology and Management
- Medical vs. Interventional therapy for (chronic) Ischemic Heart Disease: Evidences & controversies

American College of Cardiology-West Coast Forum; June 2009, San Francisco

- Chair: Session on Pathophysiology of Atherosclerosis
- Chair: Session on Acute Coronary Syndromes
- Speaker: Genomics, Proteomics, Metabolomics: What is this all about
- Speaker: Prasugrel, Aspirin and Clopidogrel Resistance

Latin American Cardiovascular Course, Sao Paulo, Brazil (August 2009):

- Course Director: PK Shah
- Speaker: Unstable Plaque
- Speaker: Vaccine for Atherosclerosis
- Speaker: HDL as a therapeutic target

Annual Transcatheter Therapeutics Meeting (TCT), San Francisco, Sept 2009:
Immunomodulation of Atherosclerosis: PK Shah, MD

9th Annual Controversies Symposium-Los Angeles, October 1-2, 2009: Keynote
Speaker: Gene therapy of atherosclerosis: Will it live up to its promise?
Los Angeles Times Magazine Healthcare and Wellness Expo, Palos Verdes October
10, 2009: Heart Disease: Novel Treatments

Blue Ribbon Panel of the Music Center, UCLA Oct 12, 2009: Heart Disease: Present
and Future

Annual Scientific Sessions of the Canadian Cardiovascular Society Acute Coronary Syndrome Symposium, Edmonton, Canada, October 2009: ACS- Looking back while Moving Forward

Wadsworth VA Hospital, Los Angeles: Cardiology Grand Rounds, December 2009: Emerging Paradigms in Athero-thrombosis

Gilbert Blount Jr, MD Visiting Professor at the University of Colorado, Denver, March 2-4, 2010:

- Emerging new paradigms in athero-thrombosis
- Activation of Endogenous Regulatory T-cell Response is Athero-protective

Annual Cedars-Sinai James Klivenberg Rheumatology Symposium, Santa Barbara, CA March 13, 2010: Emerging paradigms in Athero-thrombosis

Annual Scientific Sessions of the American College of Cardiology, Atlanta, March 2010: Lipids and Inflammation

Cedars-Sinai Endocrine Grand Rounds, April 2010: Emerging paradigms in Atherothrombosis

Annual Scientific Sessions of the American College of Physicians, Toronto, Canada, April, 2010: Meet the Professor: Management of Acute Coronary Syndromes

Dennis Visiting Professor, Baylor College of Medicine and Texas Heart Institute, Houston: May 2010: Yin and Yang of Immune System in Atherosclerosis

Los Robles Medical Center Annual Symposium, May 2010: New developments in atherosclerosis management

Mount Sinai Heart and Vascular Institute 13th Annual Live Symposium of Complex Coronary and Vascular Cases, New York, June 2010: Emerging new paradigms in athero-thrombosis

UC Irvine and Long Beach Memorial Heart Symposium, Long Beach, October 2010: Ellested Oration (Lecture): Can we Wash Away the Plaque?

Mayo Clinic Course on Coronary Artery Disease, Las Vegas, October 2010: Keynote Lecture: Emerging new therapeutic paradigms for atherosclerosis

Annual Scientific Sessions of the American Heart Association, November 2010, Chicago: Invited Speaker at a symposium "The Vulnerable Patient Role of Imaging" Topic: The Vulnerable Patient: Clinical Assessment

Dallas Leipzig Meeting, December 2010, Dallas, Texas: Invited speaker and moderator: "Genomics in Cardiology; Will it be relevant for practice"

Department of Medicine Grand Rounds at Cedars-Sinai, December 2010: New and emerging paradigms in pathophysiology and treatment of atherothrombosis

Sheila Kar Foundation-Keynote Speaker, February 2011, Los Angeles: Can we reverse atherosclerosis?

Cedars-Sinai Heart Institute Grand Rounds, February 2011: Part 1: Emerging paradigms in the pathophysiology of Athero-thrombosis

California Pacific Medical Center: Cardiology Grand Rounds, March 2011, San Francisco: Novel Therapies for Atherosclerosis

Annual Scientific Sessions of the American College of Cardiology, New Orleans, April 2011:

- Invited speaker: Pathogenesis of atherosclerosis
- Session Chairman: Unstable Angina and ACS
- Session summary presenter: Unstable angina and ACS

Cedars-Sinai Heart Institute Grand Rounds, August 2, 2011: Part 2: Novel Therapeutic Paradigms in Atherosclerosis: Focus on HDL and apo A-I

Cedars-Sinai Heart Institute Grand Rounds, August 9, 2011: Part 3: Novel Therapeutic Paradigms in Atherosclerosis: Focus on Immunomodulation and Vaccine

Robert Frye Distinguished Visiting Professorship at Mayo Clinic, Rochester, August 24, 2011:

- Medical grand rounds: emerging paradigms in atherothrombosis
- Robert Fry Lecture: Vaccine for atherosclerosis

Eleventh Annual Cedars-Sinai Controversies in Cardiology and Cardiac Surgery, Beverly Hills Oct 2011: Lecture: Have we conquered atherosclerosis?

Annual Symposium, Sacramento, October 2011: Lecture: Pathophysiology and management of atherosclerosis

Annual Orange County Symposium, Anaheim October 2011: Lecture: HDL based therapy o atherosclerosis

International Conference on Coronary Artery disease, October, Venice 2011: Lecture: Peptide based Vaccine for Atherosclerosis

Annual World Conference on Insulin Resistance, Hollywood, November 2011: Lecture: Management and prevention of ACS in Diabetes

Annual 61st Scientific Sessions of the American College of Cardiology, March 2012:

- Invited speaker at Symposium on HDL: HDL Form and Function
- Invited Speaker at Symposium on HDL: HDL Mimetics and Infusion Therapy
- Chairman: Session on Complications of Acute MI
- Chairman: Session on Legends in Cardiology

Cardiology Grand Rounds, Case Western Reserve University Hospital, Cleveland, April 2012: Emerging new paradigms in atherothrombosis

Los Robles Medical Center Annual Symposium, May 2012: Update on Aortic Dissection

American College of Cardiology-West Coast Forum: June 2012 San Francisco: Endothelium, Vaccines and Polymedicine for atherosclerosis

American College of Cardiology and 23rd Great Wall International Congress, Beijing, October 2012: Management of Dyslipidemia

International Women's Forum, San Francisco, October 2012: Vaccine for atherosclerosis

Apolipoprotein A-I Symposium, Limone sul Garda, Italy, October 2012: Apo A-I Milano gene therapy for atherosclerosis

Annual Scientific Sessions of the AHA, Los Angeles, November 2012: How to Build a Structural Heart Disease program: Hospital Perspective

Annual James T Willerson Lecture, University of Texas, Houston, November 2012: Immune System in Atherosclerosis

45th Annual New York-ACC Cardiovascular Symposium, New York, December 2012: Why is HDL such a tough Nut to Crack?

Cedars-Sinai Heart Institute Grand Rounds, January 2013: Modulation of autoimmunity in atherosclerosis with a vaccine

American College of Cardiology Annual Scientific Sessions, San Francisco, March 2013: Invited speaker

- Modification of lipid factors
- HDL based therapy

International Meeting on Cardiovascular Interventions, Snowmass, March 2013: Vulnerable plaque and Apo A-I Milano

17th Annual Heart Failure Meeting, Los Angeles, April 2013: 1st William Ganz Memorial Lecture: Path to heart failure prevention is through focus on atherothrombosis

Joint session of ACC and Asia Pacific Heart Association Annual Scientific Sessions, Singapore April 2013: Invited speaker

- Inflammation in atherosclerosis
- New LDL lowering therapies
- HDL based therapies

CSMC Medicine Grand Rounds, June 14, 2013: Jekyll and Hyde of HDL: A Lipoprotein with a Split Personality

CSMC Heart Institute Grand Rounds, August 27, 2013: LDL-C Lowering: Beyond Statins

CSMC Emergency Lecture series, July 2013: Aortic dissection

CSMC Fellow's Lecture series, July 2013: AMI complications

CSMC Fellow's Lecture series, July 2013: EKG in AMI

CSMC Emergency Lecture series, August 2013: Cardiac Tamponade

Cardiology Grand Rounds, Albert Einstein College of Medicine, New York- September 24, 2013: Modulation of auto-immunity in atherosclerosis with a vaccine

Medical Grand Rounds, Huntington Memorial Hospital, Pasadena, CA
October 4, 2013: Jekyll and Hyde of HDL: A lipoprotein with a split personality

CSHI Research Grand Rounds, CSMC, December 2013: Phenotype of TNC-C Gene Deletion identifies its protective role

International Conference (CARE) in Ahmedabad, India, January 2014

- HDL: The Fallen Angel
- New Non-statin lipid modifying interventions
- Imaging subclinical atherosclerosis

Cardiovascular Imaging Conference, CSMC, Los Angeles, CA, January, 2014:
Atherogenesis and Molecular Imaging

Medical Grand Rounds, CSMC, Los Angeles, CA, February, 2014: Management of Statin Intolerant Patient

Cardiology Grand Rounds, USC Keck School of Medicine, Los Angeles, CA

February, 2014: Jekyll and Hyde of HDL: A lipoprotein with a split personality

American College of Cardiology Symposium on Valvular Heart Disease, Los Angeles, CA, March 2014: Pathophysiology of Aortic Stenosis

Annual 63rd Scientific Sessions of the American College of Cardiology, Washington, DC, March 2014:

- State of the Art Lecture: HDL back to the future
- Non-statin interventions in atherosclerosis: Immunomodulation with Vaccination
- Inaugural Kanu and Docey Chatterjee Endowed Lecture: Path to heart failure prevention is through focus on atherothrombosis

Best of ACC 2014 Symposium, Los Angeles, CA, April 2014 and Chicago, May 2014, Program Director and Speaker

VA Wadsworth Medical Center, Los Angeles-UCLA: Endocrine Grand Rounds, June 20, 2014: HDL- A lipoprotein with a split personality

CSMC Emergency Lecture series, July 2014: Cardiac Tamponade

CSMC Fellow's Lecture series, July 2014: AMI complications-part 1

CSMC Fellow's Lecture series, July 2014: AMI complications-part 2

Heart Institute Grand Rounds, August 2014, CSMC: Pathways to Inflammation in Atherosclerosis

Ten Top Advances in Clinical cardiology, Mount Sinai Heart Institute, New York, October, 2014: Role of Imaging Subclinical Atherosclerosis

66th Cardiologic Society of India Annual Scientific Sessions, Dec 5, 2014, Hyderabad, India: Vaccine for Atherosclerosis

Endocrine Grand Rounds, Cedars-Sinai Medical Center, December 16, 2014: Novel peptide based vaccine for vascular disease

Cardiovascular Imaging Conference, CSMC, Los Angeles, CA, January, 2015: Atherogenesis and Molecular Imaging

Hypertension Grand Rounds, Cedars-Sinai Medical Center, February 2015: Immune modulation of Hypertension with a Vaccine

Annual Scientific Sessions of Am Coll Cardiol, March 2015: Using Statins without Imaging

AMGEN Headquarters, April 29, 2015: Lipid Lowering: Statins and Beyond

Institute of Cardiology, Mexico City, June 2015: Vaccine for Atherosclerosis

Department of Medicine Emergency Lecture series at CSMC, July 2015: Acute Pericarditis and Cardiac Tamponade

Department of Medicine Emergency Lecture series at CSMC, July 2015: Acute Aortic Dissection

Heart Institute Lectures Series for Fellows, July 2015: Acute MI (part 1)

Heart Institute Lectures Series for Fellows, July 2015: Acute MI (part 2)

Heart Institute Lectures Series for Fellows, July 2015: EKG in AMI (part 3)

Brazilian Society of Atherosclerosis, Sao Paulo Brazil, August 2015:

- Evolution of atherosclerosis (Opening Lecture)
- Vaccine for atherosclerosis
- Vulnerable Patient vs. Vulnerable Plaque

Controversies Symposium, November 2015: PCSK9 Inhibition for lipid management

Endocrine Research Seminar at Cedars, January 2016: Cardiovascular Phenotype of a Matrix Protein deletion

Medicine Grand Rounds, CSMC, January 2016: "Targeting PCSK9 in Hyperlipidemia: From Genomics to Therapeutics"

CSMC Imaging Symposium January 2016: Pathogenesis of atherosclerosis

CSMC Lecture Series with Fellows, February 2016: "Interesting Images/Stump the Fellows"

Texas Heart Institute Cardiology Grand Rounds, March 18, 2016: "Pathways to Inflammation in Atherosclerosis"

Annual Scientific Sessions of the American College of Cardiology, Chicago, April 2016: Great Debates in Imaging: Cardiac CT

20th Annual Heart Failure – An Update on Therapy, Los Angeles, April 16, 2016: "Contemporary Management of LDL Cholesterol – Role of Statins, Ezetimibe & PCSK9"

Mayo Clinic Grand Rounds, Arizona, April 29, 2016: "What is up with the Highly Difficult Lipoprotein"

10th Annual Women & Ischemic Heart Disease Symposium, CSMC, May 13, 2016: Cholesterol 2016: "How to Manage Statin Intolerance (PCSK9 Inhibitors)"

Heart Institute Lectures Series for Fellows, July 2016: Acute MI (part 1)

Department of Medicine Emergency Lecture series at CSMC, July 2016: Acute Pericarditis and Cardiac Tamponade

Department of Medicine Emergency Lecture series at CSMC, July 2016: Acute Aortic Dissection

Heart Institute Lectures Series for Fellows, August 2016: Acute MI (part 2)

CSMC Lecture Series with Fellows, August 2016: "Interesting Images"

Annual Frontiers in Cardiovascular Disease Symposium, New Jersey, September 2016: Update on Management of Lipid Disorders

CSMC Preventive and Consultative COE, September 2016: "Gut Microbiome and Atherosclerosis: New Insights"

7th Annual Cardiology Update: The Heart of New Developments, Newport Beach, CA, October 2016: "Cholesterol 2016: Statin Therapy, Statin Intolerance, PCSK9 Inhibitors"

26th Annual Cardiology & Electrophysiology Symposium, Sacramento, CA, October 29, 2016: "Lipid Lowering Goals & Therapeutics"

CSMC Heart Institute Cardiology Grand Rounds, November 8, 2016: "The Highly Difficult Lipoprotein"

Controversies & Advances in the Treatment of Cardiovascular Disease Symposium, Beverly Hills, CA, November 17-18, 2016: "Novel Pathways to Inflammation in Atherosclerosis: From Gut Microflora to Don't Eat Me Signals"

77th Annual Congress of the Italian Society of Cardiology, Rome, December 2016: "Vaccine for Atherosclerosis"

CSMC Imaging Symposium January 2017: Pathogenesis of Atherosclerosis: "Potential Targets for Plaque Molecular Imaging"

Department of Medicine Grand Rounds, CSMC, February 3, 2017: "Novel Pathways to Inflammation in Atherosclerosis"

CSMC Lecture Series with Fellows, February 6, 2017: “Interesting Images”

CSMC Lecture Series with Fellows, February 20, 2017: “Interesting Images – Part 2”

Annual Scientific Sessions of the American College of Cardiology, Washington DC, March 2017: “Are We There Yet? Update on Trials Testing New Therapeutics for Prevention of ASCVD”

California Pacific Medical Center Cardiology Grand Rounds, April 19, 2017: “Lipid Management Beyond Statins”

Los Angeles Cardiovascular Research Symposium, May 15, 2017: “Novel Pathways to Inflammation in Atherosclerosis”

CSMC Cardiovascular Graduate Teaching, May 24, 2017: “The Biology of Lipoproteins”

CSMC Fellows Lecture, May 25, 2017: “Lipid Management: Current Status”

CSMC Cardiovascular Graduate Teaching, May 26, 2017: “Atherosclerosis”

CSMC Fellows Lecture, June 12, 2017: “Basic Hemodynamics”

Internal Medicine Lecture Series, CSMC, June 27, 2017: “Cardiac Tamponade”

Internal Medicine Lecture Series, CSMC, July 18, 2017: “Aortic Dissection”

Hemodynamics Lecture with fellows, CSMC, August 2, 2017

CSMC Lecture Series with Fellows, August 21, 2017: Complications of Acute MI – part 1

CSMC Lecture Series with Fellows, September 11, 2017: EKG in AMI

CSMC Lecture Series with Fellows, October 2, 2017: Atherosclerosis: Pathogenesis and Rx

CSMC Lecture Series with Fellows, October 9, 2017: Images Part 1

12th International Congress on Innovations in Coronary Artery Disease (ICCAD), Venice, Italy, October 15-17, 2017: “ANGPTL3: A Novel Lipid Modifying Target”

CSMC Lecture Series with Fellows, October 23, 2017: Images Part 2

CSMC Lecture Series with Fellows, October 30, 2017: Images Part 3

CSMC Lecture Series with Fellows, November 6, 2017: Images Part 4

Controversies & Advances in the Treatment of Cardiovascular Disease Symposium, Beverly Hills, CA, November 17-18, 2017: "ANGPTL3: A Novel Lipid Modifying Target"

CSMC Lecture Series with Fellows, December 18, 2017: Complications of Acute MI – Part 2

INVITATIONS RECEIVED BUT DECLINED (2006-2012):

4th International vulnerable Plaque Meeting, Capri, Italy 2006

28th World Congress of Internal Medicine, Taiwan, November 2006

Angioplasty Summit Asia Pacific Korea 2006: Vulnerable Plaque

World Congress of Cardiology, Barcelona, Spain 2006: Vaccine for Atherosclerosis

American Society of Echocardiography, June 2007, Seattle: Vulnerable Plaque

The 16th Asia Pacific Congress of Cardiology, December 13-16, 2007, Taiwan

Invited Speaker: World Congress of Cardiology, May 2008, Argentina

Invited Speaker: ACC International Meeting in Curitiba, Brazil, September 2008

Invited Speaker: Mayo Clinic Meeting in Scottsdale, January 2009

Invited Speaker: Mayo Clinic Meeting in Sedona, Arizona, August 2009

Invited speaker: Society of CT, July 2011

World Congress of Cardiology, Dubai 2012

TCT 2012 - Eighth International Conference (in the 17th year of our Academics) of The Heart Care Clinic: CIMS (Care Institute of Medical Sciences) CIMS-CON 2012 from January 6-8, 2012 to be held in Ahmedabad, India

Mexican National Congress of Cardiology, Acapulco, Mexico December 2012

PUBLICATIONS

A. PEER REVIEWED

1. Gray RJ, Harris WS, **Shah PK**, Miyamoto ATM, Matloff JM, Swan HJC: Coronary sinus blood flow and sampling for detection of unrecognized myocardial ischemia and injury. *Circulation* 56(3 Suppl): II-58-61, 1977.
2. Pichler M, **Shah PK**, Swan HJC: [Left ventricular function in the first 24 hours of acute transmural myocardial infarction.] *Deutsche Medizinische Wochenschrift* 104(16):577-582, 1979.
3. Cohen MV, **Shah PK**, Spindola-Franco H: Angiographic-echocardiographic correlation in mitral valve prolapse. *Am Heart J* 97 (1):43-52, 1979.
4. Chew CYC, Collett J, **Shah PK**, Singh BN: Hemodynamic effects of intravenous timolol in coronary artery disease. *Clin Pharmacol Ther* 26(3):330-338, 1979.
5. **Shah PK**, Pichler M, Berman DS, Maddahi J, Peter T, Singh BN, Swan HJC: Non-invasive identification of a high risk subset of patients with acute inferior myocardial infarction. *Am J Cardiol* 46(6):915-921, 1980.
6. **Shah PK**, Pichler M, Berman DS, Singh BN, Swan HJC: Left ventricular ejection fraction determined by radionuclide ventriculography in early stages of first transmural myocardial infarction: relation to short-term prognosis. *Am J Cardiol* 45(3): 542-546, 1980.
7. Shellock FG, **Shah PK**, Berman DS, Rubin SA, Singh BN, Swan HJC: Sustained benefits of oral pentaerythritol tetranitrate on ventricular function in chronic congestive heart failure. *Clin Pharmacol Ther* 28(4):436-440, 1980.
8. **Shah PK**, Shellock FG, Berman DS, Rubin SA, Singh BN, Swan HJ. Sustained beneficial effects of oral pentaerythritol tetranitrate on ventricular function in chronic congestive heart failure. *Nouvelle Presse Medicale*, 9(34 Suppl):2447-50, 1980.
9. Nemerovski M, **Shah PK**: Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration. *Cardiology* 67(3):180-189, 1981.
10. Ganz W, Buchbinder N, Marcus H, Mondkar A, O'Connor L, Maddahi J, Berman D, Charuzi Y, Beeder C, Peter T, **Shah PK**, Shell WE: Intracoronary thrombolysis in evolving myocardial infarction. *Herz* 6(1):37-43, 1981.
11. Gray R, **Shah PK**, Singh B, Conklin C, Matloff JM. Low cardiac output states after open heart surgery. Comparative hemodynamic effects of dobutamine, dopamine, and norepinephrine plus phentolamine. *Chest*, 80(1):16-22, 1981.
12. Maddahi J, Ganz W, Ninomiya K, Hashida J, Fishbein MC, Mondkar A, Buchbinder N, Marcus H, Geft I, **Shah PK**, Rozanski A, Swan HJC, Berman DS: Myocardial salvage by intracoronary thrombolysis in evolving myocardial

- infarction: evaluation using intracoronary injection of thallium-201. *Am Heart J* 102(4):664-674, 1981.
13. Ganz W, Ninomiya K, Hashida J, Fishbein M, Buchbinder N, Marcus H, Mondkar A, Maddahi J, **Shah PK**, Berman D, Charuzi Y, Geft I, Shell W, Swan HJC: Intracoronary thrombolysis in acute myocardial infarction: Experimental background and clinical experience. *Am Heart J* 102(6 Pt 2):1145-1149, 1981.
 14. Gray R, **Shah PK**, Singh B, Conklin C, Matloff JM. Low cardiac output states after open heart surgery. Comparative hemodynamic effects of dobutamine, dopamine, and norepinephrine plus phentolamine. *Chest*, 80(1):16-22, 1981.
 15. Swan HJC, **Shah PK**, Rubin S: The role of vasodilators in the changing phases of acute myocardial infarction. *Am Heart J* 103(4 Pt 2):707-715, 1982.
 16. Nemerovski M, **Shah PK**, Pichler M, Berman DS, Shellock F, Swan HJC: Radionuclide assessment of sequential changes in left and right ventricular function following first acute transmural myocardial infarction. *Am Heart J* 104(4 Pt 1):709-717, 1982.
 17. **Shah PK**, Abdulla A, Pichler M, Shellock F, Berman D, Singh BN, Swan HJC: Effects of nitroprusside-induced reduction of elevated preload and afterload on global and regional ventricular function in acute myocardial infarction. *Am Heart J* 105(4):531-542, 1983.
 18. Ganz W, Geft I, Maddahi J, Berman D, Charuzi Y, **Shah PK**, Swan HJC: Nonsurgical reperfusion in evolving myocardial infarction. *J Am Coll Cardiol* 1(5):1247-1253, 1983.
 19. Seino Y, Staniloff HM, Shell WE, Mickle D, **Shah PK**, Vyden JK: Evaluation of a QRS scoring system in acute myocardial infarction: Relation to infarct size, early stage left ventricular ejection fraction, and exercise performance. *Am J Cardiol* 52(1):37-42, 1983.
 20. Pichler M, **Shah PK**, Peter T, Singh B, Berman D, Shellock F, Swan HJC: Wall motion abnormalities and electrographic changes in acute transmural myocardial infarction: Implications of reciprocal ST-segment depression. *Am Heart J* 106(1)(5 Pt 1):1003-1009, 1983.
 21. Bateman TM, Czer LSC, Gray RJ, Maddahi J, Raymond MJ, Geft IL, Ganz W, **Shah PK**, Berman DS: Transient pathologic Q waves during acute ischemic events: an electrocardiographic correlate of stunned but viable myocardium. *Am Heart J* 106(6):1421-1426, 1983.

22. Geft IL, **Shah PK**, Rodriguez L, Hulse S, Maddahi J, Berman DS, Ganz W: ST elevations in leads V₁-V₅ due to right coronary artery occlusion and right ventricular infarction and their mechanism. *Am J Cardiol* 53(8):991-996, 1984.
23. Ganz W, Geft I, **Shah PK**, Lew AS, Rodriguez L, Weiss T, Maddahi J, Berman DS, Charuzi Y, Swan HJC: Intravenous streptokinase in evolving myocardial infarction. *Am J Cardiol* 53:1209-1217, 1984.
24. Siegel RJ, **Shah PK**, Fishbein MC: Idiopathic restrictive cardiomyopathy. *Circulation* 70(2):165-169, 1984.
25. Eigler N, Maurer G, **Shah PK**: Effect of early systemic thrombolytic therapy on left ventricular mural thrombus formation in acute anterior myocardial infarction. *Am J Cardiol* 54(3):261-263, 1984.
26. Lew AS, Weiss AT, **Shah PK**, Fishbein MC, Berman DS, Maddahi J: Extensive myocardial salvage and reversal of cardiogenic shock following reperfusion of the left main coronary artery by intravenous streptokinase. *Am J Cardiol* 54(3):450-452, 1984.
27. Lew AS, Neer T, Rodriguez L, Geft I, **Shah PK**, Ganz W: Clinical failure of streptokinase due to an unsuspected high titer of antistreptokinase antibody. *J Am Coll Cardiol* 4(1):183-185, 1984.
28. Doherty NE, Ades A, **Shah PK**, Siegel RJ: Hypothermia as a consequence of acute myocardial infarction. *Ann Intern Med* 101(6):797-798, 1984.
29. Siegel RJ, **Shah PK**, Nathan M, Rodriguez L, Shell WE: Prostaglandin E-1 infusion in unstable angina: Effects on anginal frequency and cardiac function. *Am Heart J* 108(4 Pt 1):863-868, 1984.
30. Amin DK, **Shah PK**, Hulse S, Shellock FG, Swan HJC: Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotoxic drug, in patients with chronic severe heart failure. *Am Heart J* 108(5):1285-1292, 1984.
31. Amin DK, **Shah PK**, Shellock FG, Hulse S, Brandon G, Spangenberg R, Swan HJC: Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure. *Am Heart J* 109(1):91-98, 1985.
32. Riedinger MS, Shellock FG, **Shah PK**, Weissfeld AS, Ellrodt AG: Sterility of prefilled thermolysis cardiac output syringes maintained at room and ice temperatures. *Heart & Lung* 14(1):8-11, 1985.
33. Lew AS, Weiss AT, **Shah PK**, Peter T, Maddahi J, Ganz W, Swan HJC, Berman DS: Precordial ST segment depression during acute inferior myocardial

- infarction: early thallium-201 scintigraphic evidence of posterolateral or inferoseptal ischemia. *J Am Coll Card* 5(2 Pt 1):203-209, 1985.
34. Lew AS, Geft IL, **Shah PK**, Rodriguez L, Ganz W: Intracoronary and intravenous streptokinase in acute myocardial infarction: A comparative report. *European Heart Journal* 6 (Suppl E):223-228, 1985.
 35. **Shah PK**, Amin DK, Hulse S, Shellock F, Swan HJC: Inotropic therapy of refractory congestive heart failure with oral fenoximone (MLD-17,043): poor long term results despite early hemodynamic and clinical improvement. *Circulation* 71(2):326-331, 1985.
 36. Lew AS, Maddahi J, **Shah PK**, Weiss AT, Peter T, Berman DS, Ganz W: Factors that determine the direction and magnitude of precordial ST segment deviations during inferior wall acute myocardial infarction. *Am J Cardiol* 55(8):883-888, 1985.
 37. Amin DS, **Shah PK**, Hulse S, Shellock FG: Comparative acute hemodynamic effects of intravenous MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure. *Am Heart J* 109(5 Pt 1):1006-1012, 1985.
 38. Shellock FG, Riedinger MS, Fishbein MC, **Shah PK**: Prevalence of brown adipose tissue in chronic congestive heart failure secondary to coronary heart disease. *Am J Cardiol* 56(1):197-198, 1985.
 39. **Shah PK**, Amin DK, Horn E: Adverse clinical and hemodynamic effects of oral Levodopa in chronic congestive heart failure. *Am Heart J* 110(2):488-489, 1985.
 40. Lew AS, Laramée P, Cercek B, Rodriguez L, **Shah PK**, Ganz W: The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in acute myocardial infarction. *Circulation* 72(5):1053-1058, 1985.
 41. **Shah PK**, Maddahi J, Berman DS, Pichler M, Swan HJC: Scintigraphically detected predominant right ventricular dysfunction in acute myocardial infarction: Clinical, hemodynamic correlates and implications for therapy and prognosis. *J Am Coll Cardiol* 6(6):1264-1272, 1985.
 42. Lew AS, Laramée P, Cercek B, **Shah PK**, Ganz W: The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction. *Circulation* 72(6):1321-1326, 1985.
 43. Weiss AT, Maddahi J, Lew AS, **Shah PK**, Ganz W, Swan HJC, Berman DS: Reverse redistribution of thallium-201: a sign of nontransmural myocardial infarction with patency of the infarct-related coronary artery. *J Am Coll Cardiol* 7(1):61-67, 1986.

44. Goldberger M, Tabak SW, **Shah PK**: Clinical experience with intra-aortic balloon counterpulsation in 112 consecutive patients. *Am Heart J* 111(3):497-502, 1986.
45. Lew AS, Laramée P, **Shah PK**, Maddahi J, Peter T, Ganz W: Ratio of ST-segment depression in V₂ to ST-segment elevation in lead AVF in evolving inferior acute myocardial infarction: an aid to the early recognition of right ventricular ischemia. *Am J Cardiol* 57(13):1047-1051, 1986.
46. Lew AS, Berberian L, Cercek B, Lee S, **Shah PK**, Ganz W: Elevated serum D dimer, a degradation product of cross-linked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction. *J Am Coll Cardiol* 7(6):1320-1324, 1986.
47. **Shah PK**, Maddahi J, Staniloff H, Ellrodt AG, Pichler M, Swan HJC, Berman DS: Variable spectrum and prognostic implications of left and right ventricular ejection fractions in patients with and without clinical heart failure after acute myocardial infarction. *Am J Cardiol* 58(6):387-393, 1986.
48. Lew AS, Cercek B, Hod H, **Shah PK**, Ganz W: Usefulness of residual plasma fibrinogen after intravenous streptokinase for predicting delay or failure of reperfusion in acute myocardial infarction. *Am J Cardiol* 58(9): 680-685, 1986.
49. Gibson RS, Boden WE, and the **Diltiazem Reinfarction Study Group** (including University of California, Los Angeles — **Prediman Shah**, Devendra Amin, and Sharon Hulse.). Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized multicenter trial. *N Engl J Med* 315(7):423-9, 1986.
50. Hod H, Lew AS, Keltai M, Cercek B, Geft IL, **Shah PK**, Ganz W: Early atrial fibrillation during evolving acute myocardial infarction: a consequence of impaired left atrial perfusion. *Circulation* 75(1):146-150, 1987.
51. **Shah PK**, Nalos P, Peter T: Atropine resistant post infarction complete AV block: possible role of adenosine and improvement with aminophylline. *Am Heart J* 113(1):194-195, 1987.
52. Lew A, Hod H, Cercek B, **Shah PK**, Ganz W: Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. *Am J Cardiol* 59(1):1-5, 1987.
53. Bairey CN, **Shah PK**, Lew AS, Hulse S: Electrocardiographic differentiation of occlusion of the left circumflex versus the right coronary artery as a cause of inferior acute myocardial infarction. *Am J Cardiol* 60(7):456-459, 1987.

54. Lew AS, Hod H, Cercek B, **Shah PK**, Ganz W: Inferior ST segment changes during acute anterior myocardial infarction: a marker of the presence or absence of concomitant inferior wall ischemia. *J Am Coll Cardiol* 10(3):519-526, 1987.
55. Cercek B, Lew AS, Laramée P, **Shah PK**, Peter TC, Ganz W: Time course and characteristics of ventricular arrhythmias following reperfusion in acute myocardial infarction. *Am J Cardiol* 60(4):214-218, 1987.
56. Mohsenifar Z, Amin D, Jasper AC, **Shah PK**, Koerner S: Dependence of oxygen consumption on oxygen delivery in patients with chronic congestive heart failure. *Chest* 92(3):447-450, 1987.
57. Halpern SM, **Shah PK**, Lehrman S, Goldberg HS, Jasper AC, Koerner SK: Prostaglandin E1 as a screening vasodilator in primary pulmonary hypertension. *Chest* 92(4):686-691, 1987.
58. Lew AS, Cercek B, Lewis BS, Hod H, **Shah PK**, Ganz W: Efficacy of a two-hour infusion of 150 mg tissue plasminogen activator in acute myocardial infarction. *Am J Cardiol* 60(16):1225-1229, 1987.
59. Lewis BS, Ganz W, Laramée P, Cercek B, Hod H, **Shah PK**, Lew AS: Usefulness of a rapid initial rise of plasma creatine kinase activity as a marker of reperfusion during thrombolytic therapy for acute myocardial infarction. *Am J Cardiol* 62(1):20-24, 1988.
60. Uretsky FB, Shaver JA, Liang CS, Amin D, **Shah PK**, Levine TB, Walinsky P, LeJemtel T, Linnemeier T, Rush JE, et al: Modulation of hemodynamic effects with a converting enzyme inhibitor: Acute hemodynamic dose-response relationship of the experimental angiotensin converting enzyme inhibitor lisinopril with observations on long-term clinical, functional, and biochemical responses. *Am Heart J* 116(2 Pt 1):480-488, 1988.
61. Weiss AT, Maddahi J, **Shah PK**, Lew AS, Swan HJC, Ganz W, Berman DS: Exercise-induced ischemia in the streptokinase reperfused myocardium: relationship to extent of salvaged myocardium and degree of residual coronary stenosis. *Am Heart J* 118 (1):9-16, 1989.
62. Berman DS, Kiat H, Maddahi J, **Shah PK**: Radionuclide imaging of myocardial perfusion and viability in assessment of acute myocardial infarction. *Am J Cardiol* 64(4):9B-16B, 1989.
63. Mohsenifar Z, Amin DK, **Shah PK**: Regional distribution of lung perfusion and ventilation in patients with chronic congestive heart failure and its relationship to cardiopulmonary hemodynamics. *Am Heart J* 117(4):887-891, 1989.

64. Lepor NE, Amin DK, Berberian L, **Shah PK**: Does nitroglycerin induce heparin resistance? *Clin Cardiol* 12(8):432-434, 1989.
65. Uretsky BF, Shaver JA, Liang CS, Amin D, **Shah PK**, Levine TB, Walinsky P, LeJemtel T, Linnemeier T. Lisinopril for severe congestive heart failure. *Am J Cardiol* 63(8):8D-11D, 1989.
66. Stone CK, Uretsky BF, Linnemeier TJ, **Shah PK**, Amin DK, Snapinn SM, Rush JE, Langendorfer A, Liang CS: Hemodynamic effects of Lisinopril after long-term administration in congestive heart failure. *Am J Cardiol* 63(9):567-70, 1989.
67. Maurer G, Czer LSC, **Shah PK**, Chaux A: Assessment by Doppler color flow mapping of ventricular septal defect after acute myocardial infarction. *Am J Cardiol* 64(10):668-671, 1989.
68. Weingarten SR, Ermann B, Riedinger MS, **Shah PK**, Ellrodt AG: Selecting the best triage rule for patients hospitalized with chest pain. *Am J Med* 87(5):494-500, 1989.
69. Coll GE, **Shah PK**, Siegel RJ: Cinefluoroscopy of the aortic valve: an accurate noninvasive method of assessing critical aortic stenosis in the elderly. *J Invasive Cardiol* 2(5):193-198, 1990.
70. Lew AS, Maddahi J, **Shah PK**, Cercek B, Ganz W, Berman DS: Critically ischemic myocardium in clinically stable patients following thrombolytic therapy for acute myocardial infarction: potential implications for early coronary angioplasty in selected patients. *Am Heart J* 120(5):1015-1025, 1990.
71. Stone GW, Griffin B, **Shah PK**, Berman DS, Siegel RJ, Cook SL, Maurer G: Prevalence of unsuspected mitral regurgitation and left ventricular diastolic dysfunction in patients with coronary artery disease and acute pulmonary edema associated with normal or depressed left ventricular systolic function. *Am J Cardiol* 67(1):37-41, 1991.
72. Griffin B, **Shah PK**, Ferguson J, Rubin S: Incremental prognostic value of exercise hemodynamic variables in chronic congestive heart failure secondary to coronary artery disease or to dilated cardiomyopathy. *Am J Cardiol* 67(9):848-853, 1991.
73. Griffin BP, **Shah PK**, Diamond G, Berman DS, Ferguson J: Incremental prognostic accuracy of clinical, radionuclide and hemodynamic data in acute myocardial infarction. *Am J Cardiol* 68(8):707-712, 1991.
74. Lightsey DM, **Shah PK**, Forrester JS, Michael TA: A human immunodeficiency virus-resistant airway for cardiopulmonary resuscitation. *Am J Emerg Med* 10(1) 73-77, 1991.

75. **Shah PK**, Amin J: A low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. *Circulation* 85(4):1279-1285, 1992.
76. Anderson JL, Becker LC, Sorensen SG, Karagounis LA, Browne KF, **Shah PK**, Morris DC, Finter DJ, Mueller HS, Ross AM, et al: Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3. *J Am Coll Cardiol* 20(4):753-766, 1992.
77. Baratz DM, Westbrook PR, **Shah PK**, Mohsenifar Z: Effect of nasal continuous positive airway pressure on cardiac output and oxygen delivery in patients with congestive heart failure. *Chest* 102(5):1397-1401, 1992.
78. **Shah PK**, Cercek B, Lew A, Ganz W: Angiographic validation of bedside markers of reperfusion. *J Am Coll Cardiol* 21(1):55-61, 1993.
79. Schmidt D, **Shah PK**: Accurate detection of elevated left ventricular filling pressure by a simplified bedside application of the Valsalva maneuver. *Am J Cardiol* 71(5):462-465, 1993.
80. Ameli S, Kaul S, Castro L, Arora C, Mirea A, **Shah PK**: Effects of percutaneous transluminal coronary angioplasty on circulating endothelin levels. *Am J Cardiol* 72(18):1352-1356, 1993.
81. Ameli S, Hultgardh-Nilsson A, Cercek B, **Shah PK**, Forrester J, Ageland L, Nilsson J: Recombinant apolipoprotein A-1 Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. *Circulation* 90(4):1935-1941, 1994.
82. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, **Shah PK**, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, et al: Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. *J Am Coll Cardiol*, 24(7): 1602-1610, 1994.
83. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Maihac A, Weng D, **Shah PK**, Badimon L: Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. *J Am Coll Cardiol* 23(7): 1562-1569, 1994.
84. Zahger D, Cercek B, Cannon CP, Jordan M, **Shah PK**: Thrombolytic therapy for acute myocardial infarction in patients with prior coronary bypass surgery: results from the thrombolysis in myocardial infarction (TIMI) 4 trial. *J Thromb Thrombolysis* 2(1):45-50, 1995.

85. Zahger D, Cercek B, Cannon CP, Jordan M, Davis V, Braunwald E, **Shah PK**: How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial). *Am J Cardiol* 75(4) 232-236, 1995.
86. **Shah PK**, Falk E, Badiman JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. *Circulation* 92(6), 1565-1569, 1995.
87. Zahger D, Fishbein MC, Garfinkel LI, **Shah PK**, Forrester JS, Regnstrom J, Yano J, Cercek B: VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. *Circulation* 92(5):1269-1273, 1995.
88. **Shah PK**, Parikh A: New thrombin inhibiting strategies for coronary artery disease. *Indian Heart J* 47(4):381-386, 1995
89. Zahger D, Karagounis LA, Cercek B, Anderson JL, Sorensen S, Moreno F, **Shah PK**: Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction. *Am J Cardiol* 76(11):749-752, 1995
90. Stiko A, Regnstrom J, **Shah PK**, Cercek B, Nilsson J: Active oxygen species and lysophosphatidylcholine are involved in oxidized low density lipoprotein activation of smooth muscle cell DNA Synthesis. *Arterioscler Thromb Vasc Biol* 16(2):194-200, 1996.
91. Calara F, Ameli S, Hultgardh-Nilsson A, Cercek B, Kupfer J, Hedin U, Forrester JS, **Shah PK**, Nilsson J: Autocrine induction of DNA synthesis by mechanical injury of cultured smooth muscle cells. Potential role of FGF and PDGF. *Arterioscler Thromb Vasc Biol* 16(2):187-193, 1996.
92. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, **Shah PK**, Nilsson J: Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. *Arterioscler Thromb Vasc Biol* 16(8):1074-1079, 1996.
93. Antman EM for the **TIMI 9B Investigators** (including Cedars-Sinai Medical Center, Los Angeles, Calif. **Prediman K. Shah, MD**; Mitchell Gheorghiu, MD): Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B Trial. *Circulation* 94(5):911-921, 1996.

94. Kaul S, Makkar RR, Nakamura M, Litvack FI, **Shah PK**, Forrester JS, Hutsell TC, Eigler NL: Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study. *Circulation* 94(9):2228-2234, 1996.
95. Cercek B, Yamashita M, Dimayuga P, Zhu J, Fishbein MC, Kaul S, **Shah PK**, Nilsson J, Regnstrom J: Nuclear factor-kappaB activity and arterial response to balloon injury. *Atherosclerosis* 131(1):59-66, 1997.
96. Makkar R, Litvack F, Eigler NL, Nakamura M, Ivey PA, Forrester JS, **Shah PK**, Jordan RE, Kaul S: Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin and aspirin in an ex-vivo canine arteriovenous shunt model of stent thrombosis. *Circulation* 95(4):1015-1021,1997.
97. Yumi K, Fagin JA, Yamashita M, Fishbein MC, **Shah PK**, Kaul S, Niu W, Nilsson J, Cercek B: Direct effects of somatostatin analog octreotide on insulin-like growth factor-I in the arterial wall. *Lab Invest* 76(3):329-338,1997.
98. Naqvi TZ, Hachamovitch R, Berman D, Buchbinder N, Kiat H, **Shah PK**: Does the presence and site of myocardial ischemia on perfusion scintigraphy predict the occurrence and site of future myocardial infarction in patients with stable coronary artery disease? *Am J Cardiol* 79(11):1521-1524, 1997.
99. Kaul S, Naqvi TZ, Fishbein MC, Cercek B, Badimon JJ, Hutsell TC, Thomas S, Molloy M, **Shah PK**. Local delivery of an ultra-short-acting nitric oxide-releasing compound, DMHD/NO, is highly effective in inhibiting acute platelet-thrombus formation on injured arterial strips. *J Cardiovasc Pharmacol Ther* 2(3):181-194, 1997.
100. Papuchis G, Etter S, Feldman R, Merchant B, Cole P, Coulter L, Moore P, Platt M, Parker E, Frey M, Browning T, Rogers W, Morgan T, Laxson D, Iacarella C, Christenson B, Schweiger M, Burkott B, Warwick D, Chadow H, Matheson M, Henry T, Bosjolie C, Knox L, Hochman J, Leber R, Palozzi A, McAnulty M, Tormey D, Freeman I, Teplitz L, Alex M, Thompson C, Hooper C, Mercier B, Cutler D, Sprott D, Greene R, Healy E, Perry V, Becker R, Ball S, Kirshenbaum JM, Jarvis J, Falco T, Rush K, Zaleski C, Herson S, Carey G, McKay R, Cloutier J, Borzak S, Held C, Smith S, Douthat L, Shook T, Junio L, Kutscher A, McMahan J, Bengtson J, Adolphson M, Kwan T, Julien R, Fung A, Buller C, Davies C, Van Beek C, **Shah, PK**, Gheorghiu M, Bianchi P, Sanders K, Anderson J, Allen A, Magorien R, McCloud L, Thomas AM, Gibson CM, Lapsley D, Marshall J, Lane A, Grassman E, GalbraithE, Chakko S, Koggan D, Kawalsky D, Arnold M, Bishop R, Brunelle T, Arsenault P, Andersoon HV, weigelt L, Manning J, Steingart R, Bilodeau S, Coglianese, ME, Frey M, Browning T, Dixon EW, Neal R, Mueller H, Cosico J, Kunkel L, Macina G, Kikel M, Pier M, Rogers CP, Dolan S, Nordstrom S, Tierstein P, Haas G, Bersohn M, Silbar C: Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The

- Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. *J Am Coll Cardiol* 29(7):1474-1482, 1997.
101. Cannon CP, Sharis PJ, Schweiger MJ, McCabe CH, Diver DJ, **Shah PK**, Sequeira RF, Greene RM, Perritt RL, Poole WK, Braunwald E: Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). *Thrombolysis In Myocardial Infarction*. *Am J Cardiol* 80(6):696-699, 1997.
 102. Nilsson J, Calara F, Regnstrom J, Hultgardh-Nilsson A, Ameli S, Cercek B, **Shah PK**: Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. *J Am Coll Cardiol* 30(7):1886-1891, 1997.
 103. Kaul S, Naqvi TZ, Fishbein MC, Cercek B, Badimon JJ, Hutsell TC, Forrester JS, Thomas S, Molloy M, **Shah PK**: Comparative effects of NO donors and aspirin on arterial -injury induced platelet-thrombus formation: an ex-vivo rabbit extracorporeal perfusion study. *J Cardiovasc Pharmacol Ther* 2(3):181-194, 1997.
 104. Forrester JS, **Shah PK**. Lipid lowering versus revascularization: an idea whose time (for testing) has come. *Circulation* 96(4):1360-1362, 1997.
 105. Mueller HS, Chatterjee K, Davis KB, Fifer MA, Franklin C, Greenberg MA, Labovitz AJ, **Shah PK**, Tuman KJ, Weil MH, Weintraub WS. ACC expert consensus document. Present use of bedside right heart catheterization in patients with cardiac disease. *J Am Coll Cardiol* 32(3):840-864, 1998.
 106. LaFleur DW, Chiang J, Fagin JA, Schwartz SM, **Shah PK**, Wallner K, Forrester JS, Sharifi BG: Aortic smooth muscle cells interact with Tenascin-C through its fibrinogen-like domain. *J Biol Chem* 272(52):32798-32803, 1998.
 107. **Shah PK**, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B: Effect of recombinant apolipoprotein A-1 (Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. *Circulation* 97(8):780-785, 1998.
 108. Makkar RR, Eigler NL, Kaul S, Frimerman A, Nakamura M, **Shah PK**, Forrester JS, Herbert JM, Litvack F. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. *Eur Heart J*, 19(10):1538-46, 1998.
 109. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E, and the **TIMI 12 Investigators**: A randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrifiban, in patients after an acute

- coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. *Circulation*: 97(4):340-349, 1998.
110. Nilsson J, Dahlgren B, Ares M, Westman J, Hultgardh Nilsson A, Cercek B, **Shah PK**: Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor. *Arterioscler Thromb Vasc Biol* 18(1):13-19, 1998.
 111. **Shah PK**: Plaque size, vessel size and plaque vulnerability: bigger may not be better [editorial]. *J Am Coll Cardiol* 32(3):663-664, 1998.
 112. Calara F, Dimayuga P, Niemann A, Thyberg J, Diczfalusy U, Witztum JL, Palinski W, **Shah PK**, Cercek B, Nilsson J, Regnstrom J: An animal model to study local oxidation of LDL and its biological effects in the arterial wall. *Arterioscler Thromb Vasc Biol* 18(6):884-93, 1998.
 113. Naqvi TZ, **Shah PK**, Ivey PA, Molloy MD, Linn P, Linker-Israeli M, Cercek B, Kaul S: Therapeutic concentrations of heparin augment platelet activation at the time of coronary angiography. *J Cardiovasc Pharmacol Ther* 3(2):91-102, 1998.
 114. Wallner K, Li C, **Shah PK**, Fishbein MC, Forrester JS, Kaul S, Sharifi BG. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. *Circulation*, 99(10):1284-1289, 1999.
 115. Rajavashisth TB, Liao J, Galis ZS, Tripathi S, Laufs U, Tripathi J, Chai NN, Xu XP, Jovinge S, **Shah PK** and Libby P: Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. *J Biol Chem* 274(17):11924-11929, 1999
 116. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, **Shah PK**: Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages *Circulation* 99(8):993-998, 1999.
 117. Rajavashisth T, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, Fishbein MC, Kaul S, Cercek B, Sharifi B, **Shah PK**: Membrane type 1-matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory Mediators. *Circulation* 99:3103-3109, 1999.
 118. Yamashita M, Dimayuga P, Kaul S, **Shah PK**, Regnstrom J, Nilsson J, Cercek B: Phosphatase activity in the arterial wall following balloon injury: effect of somatostatin analog octreotide. *Lab Invest* 79(8):935-944, 1999.
 119. Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, **Shah PK**, Kaul S. Oral magnesium supplementation inhibits platelet-

- dependent thrombosis in patients with coronary artery disease. *Am J Cardiol*. 84(2):152-156, 1999.
120. Dimayuga P, Zhu J, Oguchi S, Chyu KY, Xu XO, Yano J, **Shah PK**, Nilsson J, Cercek B: Reconstituted HDL containing human apolipoprotein A-1 reduced VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. *Biochem Biophys Res Commun* 264(2):465-468, 1999.
 121. Wallner K, Li C, Fishbein MC, **Shah PK**, Sharifi BG: Arterialization of human vein grafts is associated with Tenascin-C expression. *J Am Coll Cardiol* 34(3):871-875, 1999.
 122. Chyu KY, Dimayuga P, Zhu J, Nilsson J, Kaul S, **Shah PK**, Cercek B: Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. *Circ Res* 85(12):1192-1198, 1999.
 123. Naqvi TZ, **Shah PK**, Ivey PA, Molloy MD, Thomas AM, Panicker S, Ahmed A, Cercek B, Kaul S: Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. *Am J Cardiol* 84(9):1011-1017, 1999
 124. Makkar R, Goff B, Eigler N, Sebastian M, Fischell T, Barr L, D'Haem C, **Shah PK**, Efron MB, Litvack F: Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study. *Catheter Cardiovasc Inter* 48(4):430-434, 1999.
 125. Meisel SR, Shimon I, Edgington TS, Melmed S, Cercek B, **Shah PK**: Leukaemia inhibitory factor enhances tissue factor expression in human monocyte-derived macrophages: a gp130-mediated mechanism. *Br J Haematol* 107(4):747-755, 1999.
 126. Chyu KY, Dimayuga P, Zhu J, Nilsson J, Kaul S, **Shah PK**, Cercek B: Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. *Circ Res*. 85(12):1192-1198, 1999.
 127. **Shah PK**: Circulating markers of inflammation for vascular risk prediction: Are they ready for prime time. *Circulation* 101(15):1758-1759, 2000.
 128. Kaul S, Cercek B, Rengstrom J, Xu XP, Molloy MD, Dimayuga P, Parikh AK, Fishbein MC, Nilsson J, Rajavashisth TB, **Shah PK**: Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. *J Am Coll Cardiol* 35(2):493-501, 2000.

129. Shechter M, Bairey Merz CN, Paul-Labrador MJ, **Shah PK**, Kaul S: Plasma Apolipoprotein B Levels Predict Platelet-Dependent Thrombosis in Patients with Coronary Artery Disease. *Cardiology* 92(3):151-155, 2000.
130. Kaul S, **Shah PK**: Low-molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared to unfractionated heparin? *J Am Coll Cardiol* 35(7):1699-712, 2000
131. Matetzky S, Tani S, Kangavari S, Dimayuga P, Yano J, Xu H, Chyu KY, Fishbein MC, **Shah PK**, Cercek B: Smoking increases tissue factor expression in atherosclerotic plaques: Implications for plaque thrombogenicity. *Circulation* 102(6):602-4, 2000.
132. Matetzky S, Sharir T, Domingo M, Noc M, Chyu KY, Kaul S, Eigler N, **Shah PK**, Cercek B: Elevated troponin I level on admission is associated with adverse outcome of primary angioplasty in acute myocardial infarction. *Circulation* 102(14):1611-6, 2000.
133. Rajavashisth T, Jovinge S, Chai NN, Liu M, Shukla A, Zelby L, Harpf A, **Shah PK**: Stable and preferential transfer of genes to granulocytic cells by lentiviral vectors in a mouse bone-marrow transplantation model. *Molecular Therapy*, 2000.
134. Chai NN, Liu M, Arun K, Shukla AK, Kumar A, **Shah PK**, Rajavashisth TP: Adenovirus-mediated delivery of antisense *c-fms*, the receptor for macrophage colony-stimulating factor, inhibits survival of cultured macrophages. *Molecular Therapy*, 2000.
135. Meisel SR, Xu XP, Edgington TS, Kaul S, Lee S, Cercek B, **Shah PK**: Differentiation of adherent human monocytes into macrophages markedly enhances tissue factor protein expression and procoagulant activity. *Cardiol Res*, 2000.
136. Meisel SR, Quyang Y, Fishbein MC, Edgington TS, Ruan XM, Cercek B, **Shah PK**, Chaux A: Tissue factor expression in veno-arterial grafts in the hypercholesterolemic rabbit: a potential mechanism for early vein graft failure *Circulation*, 2000.
137. Wallner K, Sharifi BG, **Shah PK**, Noguchi S, DeLeon H, Wilcox JN: Adventitial remodeling after angioplasty is associated with expression of tenascin mRNA by adventitial myofibroblasts. *J Am Coll Cardiol*, 37(2):655-61, 2001
138. Rukshin V, Babak A, **Shah PK**, Tsang VT, Shechter M, Cercek B, Kaul S: Intravenous magnesium in experimental stent thrombosis in swine. *Arteriosclerosis, Thrombosis and Vascular Biology* 2001 ;21(9):1544-9138.

139. Crisby, M; Nordin-Fredriksson, G; **Shah, P. K**; Yano, J; Zhu, J; Nilsson, J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. *Circulation*. 2001 Feb 20;103(7):926-33.
140. Remskar M, Li H, Chyu KY, **Shah PK**, Cercek B: Absence of CD40 signaling is associated with an increase in intimal thickening after arterial injury. *Circ Res*. 2001 Mar 2;88(4):390-4.
141. **Shah PK**, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, Drake S, Cercek B: High-dose recombinant apolipoprotein a-i(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice: potential implications for acute plaque stabilization. *Circulation*. 2001 Jun 26;103(25):3047-50.
142. Matetzky S, Noc M, Domingo M, Eigler N, Kar S., **Shah PK**, Cercek B: Primary angioplasty in octogenarians. *Am J Cardiol*. 2001 Sep 15;88(6):680-3.
143. **Shah PK**, Kaul S, Nilsson J, Cercek B: Exploiting the vascular protective effects of HDL and its apolipoproteins: An idea whose time for testing is here. Part I *Circulation*, 2001;104:2376
144. **Shah PK**, Kaul S, Nilsson J, Cercek B: Exploiting the vascular protective effects of HDL and its apolipoproteins: An idea whose time for testing is here. Part II. *Circulation*, 2001;104:2498 (**Featured on the Cover of Circulation**)
145. **Shah PK**, Galis Z: MMP-hypothesis of plaque rupture: players keep piling up but questions remain. *Circulation* 2001;104:1878-1880
146. Xu XH, **Shah PK**, Faure E, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth T, Yano J, Kaul S, Equils O, Arditi M: Toll-like receptor –4(TLR4) is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. *Circulation* 2001;104:3103-3108 (**Featured on the Cover of Circulation**).
147. **Shah PK**: Reduced Tissue Factor Pathway Inhibitor-1 after Pharmacological Thrombolysis: An Epiphenomenon or Potential Culprit in Re-thrombosis? *Circulation* 2002;105:270-271
148. Dimayuga P, Cercek B, Oguchi S, Fredrikson GN, Yano J, **Shah PK**, Joving S, Nilsson J: Inhibitory effects of arterial injury induced neointima formation by B cell transfer in Rag-1 knockout Mice. *Arteriosclerosis, Thrombosis and Vascular Biology* 2002 ;22(4):644-9.
149. **Shah PK**: Chronic infections and atherosclerosis/thrombosis. *Curr Atheroscler Rep* 2002 Mar;4(2):113-9.

150. Wallner Kurt , **Shah K**, Sharifi Behrooz G., Balloon catheterization induces arterial expression of new Tenascin-C isoform *Atherosclerosis* 2002;161(1):75-83.
151. Meisel SR, Xu XP, Edgington TS, Dimayuga P, Kaul S, Lee S, Fishbein MC, Cercek B, **Shah PK**. Differentiation of adherent human monocytes into macrophages markedly enhances tissue factor protein expression and procoagulant activity. *Atherosclerosis* 2002 Mar;161(1):35-43.
152. Doherty TM, Asotra K, Pei D, Uzui H, Wilkin DJ, **Shah PK**, Rajavashisth TR: Therapeutic developments in Matrix Metalloproteinase Inhibition. *Expert Opinions in Therapeutic Patents* 2002: 12(5):665-707
153. **Shah PK**: LDL lowering and Progression of Atherosclerosis: Does More Mean Less? *Circulation* 2002; 106:2039-2040
154. Uzui H, Harpf A, Doherty TM, Shukla A, Chai NN, Tripathi PV, Jovinge S, Wilkin DJ, Asotra K, **Shah PK**, Rajavashisth TR: Increased expression of Membrane Type-3 Metalloproteinase in Human Atherosclerotic Plaque: Role of Activated Macrophages and Inflammatory Cytokines. *Circulation* 2002; 106(24):3024-30
155. Finkelstein A, Makkar R, Doherty TM, Vegesna VR, Liu M, Shikla A, Bergman J, Fishbein MC, Hausleiter J, Takizawa K, Rukshin V, **Shah PK**, Rajavashisht T: Increased expression of M-CSF following coronary artery balloon injury is inhibited by intracoronary brachytherapy. *Circulation* 2002 ;105(20):2411-5
156. Swissa M, Ohara T, Lee MH, Kaul S, **Shah PK**, Hayashi H, Chen PS, Karagueuzian HS. Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricle. *Am J Physiol Heart Circ Physiol*. 2002 May;282(5):H1787-92.
157. Rukshin V, **Shah PK**, Cercek B, Finkelstein A, Tsang V, Kaul S: Comparative antithrombotic effects of magnesium sulfate and platelet GP iib/iiiia inhibitors, Tirofiban and Eptifibatide, in a canine model of stent thrombosis. *Circulation* 2002; 105(16):1970-5.
158. Cannon CM, Bahit MC, Haugland JM, Henry TD, Schweiger MJ, McKendall GR, **Shah PK**, Murphy S, Gibson CM, McCabe CH, Antman EM, Braunwald E: Underutilization of Evidence-Based Medications in Acute ST Elevation Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. *Crit Pathw Cardiol*. 2002 Mar;1(1):44-52.
159. Doherty TM, **Shah PK**, Rajavashisth TB: The Cellular Origins of Atherosclerosis: Towards Ontogenetic Endgame: **FASEB** journal 2003 ;17:1-6.

160. **Shah PK**: Mechanisms of Plaque Vulnerability and Plaque Rupture. *J Am Coll Cardiol* 2003 41:15S-22S.
161. Cercek B, **Shah PK**, Noc M, Zahger D, Zeymer U, Hod H, Maurer G, Mahrer P: The effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndromes. *Lancet* 2003;361(9360): 809-813
162. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, **Shah PK**, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. *Circulation*. 2003;107:1359-65.
163. Qin M, Zeng Z, Zheng J, **Shah PK**, Schwartz SM, Adams LD, Sharifi BG. Suppression subtractive hybridization identifies distinctive expression markers for coronary and internal mammary arteries. *Arterioscler Thromb Vasc Biol*. 2003;23:425-33.
164. Fredrikson Gunilla Nordin, Söderberg Ingrid, Lindholm Marie, Dimayuga Paul Chyu KY, Cercek B, **Shah PK** and Nilsson Jan. Identification of immune responses against aldehyde-modified peptide sequences in apolipoprotein B that predict risk for development of coronary heart disease. *Arteriosclerosis Thrombosis Vascular Biology* 2003;23:872-878.
165. Fredrikson Gunilla Nordin, Söderberg Ingrid, Lindholm Marie, Dimayuga Paul, Chyu KY, **Shah PK** and Nilsson Jan. Inhibition of atherosclerosis in apo E null mice by immunization with native and MDA-modified apo B-100 peptide sequences. *Arteriosclerosis Thrombosis Vascular Biology* 2003;23:879-884.
166. **Shah PK**: Inflammation, neointimal hyperplasia and restenosis: As the leucocytes roll the arteries thicken. *Circulation* 2003;107:2175-2177.
167. Kaul S, Rukshin V, Santos R, Azarbal B, Bishaier C, Johansson J, Tsang VT, Chyu KY, Cercek B, Mirocha J, **Shah PK**: Intramural delivery of recombinant apolipoprotein A-*Imilano* phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. *Circulation* 2003;107:2551-2554.
168. **Shah PK**. Myocardial infarction and ischemia. *J Am Coll Cardiol*. 2003 Jul 16;42(2):375-7.
169. Rukshin V, Santos R, Gheorghiu M, **Shah PK**, Kar S, Padmanabhan S, Azarbal B, Tsang VT, Makkar R, Samuels B, Lepor N, Geft I, Tabak S, Khorsandhi M, Buchbinder Eigler N, Cercek B, Hodgson K, Kaul S. Related Articles, A prospective, nonrandomized, open-labeled pilot study investigating the use of magnesium in patients undergoing nonacute percutaneous coronary intervention with stent implantation. *J Cardiovasc Pharmacol Ther*. 2003 Sep;8(3):193-200.

170. Doherty TM, Asotra, K, Fitzpatrick L, Dunstan C, Qiao JH, Wilkin D, Detrano R, **Shah PK**, Rajavashisth TB: Calcification in Atherosclerosis: Bone Biology and Chronic Inflammation at the Arterial Crossroads: Proceedings of National Academy of Sciences (PNAS) USA 2003 September 30; 100(20): p. 11201-11206.
171. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, **Shah PK**, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. *Circulation*. 2003 Oct 7;108(14):1664-72.
172. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, **Shah PK**, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. *Circulation*. 2003 Oct 14;108(15):1772-8.
173. Meisel SR, Shechter M, Xu XP, Edgington TS, Cercek B, **Shah PK**. Related Articles, Platelet-induced expression of tissue factor procoagulant activity in freshly isolated human mononuclear cells: implications for experimental use. *Clin Lab Haematol*. 2003 Oct;25(5):321-5.
174. Doherty T, FitzPatrick L, Inoue D, Qiao JH, Fishbein M, Detrano R, **Shah PK**, Rajavashisth T: Molecular, endocrine, and genetic mechanisms of arterial calcification. *Endocrine Reviews* 2004; 25(4): 629-672.
175. Kuang-Yuh Chyu, Stephanienie M. Babbidge*, Xiaoning Zhao*, Ram Dandillaya, Juliana Yano, Paul Dimayuga, Bojan Cercek, **Prediman K Shah**: Differential Effects of Green Tea Derived Catechin on Developing versus Established Atherosclerosis in Apo E Null Mice. *Circulation* 2004 ;109(20): 2448-2453.

176. Wallner K, Li Chen, **Shah Prediman K**, Wu KJ, Schwartz S, Sharifi B: The EGF-like domain of Tenascin-C is pro-apoptotic for cultured smooth muscle cells *ATVB* 2004; 24(8): 1416-1421.
177. Nord JE, **Shah PK**, Rinaldi RZ, Weisman MH.: Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. *Semin Arthritis Rheum.* 2004 Apr;33(5):336-51.
178. Chyu KY, Dimayuga P, Zhao X, Nilsson J, **Shah PK**, Cercek B: Altered AP-1/Ref-1 redox pathway and reduced proliferative response in iNOS-deficient vascular smooth muscle cells. *Vasc Med* 2004 May; 9(3): 177-183.
179. Chyu KY, Reyes O, Zhao Xiao-Ning, Yano Juliana, Nilsson Jan *, Cercek Bojan, **Shah Predimen K**: Timing affects the Effect of LDL Immunization On Atherosclerotic Lesions in Apo E (-/-) Mice. *Atherosclerosis* 2004 ;176(1): 27-35.
180. Kaul S, Coin BD, Hedayiti A, Yano J, Cercek B, Chyu K-Y, **Shah PK**. Rapid Reversal of Endothelial Dysfunction in Hypercholesterolemic Apo E-Null Mice by Recombinant Apolipoprotein A-I^{Milano}-Phospholipid Complex. *J Am Coll Cardiol.* 2004 Sep 15;44(6):1311-9)
181. Anazawa T, Chyu KY, Kaul S, **Shah PK**, Cercek B: Effect of exposure to cigarette smoke on carotid artery intimal thickening: The role of inducible nitric oxide synthase. *Arterioscler Thromb Vasc Biol.* 2004 Sep;24(9):1652-8
182. Michelsen K, Wong M, **Shah P K**, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth T, Arditi M: Lack of Toll-like receptor4 or myeloid differentiation factor 88, reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. *Proceedings of the National Academy of Sciences (PNAS) USA* 2004; 101(29): 10679-10684
183. Tani S, Dimayuga PC, Anazawa T, Chyu KY, Li H, **Shah PK**, Cercek B. Aberrant antibody responses to oxidized LDL and increased intimal thickening in apoE^{-/-} mice exposed to cigarette smoke. *Atherosclerosis.* 2004;175(1):7-14.
184. Chyu KY, Babbidge SM, Zhao X, Dandillaya R, Rietveld AG, Yano J, Dimayuga P, Cercek B, **Shah PK**. Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice. *Circulation.* 2004; 109(20):2448-53
185. Li X, Chyu KY, Neto JF, Yano J, Nathwani N, Dimayuga P, Cercek B, Kaul S, **Shah PK**: Differential effects of apolipoprotein A1 mimetic peptide on evolving and established atherosclerosis in apo E null mice. *Circulation.* 2004 Sep 21;110(12):1701-5.

186. Schiopu A; Bengtsson J, Söderberg I, Janciauskiene S, Lindgren S, Ares MPS, **Shah PK**, Carlsson R, Nilsson J, Nordin Fredrikson G,: Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. *Circulation*. 2004 Oct 5;110(14):2047-52.
187. Michelsen K, Doherty T, **Shah PK** and Arditi M: Toll-like receptor signaling: An emerging bridge from innate immunity and atherogenesis. *J Immunol*. 2004 Nov 15;173(10):5901-7.
188. Michelsen KS, Doherty TM, **Shah PK**, Arditi M: Role of Toll-like receptors in atherosclerosis. *Circ Res* Dec 2004;95(12):96-97.
189. Taylor KD, Scheuner MT, Yang H, Wang Y, Haritunians T, Fischel-Ghodsian N, Gray RJ, **Shah PK**, Forrester, JS, Knatterud G, The Post-CABG Clinical Trial Investigators, Rotter JI: The lipoprotein lipase locus and progression of obstruction in coronary-artery bypass grafts. *Genetics in Medicine*. November/December 2004, Vol. 6, No. 62004: 481-486.
190. **Shah PK**, Chyu KY, Fredrikson GN, Nilsson J: Vaccination for atherosclerosis: a novel therapeutic paradigm. *Expert Review in Vaccines* Dec. 2004;3(6): 711-716
191. Kangavari S, Matetzky S, **Shah PK**, Yano J, Chyu KY, Fishbein MC, Cercek B: Smoking increases inflammation and metalloproteinase expression in human carotid atherosclerotic plaques. *J Cardiovasc Pharmacol Ther*. 2004 Dec;9(4):291-8.
192. Nilsson J, Hansson GK, **Shah PK**: Immunomodulation of Atherosclerosis. Implications for Vaccine Development. *Arterioscler Thromb Vasc Biol*. Feb.2005; 25(1)18-28
193. Forrester JS, Makkar R, **Shah PK**: Increasing HDL cholesterol in Dyslipidemia by Cholesterol Ester Transfer Protein Inhibition: An update for the Clinicians. *Circulation* 2005; 111:1847-1854
194. **Shah PK**: Insights into the molecular mechanisms of plaque rupture and thrombosis. **Indian Heart Journal 2005; 57: 21-31**
195. **Shah PK**: Preservation of extracellular matrix by passive myocardial restraint: A new paradigm for prevention of adverse remodeling and progressive heart failure. *Circulation* 2005 ;112(9):1245-1247.
196. **Shah PK**, Chyu KY, Fredriksson GN, Nilsson J: Immunomodulation of atherosclerosis with a vaccine. *Nature: CPC* 2005;2(12):639-646.

197. **Shah PK** and Chyu KY: Apolipoprotein A-I Mimetic Peptides: Role in atherosclerosis management. *Trends in Cardiovascular Medicine* 2005; 15(8): 291-296.
198. Price MJ, Chou CC, Frantzen M, Miyamoto T, Kar S, Lee S, **Shah PK**, Martin BJ, Lill M, Forrester JS, Chen PS, Makkar R: Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiological properties. *International Journal of Cardiology* 2005; 10(4):225-233.
199. Chyu, Kuang-Yuh, Zhao X, Reyes OS, Babbidge SM, Dimayuga PC, Yano Juliana, Cercek Bojan, Fredrikson GN, Nilsson J, **Shah P K**: Immunization Using Apolipoprotein B 100 Related Peptide Sequences Inhibits Atherosclerosis and Plaque Inflammation in Apo E (-/-) Mice. *Biochemical Biophysical Research Communication* 2005;338(4): 1982-1989.
200. Kaul S, **Shah PK**: Apo A-I Milano /phospholipid complexes: Emerging strategies and medications for prevention of atherosclerotic plaque progression. *Curr Drug Targets Cardiovasc Hematol Disord* 2005;5(6) 471-479.
201. Dimayuga P, Li H, Chyu Kuang-Yuh, Fredrikson GN, Nilsson J, Fishbein MC, **Shah PK**, Cercek B: T-cell modulation of intimal thickening after vascular injury: The bimodal role of IFN-(gamma) in immune deficiency. *Arterioscler Thromb Vascl Biol* 2005; 25(12): 2528-2534.
202. Moses JW, **Shah PK**: Enhanced long-term antiplatelet therapy after coronary stenting. *Journal of invasive cardiology*. 2005;17(12): 669-676.
203. Cercek M, Matsumoto M, Li H, Chyu KY, Peter A, **Shah PK**, Dimayuga PC: Autocrine role of vascular IL-15 in intimal thickening. *Biochem Biophys Res Commun*. 2005 18;339(2):618-623
204. Makkar RR, Price MJ, Lill M, Frantzen M, Takizawa K, Kleisli T, Zheng J, Kar S, McClellan R, Miyamota T, Bick-Forrester J, Fishbein MC, **Shah PK**, Forrester JS, Sharifi B, Chen PS, Qayyum M. Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction. *J Cardiovasc Pharmacol Ther*. 2005 Dec;10(4):225-33.
205. Kangavari S, Gupta N, **Shah PK**, Chen PS: Complete heart block induced and terminated by a premature contraction. *J Cardiovasc Electrophysiol* 2005;16: 1394.
206. Faria-Neto JR, Chyu, Kuang-Yuh, Zhao Xiaojun Li, Dimayuga P, Ferreira C, Yano Juliana, Cercek Bojan, **Shah P K**: Passive Immunization with Mono-clonal IgM Antibodies Against Phosphoryl-choline Reduces Accelerated Vein Graft

- Atherosclerosis in Apolipoprotein E-Null Mice. *Atherosclerosis Vein Graft* 2006;189(1):83-90.
207. Michael S. Lee, Nikhil Kapoor, Faizi Jamal, Lawrence Czer, Joseph Aragon, James Forrester, Saibal Kar, Suhail Dohad, Neal Eigler, Alfredo Trento, **Prediman K. Shah**, Raj R. Makkar. Comparison of Coronary Artery Bypass Surgery with Percutaneous Coronary Intervention with Drug-Eluting Stents for Unprotected Left Main Coronary Artery Disease. *J Am Coll Cardiol* 2006; 47(4): 864-870.
208. Tung R, Kaul S, Diamond G, **Shah PK**: Drug eluting stents: A critical appraisal of Evidence. *Annals of Internal Medicine* 2006;144(12): 913-919.
209. Nilsson J, Fredrikson GN, Chyu KY, **Shah PK**, Bjorkbacka B: Oxidized lipoprotein autoimmunity- an emerging drug target in cardiovascular disease. *Future Lipidology* 2006
210. **Shah P.K**: HDL/Apolipoprotein A-I infusion for atherosclerosis management: An emerging new therapeutic paradigm. *Future Lipidology* Feb 2006; Vol 2, No. 1 55-64
211. **Shah PK**: Acute HDL/Apo A-I Infusion Therapy for remodeling/regression of atherosclerosis: a promising new treatment paradigm. *Indian Heart Journal* May/June 2006; 58(3): 209-215
212. Iida K, Luo H, Hagiwara K, Akima T, **Shah PK**, Naqvi T, Siegel RJ: Non-invasive low frequency ultrasound energy causes vasodilation in humans. *Journal of American College of Cardiology* 2006;48: 532-537.
213. Sharifi BG, Zeng Z, Wang L, Song L, Chen H, Qin M, Sierra-Honigmann MR, Wachsman-Hogiu S, **Shah PK**: Pleiotrophin induces Transdifferentiation of Monocytic Cells into functional Endothelial Cells. *Arterioscler Thromb Vasc Biol.* 2006 Jun;26(6):1273-80.
214. Fredrikson GN, Berglund G, Alm R, Nilsson JA, **Shah PK**, Nilsson J. Identification of autoantibodies in human plasma recognizing an apo B-100 LDL receptor-binding site peptide. *J Lipid Res.* 2006; 47(9):2049-2054.
215. Wang L, Sharifi BG, Pan T, Song L, Yukht A, **Shah PK**: Bone marrow transplantation demonstrates superior athero-protective effects of gene therapy with Apo A-I Milano compared to wild type Apo A-I in hyperlipidemic mice. *Journal of the American College of Cardiology (JACC)* 2006; 48: 1459-1468.
216. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy

- Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, **Shah PK**; for the SHAPE Task Force: From Vulnerable Plaque to Vulnerable Patient-Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report. *Am J Cardiol.* 2006 Jul 17;98(2 Suppl 1):2-15. Epub 2006 Jun 12.
217. Forrester JS and **Shah PK**: Emerging strategies for increasing HDL: *American Journal of Cardiology* 2006; 98(11):1542-1549.
218. Forrester JS, Makkar R, **Shah PK**: Myocardial regeneration by stem cells: Seeing the Unseeable. *Journal of the American College of Cardiology* 2006; 48(8): 1722-1724.
219. Naghavi M, Falk E, Hecht HS, **Shah PK**, for the SHAPE Task Force: The first SHAPE guideline. *Crit Pathw Cardiol.* 2006 Dec;5(4):187-190.
220. Kaul S, Zadeh A, **Shah PK**: Homocysteine hypothesis for atherothrombotic cardiovascular disease: Not Validated. *Journal of American College of Cardiology* 2006; 48: 914-923.
221. Chyu KY, Nilsson J, **Shah PK**: Immunization for atherosclerosis. *Current Atherosclerosis Reports*, 2007 ;9(2):104-109.
222. Chyu KY, Nilsson, **Shah PK**: Active and passive immunization for atherosclerosis. *Current Opinion in Molecular Therapeutics*, 2007;9(2):176-182.
223. Goodarzi MO, Taylor KD, Scheuner MT, Antoine HJ, Guo X, **Shah PK**, Rotter JI: Haplotypes in the Lipoprotein Lipase Gene Influence HDL Cholesterol Response to Statin Therapy and Progression of Atherosclerosis in Coronary Artery Bypass Grafts. *The Pharmacogenomics Journal* 2007;7(1):66-73.
224. Cheng VY, Lepor NE, Madyoon H, Eshaghian S, Naraghi AL, **Shah PK**. Presence and Severity of Noncalcified Coronary Artery Plaque on 64-Slice Computed Tomographic Coronary Angiography in Patients with Zero and Low Coronary Artery Calcification. *American Journal of Cardiology* 2007; 99(9):1183-6.
225. **Shah PK**: Emerging HDL-based therapies for atherothrombotic vascular disease. *Current Treatment Options in Cardiovascular Medicine* 2007;9(1):60-70.
226. **Shah PK**: Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. *European Heart Journal* 2007;28(1):5-12.
227. **Shah PK**: Apo A-I Milano infusion for plaque stabilization. *Current Pharmaceutical Design* 2007; 13(10); 1031-1038.

228. Fredrikson GN, Schiopu A, Berglund G, Alm R, **Shah PK**, Nilsson J: Autoantibody against amino acid sequence 661-680 in apo B 100 is associated with decreased carotid stenosis and cardiovascular events. *Atherosclerosis* 2007;194 (2):e188-92.
229. Eshaghian S, Kaul S, Amin S, **Shah PK**, Diamond GA: Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease. *Annals of Internal Medicine* 2007;146 (6):434-441.
230. Kupferwasser LI, Amorn A, Kapoor N, Lee MS, Kar S, Cercek B, Dohad S, Mirocha J, Forrester J, **Shah PK**, Makkar R: Comparison of drug eluting stents with bare metal stents in unselected patients with acute myocardial infarction. *Catheterization and cardiovascular interventions* 2007;70(1):1-8.
231. Kaul S, **Shah PK**, Diamond G: As time goes by: Current status and directions in the controversy over stenting. *Journal of American College of Cardiology* 2007; 50(2) :128-137.
232. Mensah GA, Grant AO, Pepine CJ, Baddour LM, Cooper LT Jr, Dunbar SB, Froelicher ES, Greenlund KJ, Kaplan EL, Kloner RA, Labarthe DR, Luepker RV, Madjid M, Muller JE, O'Connor S, Ornato JP, Robertson RM, Roy MJ, **Shah PK**, Taubert KA, Wilson WR, Zheng ZJ, Harrington RA, Abrams J, Anderson JL, Bates ER, Eisenberg MJ, Grines CL, Hlatky MA, Lichtenberg RC, Lindner JR, Pohost GM, Schofield RS, Shubrooks SJ Jr, Stein JH, Tracy CM, Vogel RA, Wesley DJ. ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats: the clinical and public health implications for the prevention and control of cardiovascular diseases. *Circulation*. 2007 Mar 27;115(12):1656-95.
233. Cooper LT Jr, Mensah GA, Baddour LM, Dunbar SB, Kaplan EL, Wilson WR, **Shah PK**. Task Force III: prevention and control of cardiovascular complications of emerging infectious diseases and potential biological terrorism agents and diseases. *J Am Coll Cardiol*. 2007 Mar 27;49(12):1398-406.
234. Mensah GA, Grant AO, Pepine CJ, Baddour LM, Cooper LT Jr, Dunbar SB, Froelicher ES, Greenlund KJ, Kaplan EL, Kloner RA, Labarthe DR, Luepker RV, Madjid M, Muller JE, O'connor S, Ornato JP, Robertson RM, Roy MJ, **Shah PK**, Taubert KA, Wilson WR, Zheng ZJ, Harrington RA, Abrams J, Anderson JL, Bates ER, Eisenberg MJ, Grines CL, Hlatky MA, Lichtenberg RC, Lindner JR, Pohost GM, Schofield RS, Shubrooks SJ Jr, Stein JH, Tracy CM, Vogel RA, Wesley DJ. ACCF/AHA/CDC Conference Report on Emerging Infectious Diseases and Biological Terrorism Threats The Clinical and Public Health Implications for the Prevention and Control of Cardiovascular Diseases. *J Am Coll Cardiol*. 2007 Mar 27;49(12):1373-1375.

235. Fredrikson GN, Hedblad B, Berglund G, Alm R, Nilsson JA, Schiopu A, **Shah PK**, Nilsson J. Association Between IgM Against an Aldehyde-Modified Peptide in Apolipoprotein B-100 and Progression of Carotid Disease. *Stroke*. 2007; 38(5):1495-1500.
236. **Shah PK**: Innate immune pathway links obesity to insulin resistance. *Circulation Research*, 2007 ;100(11): 1531-5133
237. **Shah PK**: Molecular mechanisms of plaque rupture. *Current Opinions in Lipidology* 2007;18(5): 492-499
238. Fredrikson GN, Lindholm MW, Ljungcrantz I, Soderberg I, **Shah PK**, Nilsson J. Autoimmune responses against the apo B-100 LDL receptor-binding site protect against arterial accumulation of lipids in LDL receptor deficient mice. *Autoimmunity*. 2007 Mar;40(2):122-30.
239. Cooper LT Jr, Mensah GA, Baddour LM, Dunbar SB, Kaplan EL, Wilson WR, **Shah PK**; American College of Cardiology Foundation; American Heart Association, Inc; Centers for Disease Control and Prevention. ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats. Task Force III: prevention and control of cardiovascular complications of emerging infectious diseases and potential biological terrorism agents and diseases. *Circulation*. 2007 Mar 27;115(12):1681-9.
240. Chyu KY, Nilsson J, **Shah PK**: Active and passive immunization for atherosclerosis. *Current Opinions in Molecular Therapy* 2007; Apr;9(2) 176-182
241. **Shah PK**: Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach. *Curr Pharm Des*. 2007;13(10):1031-8.
242. Nilsson J, Nordin Fredrikson G, Schiopu A, **Shah PK**, Jansson B, Carlsson R. Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease. *Curr Pharm Des*. 2007;13(10):1021-30.
243. Chyu KY, **Shah PK**: Choking off plaque neovascularity: a promising athero-protective strategy or a double edged sword. *Arteriosclerosis, Thrombosis and Vascular Biology* 2007 May;27(5):993-5.
244. Diamond GA, Kaul S, **Shah PK**: Screen testing cardiovascular prevention in asymptomatic diabetic patients. *J Am Coll Cardiol*. 2007 May 15;49(19):1915-7.
245. **Shah PK**: Emerging HDL-based Therapies for Atherothrombotic Vascular Disease. *Current Treatment Options in Cardiovascular Medicine* 2007; 9(1): 60-70.

246. **Shah PK**: Distal Embolization After PCI: Prediction, Prevention and Relevance. *J of Am Coll Cardiol* 2007; 50(17): 1647-1648
247. **Shah PK**: HDL-mimetics: Focus on synthetic HDL. *Am J of Cardiol* 2007; 100(11A): S62-67.
248. Schiopu A, Frenedesous B, Jansson B, Soderberg I, Ljungcrantz I, Araya Z, **Shah PK**, Carlsson R, Jan Nilsson, Fredrikson GN, : Plaque Regression Induced by Human Recombinant Antibodies to an oxLDL Epitope induce rapid regression of atherosclerosis in Apobec Mice LDLR-/- mice. *Journal of American College of Cardiology* 2007;50(24):2313-2318
249. Nilsson J, Fredrikson GN, Schiopu A, **Shah PK**, Jansson B, Carlsson R: Oxidized LDL antibody in treatment and risk assessment of atherosclerosis and associated cardiovascular disease. *Current Pharmaceutical Design* Dec. 2007;13(10):1021-1030
250. Polk, D. and Shah, P.K. Cholesterol ester transfer protein (CETP) and atherosclerosis, *Drug Discov Today: Ther Strategies* (2008),
251. **Shah PK**: Oxidant hypothesis of CVD. *American Journal of Cardiology*, 2008;101(10A):3D
252. Boden WE, **Shah PK**, Gupta V, Ohman EM: Contemporary approach to the diagnosis and management of non-ST elevation acute coronary syndromes. *Progress in cardiovascular disease* 2008; 50(5):311-51.
253. Goldberger JJ, Bonow RO, Cuffe M, Dyer A, Greenland P, Rosenberg Y, O'Rourke R, **Shah PK**, Smith S : Post-myocardial infarction beta-blocker therapy: the bradycardia conundrum. Rationale and design for the Pacemaker & beta-blocker therapy post-MI (PACE-MI) trial. *Am Heart J*. 2008 Mar;155(3):455-64.
254. Cannon CP; **STRIVE Scientific Committee (Shah PK included as collaborator)**. Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit. *Crit Pathw Cardiol*. 2008 Mar;7(1):43-81.
255. Friedwald VE, Ballantyne CM, Nissen SE, **Shah PK**, Roberts WC: The Editor's Roundtable: Atherosclerosis Regression. *Am J Cardiol*. 2008 Apr 1;101(7):967-974.
256. Falk E, Naghavi M, **Shah PK**. Legislating screening for Atherosclerosis. *JAMA*. 2008 May 14;299(18):2147-8.
257. Naiki Y, Sorrentino R, Wong MH, Michelsen KS, Shimada K, Chen S, Yilmaz A,

- Slepenkin A, Schröder NW, Crother TR, Bulut Y, Doherty TM, Bradley M, Shaposhnik Z, Peterson EM, Tontonoz P, **Shah PK**, Arditi M. TLR-MyD88 and Liver X receptor signaling Pathways Reciprocally control Chlamydia-induced acceleration of atherosclerosis. *Journal of Immunology*, 2008;181 (10): 7176-7185.
258. White AJ, Kedia G, Mirocha JM, Lee MS, Forrester JS, Morales WC, Dohad S, Kar S, Czer LS, Fontana GP, Trento A, **Shah PK**, Makkar RR. Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis. *JACC Cardiovasc Interv*. 2008 Jun;1(3):236-45
259. Matsumoto M, Dimayuga PC, Wang C, Kirzner J, Cercek M, Yano J, Chyu KY, **Shah PK**, Cercek B: Exogenous heat shock protein-70 inhibits cigarette smoke-induced intimal thickening. *Am J Physiol Regul Integr Comp Physiol*. 2008 Oct;295(4):R1320-7. Epub 2008 Aug 13
260. **Shah PK**: Inflammation and plaque vulnerability. *Cardiovascular Drug Therapy* 2009; 23:31–4
261. **Shah PK**. Diabetes: Does screening for inducible ischemia improve outcomes? *Nature Reviews Cardiol*. 2009 Jul;6(7):452-3.
262. Fredrikson GN, Anand DV, Hopkins D, Corder R, Alm R, Bengtsson E, **Shah PK**, Lahiri A, Nilsson J. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. *Diabetologia*. 2009 Jul;52(7):1426-33.
263. Naik H, White AJ, Chakravarty T, Forrester J, Fontana G, Kar S, **Shah PK**, Weiss RE, Makkar R. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. *JACC Cardiovasc Interv*. 2009 Aug;2(8):739-47.
264. Nilsson J, Fredrikson GN, Björkbacka H, Chyu KY, **Shah PK** *Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease.* *J Intern Med*. 2009 Sep;266(3):221-31.
265. **Shah PK**: Imaging inflammation in atherosclerosis: Another Step Forward? *JACC Cardiovasc Imaging*. 2009 Oct;2(10):1223-5
266. Dimayuga PC, Cesena FH, Chyu KY, Yano J, Amorn A, Fishbein MC, **Shah PK**, Cercek B. *Natural antibodies and complement modulate intimal thickening after arterial injury.* *Am J Physiol Regul Integr Comp Physiol*. 2009 Nov;297(5):R1593-600.
267. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter

- LA, Leitersdorf E, McMurray JJ, **Shah PK**, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. *Am Heart J*. 2009 Dec;158(6):896-901.e3.
268. Arsenault BJ, Rana JS*, Stroes ESG, Despres JP, **Shah PK**, Kastelein JP, Wareham NJ, Boekholdt M, Khaw KT. Beyond LDL cholesterol: Respective contributions of non-HDL cholesterol levels, triglycerides and the total cholesterol/HDL cholesterol ratio to coronary heart disease risk in apparently healthy men and women. *Journal of American College of Cardiology* 2009 Dec 29;55(1):35-41
269. **Shah PK**: The **Yin and Yang** of CETP inhibition in cardiovascular disease. *Circulation* 2009 Dec 15;120(24):2408-10
270. **Shah PK**: The SHAPE Paradigm. *Circulation Outcomes and Quality*. 2010 Jan 1;3(1):106-9
271. Dhese P, Ng Rita, Shehata M, **Shah PK**: Ventricular tachycardia after ingestion of ayurveda herbal antidiarrheal medication containing aconitum. *Arch Intern Med*. 2010 Feb 8;170(3):303-5.
272. Fuqiang Li, Fang Tian, Lai Wang, Ian K. Williamson, Behrooz G. Sharifi, **Prediman K. Shah**: Pleiotrophin (PTN) is Expressed in Vascularized Human Atherosclerotic Plaques: IFN- γ /JAK/STAT1 Signaling is Critical for the Expression of PTN in Macrophages. *FASEB J*. 2010 Mar;24(3):810-22.
273. Meisel SR, Ouyang Y, Fishbein MC, Edgington TS, Ruan XM, Cercek B, **Shah PK**, Chaux A. Prolonged hypercholesterolemia-induced tissue factor expression in rabbit vein grafts: a potential mechanism for graft failure. *Coron Artery Dis*. 2010 Mar;21(2):97-103.
274. Eshaghian S, **Shah PK**, Kaul S: Advances in Antiplatelet Treatment for Acute Coronary Syndromes. *Heart*. May 2010; 96:656-661.
275. Bairey Merz CN, Mark S, Boyan BD, Jacobs AK, **Shah PK**, Shaw LJ, Taylor D, Marbán E. Proceedings from the Scientific Symposium: Sex differences in cardiovascular disease and implications for therapies. *J Womens Health Larchmt*. 2010 Jun;19(6):1059-72
276. **Shah PK**: Screening Asymptomatic Patients for for Atherosclerosis: Can we, does it matter and should we? *J Am Coll Cardiol*. 2010 Jul 6;56(2):98-105
277. Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, Walton A, Adamson P, Kar S, **Shah PK**, Richards M, Eigler NL, Whiting JS, Haas GJ, J.

- Heywood JT, Frampton C, Abraham WT on behalf of the HOMEOSTASIS Study Group. Physician-Directed, Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure. *Circulation* 2010;21:1086-1095.
278. Nilsson, J, Wigren M, **Shah PK**: Regulatory T-cells and the control of modified lipoprotein induced autoimmunity driven atherosclerosis: Trends in Cardiovascular Medicine 2010;19:272-276 (featured on the cover)
279. Muntendam P, McCall C, Sanz J, Falk E, Fuster V et al; High-Risk Plaque Initiative. **(included in HRP Scientific Program Board as Predimon K. Shah, MD)** The Biolmage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease--study design and objectives. *Am Heart J.* 2010 Jul;160(1):49-57.e1.
280. Naqvi TZ; Mendoza F; Rafii F; Gransar H, Guerra M; Lepor N; Berman DS; **Shah PK**: High Prevalence of Ultrasound Detected Carotid Atherosclerosis in Subjects with Low Framingham Risk Score: Potential Implications for Screening for Subclinical Atherosclerosis. *J Am Soc Echocardiogr.* 2010 Aug;23(8):809-15. Epub 2010 May 31
281. Song L, Wang L, Sun X, **Shah PK**, Chaux A, Sharifi BG: Bioengineered vascular graft grown in the mouse peritoneal cavity. *Journal of Vascular Surgery:* 2010 Oct;52(4):994-1002, 1002.e1-2. Epub 2010 Aug 8
282. **Shah PK**: Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. *Current Opinion in Cardiology* 2010 Nov;25(6):603-8.
283. Goldberger JJ, Bonow RO, Cuffe M, Dyer A, Rosenberg Y, O'Rourke R, **Shah PK**, Smith SC Jr; PACE-MI Investigators beta-Blocker use following myocardial infarction: Low prevalence of evidence-based dosing. *Am Heart J.* 2010 Sep;160(3):435-442.e1.
284. Troughton RW; Ritzema J, Eigler N; Melton L; Krum H; Adamson P; Kar S, MD; **Shah PK**; Whiting J; Heywood JT; Rosero S; Singh J; Saxon L; Matthews R; Crozier I; Abraham WT for the HOMEOSTASIS Investigators Direct left atrial pressure monitoring in severe heart failure: long-term sensor performance; *Journal of Cardiovascular Translational Research* 2010 Oct 14. [Epub ahead of print]
285. **Shah PK**: Residual risk and HDL-C levels: Is there a relationship? *Reviews in Cardiovascular Medicine* 2011;12(2): e55-9.
286. Chyu KY, Nilsson J, **Shah PK**. Immune Mechanisms in Atherosclerosis and Potential for an Atherosclerosis Vaccine. *Discov Med* 11(60):403-412, 2011

287. **Shah PK**: Induction of endogenous apolipoprotein A-I: A new approach to raise HDL. *Nature reviews in cardiology* 2011 Apr;8(4):187-8.
288. Morrison R, Czer L, **Shah PK**: Chronic Heart Failure: Current Evidence, Challenges to Therapy, and Future Directions. *American Journal of Cardiovascular drugs. Am J Cardiovasc Drugs.* 2011 Jun 1;11(3):153-71
289. Meisel SR, Xu XP, Edgington TS, Cercek B, Ong J, Kaul S, **Shah PK**.: Dose-Dependent Modulation of Tissue Factor Protein and Procoagulant Activity in Human Monocyte-Derived Macrophages by Oxidized Low Density Lipoprotein..J *Atheroscler Thromb. J Atheroscler Thromb.* 2011 Jul 22;18(7):596-603.
290. Paul C. Dimayuga, Kuang-Yuh Chyu, Jonathan Kirzner, Juliana Yano, Xiaoning Zhao, Jianchang Zhou, Prediman K. Shah, Bojan Cercek: Enhanced Neointima Formation Following Arterial Injury in Immune Deficient Rag-1^{-/-} Mice is Attenuated by Adoptive Transfer of CD8⁺ T cells. *PLoS One.* 2011;6(5):e20214.
291. Chyu KY, **Shah PK** Emerging therapies for atherosclerosis prevention and management. *Cardiol Clin.* 2011 Feb;29(1):123-35
292. Engelbertsen D, Anand DV, Fredrikson GN, Hopkins D, Corder R, **Shah PK**, Lahiri A, Nilsson J, and Bengtsson E: High levels of IgM against methylglyoxal-modified apolipoprotein B100 is associated with less coronary artery calcification in patients with type 2 diabetes. *J Intern Med.* 2011 Jun 13 doi: 10.1111/j.1365-2796.2011.02411.x. (Epub ahead of print)
293. Chyu KY, Peter A, **Shah PK**: Progress in HDL-based therapies for atherosclerosis. *Current Atherosclerosis reports* 2011 Oct;13(5):405-12)
294. Falk E and **Shah PK**: The SHAPE Guideline: Ahead of Its Time or Just in Time? *Current Atherosclerosis reports* 2011 Oct;13(5):345-52.
295. Fernando H.Y. Cesena¹, Paul C. Dimayuga¹, Juliana Yano, Xiaoning Zhao, Jonathan Kirzner, Jianchang Zhou, Lai Fan Chan, Wai Man Lio, Bojan Cercek, **Prediman K. Shah**, Kuang-Yuh Chyu. Immune-modulation by polyclonal IgM treatment reduces atherosclerosis in hypercholesterolemic apoE^{-/-} mice. *Atherosclerosis* 2012 Jan;220(1):59-65.
296. Kuang-Yuh Chyu, Xiaoning Zhao, Paul C. Dimayuga, Jianchang Zhou, Juliana Yano, Wai Man Lio, Lai Fan Chan, Jonathan Kirzner, Portia Trinidad, Bojan Cercek, **Prediman K. Shah**: CD8 T-cells mediate the athero-protective effect of immunization with an apoB-100 peptide. *PLoS1* 2012;7(2):e30780.
297. Rana JS, Boekholdt SM, Kastelein JJ, **Shah PK**. The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease. *Curr Atheroscler Rep.* 2012 Apr;14(2):130-4. doi: 10.1007/s11883-011-0224-x.

298. **Shah PK**: Cholesteryl ester transport protein inhibition and endothelial function: enough with the surrogates. *European Heart Journal* 2012 Apr;33(7):819-21.
299. **Shah PK**: Severe aortic stenosis should not be operated on before symptom onset. *Circulation*. 2012 Jul 3;126(1):118-25
300. Shuang Chen, M.D., Ph.D.¹, Young Ho Lee, PhD.¹, Wenxuan Zhang¹, Atilla Yilmaz, M.D.², Danica J Schulte, M.D.¹, Kenichi Shimada, Ph.D.¹, Timothy R. Crother, Ph.D.¹, Michael Fishbein, M.D.³, Shawn Wagner, Ph.D.⁴, Debiao Li, Ph.D.⁴, Thomas J.A. Lehman, M.D.⁵, **Prediman K. Shah, M.D.**⁶, and Moshe Arditi, M.D. Marked Acceleration of Atherosclerosis following *Lactobacillus casei* Extract-induced Coronary Arteritis in a Mouse Model of Kawasaki Disease. *Arterioscler Thromb Vasc Biol* 2012 Aug;32(8):e60-71. doi: 10.1161/ATVBAHA.112.249417. Epub 2012 May 24.
301. Wang L, Wang W, **Shah PK**, Song L, Yang M, Sharifi BG: Deletion of Tenascin-C Gene Exacerbates Atherosclerosis and Induces Intraplaque Hemorrhage in Apo E Deficient Mice. *J of Cardiovascular Pathology* 2012 Sept-Oct;21(5): 398-413.
302. Ibebuogu UN, Cercek B, Makkar R, Dinh H, Kwarteng C, Mirocha J, HUsaini A, Singh S, Dohad S, **Shah PK**, Khorsandi M, Kar S: Comparison between transradial and transfemoral percutaneous intervention in acute ST-Elevation myocardial infarction. *Am J Cardiol* 2012 Nov 1;110(9):1262-5. doi: 10.1016/j.amjcard.2012.06.024. Epub 2012 Jul 26.
303. Gregory G. Schwartz, M.D., Ph.D.¹ Anders G. Olsson, M.D., Ph.D.²Markus Abt, Ph.D.³Christie M. Ballantyne, M.D.⁴Philip Barter M.D., Ph.D.⁵Bernard M. Chaitman, M.D.⁶Ingar M. Holme, Ph.D.⁷David Kallend, M.B.B.S. (Lon)³Lawrence Leiter, M.D.⁸Eran Leitersdorf, M.D., Ph.D.⁹John J.V. McMurray, M.D.¹⁰Hardi Mundl, M.D.³Stephen Nicholls, M.B.B.S., Ph.D.¹¹**Prediman K. Shah, M.D.**¹²Jean-Claude Tardif, M.D.¹³R. Scott Wright, M.D.¹⁴ Effects of the Cholesteryl Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndrome. *N Engl J Med*. 2012 Nov 29;367(22):2089-99.
304. Fuqiang Li, Mingjie Yang, Lai Wang, Ian Williamsons, Fang Tian, Minghui Qin, **Prediman K Shah**, Behrooz G Sharifi. Autofluorescence contributes to False-positive intracellular Foxp3 staining in Macrophages: A lesson learned from flow cytometry. *Journal of Immunological Methods*: 2012 Dec 14;386(1-2):101-7. doi: 10.1016/j.jim.2012.08.014. Epub 2012 Sep 4.
305. Cuchel M.¹, Meagher E.A.¹, Theron H. du Toit², Blom D.J.³, Marais A.D.⁴, Hegele R.A.⁵, Averna M.⁶, Sirtori C.⁷, **Shah P.K.**⁸, Gaudet D.⁹, Stefanutti C.¹⁰, Vigna G.B.¹¹, Du Plessis A.M.E.¹², Propert K.J.¹, Sasiela W.J.¹³, Bloedon L.T.^{1,13}, Rader D.J.¹, for the Phase 3 HoFH Lomitapide Study Investigators : A Phase III Trial of a Microsomal Triglyceride Transfer Protein Inhibitor in

- Homozygous Familial Hypercholesterolemia *Lancet* 2013 Jan 5;381(9860):40-6. doi: 10.1016/S0140-6736(12)61731-0. Epub 2012 Nov 2.
306. Nilsson J, Wigren M, **Shah PK**. Vaccines against atherosclerosis. *Expert Rev Vaccines*. 2013 Mar;12(3):311-21. doi: 10.1586/erv.13.4.
307. Wang L, Wang W, **Shah PK**, Song L, Sharifi BG: Tenascin-C Deficiency in Apo E^{-/-} Mouse Increases Eotaxin Levels: Implications for Atherosclerosis. *Atherosclerosis* 2013 Apr;227(2):267-74
308. Dimayuga PC, Chyu KY, Lio WM, Zhao X, Yano J, Zhou J, Honjo T, **Shah PK**, Cercek B. Reduced Neointima Formation After Arterial Injury in CD4^{-/-} Mice Is Mediated by CD8⁺CD28^{hi} T Cells. *J Am Heart Assoc*. 2013 May 23;2(3):e000155. doi: 10.1161/JAHA.113.000155.
309. **Shah PK**: Rapid Detection of Subclinical Atherosclerosis: Potential Implications for Primary Prevention in LMIC Global Heart, Volume 8, Issue 2, June 2013, Pages 91-93
310. Sondermeijer BM, Rana JS, Arsenault BJ, **Shah PK**, Kastelein JJ, Wareham NJ, Boekholdt SM, Khaw KT: Non-HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. *Eur J Clin Invest*. 2013 Jun 21. doi: 10.1111/eci.12129. [Epub ahead of print]
311. **Shah PK**: Can carotid plaque predict coronary plaque? *JACC Cardiovasc Imaging*. 2013 Nov;6(11):1168-71. doi: 10.1016/j.jcmg.2013.09.005.
312. **Shah PK**: The Jekyll and Hyde of HDL: A lipoprotein with a split personality. *Eur Heart J*. 2013 Dec;34(46):3531-4. doi: 10.1093/eurheartj/eh382. Epub 2013 Sep 23
313. Chyu KY, **Shah PK**. Can we vaccinate against atherosclerosis? *J Cardiovasc Pharmacol Ther*. 2014 Jan;19(1):77-82. doi: 10.1177/1074248413498822. Epub 2013 Sep 13.
314. Zhou J, Dimayuga PC, Zhao X, Yano J, Lio WM, Trinidad P, Honjo T, Cercek B, **Shah PK**, Chyu KY. CD8⁺CD25⁺ T cells reduce atherosclerosis in apoE^{-/-} mice. *Biochem Biophys Res Commun*. 2014 Jan 17;443(3):864-70. doi: 10.1016/j.bbrc.2013.12.057. Epub 2013 Dec 14. PubMed PMID: 24342615.
315. Chyu KY, **Shah PK**. Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases. *Ther Adv Vaccines*. 2014 Mar;2(2):56-66. Review.

316. Chyu KY, Lio WM, Dimayuga PC, Zhou J, Zhao X, Yano J, Trinidad P, Honjo T, Cercek B, **Shah PK**. Cholesterol lowering modulates T cell function in vivo and in vitro. *PLoS One*. 2014 Mar 19;9(3):e92095.
317. Toth PP, **Shah PK**, Wilkinson MJ, Davidson MH, McCullough PA Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. *Rev Cardiovasc Med*. 2014;15(1):1-10.
318. **Prediman K. Shah**, Kuang-Yuh Chyu, Paul Dimayuga, Jan Nilsson: Vaccine for Atherosclerosis. *Journal of Am Coll Cardiol* 2014; 64: 2779-2791
319. Zhaoyanf F, Weis Yu, Yibin Xie, Li dong, lixin Yang, Zanhong Wang, Antonio Hernandez –Conte, Xiaming Bi, Jing An, Tianzhang Zhang, Gerhard laub, **PK Shah**, Zhaoqi Zhang, Debiao Li: Multi-contrasts atherosclerosis characterization (MATCH) of carotid plaque with a single 5-min scan: technical development and clinical feasibility. *J of Cardiovasc Magnetic Resonance* 2014; 16:53
320. **Shah PK**: Biomarkers of Plaque Instability. *Curr Cardiol Rep* (2014) 16:547.
321. Micheala Hell¹, Stephan Achenbach¹, **Prediman K Shah**², Daniel S Berman³, Damini Dey, PhD⁴. Noncalcified plaque in Cardiac CT : Quantification and clinical implications. *Current Cardiovascular Imaging Reports*. 2015 8:27.doi:10.007/s12410-015-9343-z.
322. Yafim Brodov, Heidi Gransar, Alan Rozanski, Sean W. Hayes, John D. Friedman, Louise E. J. Thomson, Damini Dey, Piotr J Slomka, James K. Min, Leslee J. Shaw, **Shah PK**, Guido Germano, Daniel S. Berman: Extensive Thoracic Aortic Calcification is an Independent Predictor of Development of Coronary Artery Calcium among Individuals with Coronary Artery Calcium Score of Zero. *Atherosclerosis*. 2015 Jan;238(1):4-8.
323. Tian F, Wang L, Arias A, Yang M, Sharifi BG, **Shah PK**: Comparative Anti-atherogenic Effects of Intravenous AAV8 and AAV2 Mediated Apo A-I Milano gene Transfer in Hypercholesterolemic Mice. *J Cardiovasc Pharmacol Ther*. 2015 Jan;20(1):66-75. doi: 10.1177/1074248414530041. Epub 2014 Apr 17.
324. Tomoyuki Honjo, Kuang-Yuh Chyu, Paul Dimayuga, Juliana Yano, Wai Man Lio, Portia Trinidad, Xiaoning Zhao, Jianchang Zhou, Shuang Chen, Bojan Cercek, Moshe Arditi, and **Prediman K. Shah**. ApoB-100 Related Peptide Vaccine Protects Against Angiotensin II-induced Aortic Aneurysm Formation and Rupture. *J Am Coll Cardiol*. 2015 Feb 17;65(6):546-56. doi: 10.1016/j.jacc.2014.11.054
325. **Stefanuiti C**, DJ Blom, MR Aversa. EA Meagher, H dT Theron, AD Marais, RA Hegele, CR Sirtori, **PK Shah**, D Gaudet, GB Vigna, BS Sachais, S Di Giacomo, AME du Plessis, LT Bloedon, JBalsler, DJ Rader and M Cuchel for the Phase 3

- HoFH Lomitapide Study Investigators. The lipid-lowering effects of lomitapide are independent of adjunctive apheresis in patients with homozygous familial hypercholesterolemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. *Atherosclerosis*. 2015 Jun;240(2):408-14
326. Lai Wang, Mingjie Yang, Ana Arias, Lei Song, Fuqiang Li, Fang Tian, Minghui Qin, Ada Yukht, Ian Williamson, **Prediman K Shah**, Behrooz G Sharifi: Splenocytes Seed Bone Marrow of Myeloablated Mice: Implication for Atherosclerosis. *PLoS One*. 2015 Jun 3;10(6):e0125961
327. **Shah PK**, Parmley W, Heistad D: Remembering Kanu Chatterjee: A Gentle Giant of Cardiology. *J Am Coll Cardiol*. 2015 Jun 23;65(24):2662-3.
328. **Shah PK**, Parmley W, Heistad D: Remembering Kanu Chatterjee: A Gentle Giant of Cardiology. *Circulation*. 2015 Jun 23;131(25):2236-7
329. Honjo T, Chyu Kuang-Yuh, Dimayuga Paul C., Lio Wai Man, Yano Juliana, Trinidad Portia, Zhao Xiaoning, Zhou Jianchang, Cercek Bojan, **Shah Prediman K.**; Immunization with an ApoB-100 Related Peptide Vaccine Attenuates Angiotensin-II Induced Hypertension and Renal Fibrosis. *PLoS One* 2015 Jun 29;10(6):e0131731. doi: 10.1371/journal.pone.0131731.
330. Chyu KY and **Shah PK**: Recombinant HDL/apo A-1 Infusion and Apo A-1 Gene Therapy in Experimental Atherosclerosis. *Frontiers in Pharmacology Research Front Pharmacol*. 2015 Sep 1;6:187 doi: 10.3389/fphar.2015.00187
331. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, **Shah PK**, Smith SC Jr, Subačius H; OBTAIN Investigators Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. *J Am Coll Cardiol*. 2015 Sep 29;66(13):1431-41. doi: 10.1016/j.jacc.2015.07.047.
332. Shah PK. [Temporal Change in CAC Score and Prognosis: Follow-Up Score Is Simpler and as Good as a Change in Score](#). *JACC Cardiovasc Imaging*. 2016 Dec;9(12):1430-1431. doi: 10.1016/j.jcmg.2016.05.002. Epub 2016 Jun 29. No abstract available.
333. Lai Wang, Fang Tian, Ana Arias, BS, Mingjie Yang, MD, Behrooz G Sharifi, PhD and **Prediman K Shah, MD.**: Comparative effects of Diet Induced Lipid Lowering versus Lipid Lowering along with Apo A-I Milano gene Therapy on Regression of Atherosclerosis. *Journal of Cardiovascular Pharmacology and Therapeutics* 2016;2(3):320-328.
334. Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, Mancini GB, Ballantyne CM, Catapano A, Gouni-Berthold I, Stein EA, Xue A, Wasserman SM, Scott R, Thompson PD; GAUSS-3 Investigators. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of

- the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial Epub 2016 Mar 4. *Clin Cardiol.* 2016 Mar;39(3):137-44. doi: 10.1002/clc.22518.
335. Wakita D, Kurashima Y, Crother TR, Rivas MN, Lee Y, Chen S, Fury W, Bai Y, Wagner S, Li D, Lehman T, Fishbein MC, Hoffmann H, **Shah PK**, Shimada K, Arditi M. Role of Interleukin-1 Signaling in a Mouse Model of Kawasaki Disease-Associated Abdominal Aortic Aneurysm. *Arterioscler Thromb Vasc Biol.* 2016 Mar 3. pii: ATVBHA.115.307072. [Epub ahead of print]
336. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA; GAUSS-3 Investigators.. [Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.](#) *JAMA.* 2016 Apr 19;315(15):1580-90. doi: 10.1001/jama.2016.3608.
337. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG; PARTNER 2 Investigators.. [Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.](#) *N Engl J Med.* 2016 Apr 28;374(17):1609-20. doi: 10.1056/NEJMoa1514616. Epub 2016 Apr 2.
338. Zhao XQ, Yuan C, **Shah PK**: Imaging to assess the effect of Anti-inflammatory therapy in aortic and carotid atherosclerosis. *J Am Coll Cardiol.* 2016 Oct 18;68(16):1781-1784. doi: 10.1016/j.jacc.2016.08.011.
339. Xie Y, Kim YJ, Kim JS, Yang Q, Wei J, Nguyen CT, Deng Z, Choi BW, Fan Z, Bairey-Merz CN, **Shah PK**, Berman DS, Chang HJ, Li D: Coronary Atherosclerosis T₁-Weighted Characterization with Integrated Anatomical Reference: Comparison with High-Risk Plaque Features Detected by Invasive Coronary Imaging. *JACC Cardiovasc Imaging.* 2016 Oct 6. pii: S1936-878X(16)30642-8. doi:10.1016/j.jcmg.2016.06.014. [Epub ahead of print]
340. Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Nicholls SJ, Niesor EJ, Olsson AG, Shah PK, Tardif JC, Kittelson J, Schwartz GG. [Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein.](#) *J Am Coll Cardiol.* 2016 Dec 6;68(22):2488-2490.
341. Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, Nicholls SJ, Shah PK, Tardif JC, Olsson AG, McMurray JJ, Kittelson J, Schwartz GG. [Aldosterone Does Not Predict Cardiovascular Events](#)

- [Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.](#) *J Am Heart Assoc.* 2017 Jan 10;6(1). pii: e004119. doi: 10.1161/JAHA.116.004119.
342. Chyu KY, Dimayuga PC, Shah PK. Vaccine against arteriosclerosis: an update. *Ther Adv Vaccines.* 2017 Apr;5(2):39-47. doi: 10.1177/2051013617693753. Epub 2017 Feb 1. Review. PubMed PMID: 28515939; PubMed Central PMCID: PMC5418889.
343. Kalra A, Shah PK, Zoghbi WA. Travel Bans and Threats to US Health Care-Our Hearts Are at Stake. *JAMA Cardiol.* 2017 Apr 1;2(4):351-352. doi: 10.1001/jamacardio.2017.0834. PubMed PMID: 28288259.
344. Qin M, Wang L, Li F, Yang M, Song L, Tian F, Yukht A, Shah PK, Rothenberg ME, Sharifi BG. Oxidized LDL activated eosinophil polarize macrophage phenotype from M2 to M1 through activation of CD36 scavenger receptor. *Atherosclerosis.* 2017 May 20;263:82-91. doi: 10.1016/j.atherosclerosis.2017.05.011. [Epub ahead of print] PubMed PMID: 28623741.
345. Shah PK. Sugar-Sweetened Beverage and Vascular Function: Not So Sweet After All. *Arterioscler Thromb Vasc Biol.* 2017 Jun;37(6):1020-1021. doi: 10.1161/ATVBAHA.117.309450. PubMed PMID: 28539491.
346. Dimayuga PC, Zhao X, Yano J, Lio WM, Zhou J, Mihailovic PM, Cercek B, Shah PK, Chyu KY. Identification of apoB-100 Peptide-Specific CD8+ T Cells in Atherosclerosis. *J Am Heart Assoc.* 2017 Jul 15;6(7). pii: e005318. doi: 10.1161/JAHA.116.005318. PubMed PMID: 28711866.
347. Blom DJ, Aversa MR, Meagher EA, du Toit Theron H, Sirtori CR, Hegele RA, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Larrey D, Bloedon LT, Foulds P, Rader DJ, Cuchel M. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. *Circulation.* 2017 Jul 18;136(3):332-335. doi: 10.1161/CIRCULATIONAHA.117.028208. PubMed PMID: 28716835.
348. Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, Chyu KY, Sasiela WJ, Chan KC, Brisson D, Khoury E, Banerjee P, Gusarova V, Gromada J, Stahl N, Yancopoulos GD, Hovingh GK. ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. *N Engl J Med.* 2017 Jul 20;377(3):296-297. doi: 10.1056/NEJMc1705994. PubMed PMID: 28723334.
349. Mihailovic PM, Lio WM, Yano J, Zhao X, Zhou J, Chyu KY, Shah PK, Cercek B, Dimayuga PC. The cathelicidin protein CRAMP is a potential atherosclerosis self antigen in ApoE(-/-) mice. *PLoS One.* 2017 Nov 1;12(11):e0187432. Doi 10.1371/journal.pone.0187432. eCollection 2017.

350. Schwartz GG, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, Kittelson J. Association of Lipoprotein(a) with Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. *JAMA Cardiol.* 2017 Oct 25. Doi: 10.1001/jamacardio.2017.3833. {Epub ahead of print}
351. Pothineni NVK, Subramany S, Kuriakose K, Shirazi LF, Romeo F, Shah PK, Mehta JL. [Infections, atherosclerosis, and coronary heart disease.](#) *Eur Heart J.* 2017 Nov 14;38(43):3195-3201. doi: 10.1093/eurheartj/ehx362.
352. Song L, Wang L, Li F, Yukht A, Qin M, Ruther H, Yang M, Chaux A, Shah PK, Sharifi BG. [Bone Marrow-Derived Tenascin-C Attenuates Cardiac Hypertrophy by Controlling Inflammation.](#) *J Am Coll Cardiol.* 2017 Sep 26;70(13):1601-1615. doi: 10.1016/j.jacc.2017.07.789.
353. Arditi M and Shah PK: Slow the TRAFFIC and Reduce the plaque. *J Am Coll Cardiol.* 2018 Feb 6;71(5):543-546. doi: 10.1016/j.jacc.2017.12.023. No abstract available. PMID:29406860

B. MANUSCRIPTS UNDER PREPARATION/REVIEW

1. Xiaoning Zhao, *Paul C. Dimayuga, *Lai Fan Chan, Svetlana Fischer, Jianchang Zhou, Juliana Yano, Portia Trinidad, Wai Man Lio, Tomoyuki Honjo, Bojan Cercek, **Prediman K. Shah**, Kuang-Yuh Chyu . ApoB-100 derived peptide p210-loaded dendritic cells provoke CD8+ T cell activity and reduce atherosclerosis: **Submitted to Cardiovascular research 2016**
2. Fuqiang Li, Mingjie Yang, Lai Wang, Ian K. Williamson, Ana Arias, Lei Song, MinghuiQin, Ada Yukht, Fang Tian, **Prediman K. Shah** and Behrooz G. Sharifi. The phenotype of MerTK-positive macrophage subsets is determined by tissue environment under steady state conditions and in inflamed tissue: **Submitted to Immunology 2016**

C. NON-PEER REVIEWED PAPERS:

1. **Shah PK**, Swan HJC: Predominant right ventricular dysfunction in acute myocardial infarction. *Medical Grand Rounds* 3:209, 1984.
2. Siegel RJ, **Shah PK**, Fishbein MC: Restrictive cardiomyopathy of unknown cause. *Cardiology Board Review.* 2:51-60, 1985.
3. **Shah PK**, Berman DS, Maddahi J, Pichler M: Clinical implications of post-infarction predominant right ventricular dysfunction. *Cardiology Board Review.* 30:17, 1986.

4. Falk E, Fallon JT, Mailhac A, Fernandez-Ortiz A, Meyer BJ, Weng D, **Shah PK**, Badimon JJ, Fuster V: Muramidase: A useful monocyte/macrophage immunocytochemical marker in swine of special interest in experimental cardiovascular disease. *Cardiovascular Pathology* **1994**.
5. **Shah PK**, Moreno P, Falk E: Pathophysiology of plaque rupture. *J Vasc Biol* 5:(5-6): 244-258,1994.
6. **Shah PK**: Novel Therapeutic Directions Against Atherosclerosis. *Cardiology Today* 1:25-29, 1997.
7. Stone CK, Uretsky BF, Linnemeier TJ, **Shah PK**, Amin DK, Liang C: Hemodynamic effects of lisinopril in congestive heart failure. *Cardiology Board Review*, June 1990.
8. Chyu KY, **Shah PK** The role of inflammation in plaque disruption and thrombosis. *Rev Cardiovasc Med*. 2001 Spring;2(2):82-91.
9. Price MJ, **Shah PK**. New strategies in managing and preventing atherosclerosis: focus on HDL. *Rev Cardiovasc Med*. 2002 Summer;3(3):129-37. Review
10. Eshaghian S, Kaul S, **Shah PK**: Cardiac Amyloidosis. *Reviews in Cardiovascular Medicine* 2007 ;8(4):189-199.
11. Giant saphenous vein graft aneurysm causing left atrial compression and cardiogenic shock. Ng CY, Stevens S, Buch M, Dohad S, **Shah PK**, Cercek B, Chyu KY. *Rev Cardiovasc Med*. 2010 Summer;11(3):e170-5.

BOOKS:

1. **Shah PK, editor**. Acute Cardiac Care (Cardiology Clinics). New York: Saunders, 1991.
2. Mohsenifar Z and **Shah PK, editors**. Practical critical care in cardiology. New York: Marcel Dekker, 1998.
3. **Shah PK**, Falk, E, section editors. Ischemic Heart Disease. In: Crawford MH, DiMarco JP, lead editors. *Cardiology*. Harcourt Brace Jovanovitch, 2000.
4. **Shah PK**, Falk, E, **section editors**. Ischemic Heart Disease. In: Crawford MH, DiMarco JP, lead editors. *Cardiology*. Second Edition. Harcourt Brace Jovanovitch, 2003.

5. Falk E, **Shah P.K**, Feyter PD (**Co-Editors**): Ischemic Heart Disease, Manson Publishing 2007.
6. **Shah PK (Editor)**: Risk factors for coronary artery disease. Publisher: Taylor and Francis, 2006
7. **Shah PK** (Editor and Author): Dyslipidemia in Women. 2010
8. Asymptomatic Atherosclerosis 2010: Editor: Mort Nagahvi; Co-Editor: **PK Shah**

BOOK CHAPTERS:

1. Spindola-Franco H, **Shah PK**, Cohen MV. Mitral Valve Prolapse: An angiographic and echocardiographic study. In: VIIIth World Congress of Cardiology, Tokyo, Japan. Excerpta Medica, Tokyo, pp 1127-1130, 1978.
2. Maddahi J, Berman D, Diamond G, Gray R, **Shah PK**, Forrester J: Evaluation of left ventricular ejection fraction and segmental wall motion by multiple gated equilibrium cardiac blood pool scintigraphy. In: Computers in Cardiology, Marcel Dekker, Inc, New York, pp 389-416, 1978.
3. **Shah PK**, Singh BN: Can vasodilators limit ischemic injury following acute coronary artery occlusion. In: Corday E and Swan HJC, editors. Clinical Strategies in Ischemic Heart Disease, Williams & Wilkins, Baltimore, pp 440-452, 1979.
4. **Shah PK**, Pichler M, Berman D, Swan HJC: Noninvasively determined global and regional ventricular function in early acute myocardial infarction and its relation to prognosis. Excerpta Medica, Amsterdam, pp 193-196, 1979.
5. Swan HJC, **Shah PK**, Pichler M, Berman D: Early sequential measurements of left ventricular ejection fraction in the acute phase of myocardial infarction by equilibrium blood pool scintigraphy: a preliminary report. In: Advances in Clinical Cardiology, Volume II. Gerhard Witzstrock Publishing House Co, New York, 1980.
6. Swan HJC, **Shah PK**, Forrester JS: Hemodynamic consequences of heart disease with particular reference to myocardial ischemia and infarction. In: Variations Hemodynamique en Anesthesie, Proceedings of the Vth European Congress of Anesthesia, Tome 2, pp 815-820, 1980.
7. Berman DS, Maddahi J, Garcia EV, Freeman MR, **Shah PK**: Assessment of left and right ventricular function with multiple gated equilibrium cardiac blood

- pool scintigraphy. In: Berman D, Mason DT, editors. *Clinical Nuclear Cardiology*, Grune & Stratton, New York, 1980.
8. **Shah PK**, Berman DS, Shellock F: Clinical applications of equilibrium blood pool imaging in acute myocardial infarction. In: *Cardiac Disease and Rehabilitation*, Marcel Dekker, New York, 1983.
 9. Pantaleo N, **Shah PK**, Berman DS: Clinical applications of radionuclide angiography in congestive heart failure. In: *Congestive Heart Failure*, C.V. Mosby, St. Louis, 1983.
 10. Bunoy M, **Shah PK**: Physiological basis and clinical applications of bedside hemodynamic monitoring. In: *Congestive Heart Failure*, C.V. Mosby, St. Louis, 1983.
 11. Ganz W, Mercier JC, Lando U, Kanmatsuse K, Ninomiya K, Meerbaum S, Fishbein MC, Swan HJC, **Shah PK**: Divergent effects of inotropic stimulation on the mechanical function of ischemic and the severely depressed reperfused myocardium. In: Sigwart U and Heintzen PH. *Ventricular Wall Motion*. George Thieme Verlag, 1984.
 12. Swan HJC, **Shah PK**: Bedside hemodynamic monitoring in critically ill patients. In: Parillo J, editor. *Current Therapy in Critical Care Medicine*. 1986.
 13. Swan HJC, **Shah PK**: Acute myocardial infarction. In: Cheng TO, editor. *International Textbook of Cardiology*, Pergamon Press, New York, 1986.
 14. Kimchi A, Ellrodt GA, **Shah PK**, Riedinger MS, Charuzi Y, Berman DS, Swan HJC: Hemodynamic effects of nisoldipine in patients with severe heart failure. In: *Proceedings of the First International Nisoldipine symposium*, 1987.
 15. **Shah PK**, Swan HJC: Complicated acute myocardial infarction. In: Parmley W and Chatterjee K, editors. *Cardiology*, 1987.
 16. Lee W, **Shah PK**, Amin D, Elkayam U: Hemodynamic monitoring of cardiac patients during pregnancy. In: Elkayam U and Gleicher N, editors. *Cardiac Problems in Pregnancy*. 1989.
 17. Maddahi J, **Shah PK**, Berman DS: Clinical applications of radionuclide assessment of right ventricular function. In: Lyons KP, editor. *Cardiovascular Nuclear Medicine*. 1988.
 18. **Shah PK** and Swan HJC: Thrombolytic therapy in evolving acute myocardial infarction. In: Henning RJ and Grenvik A, editors. *Critical Care Cardiology*. 1989.

19. **Shah PK**, Francis G: Mechanical Complications of Acute Myocardial Infarction. In: Francis G and Alpert J, editors. Modern Coronary Care. 1989.
20. **Shah PK**: New Insights into the Electrocardiogram in Acute Myocardial Infarction. In: Gersh B and Rahimtoola S, editors. Acute Myocardial Infarction. Elsevier, 1990.
21. **Shah PK**, Zahger D: Unstable angina: Pathophysiology and treatment. In: Crawford M, editor. Current concepts in therapy. Lange Publications, 1994.
22. **Shah PK**, Francis G: Pump failure in acute myocardial infarction. In: Francis G and Alpert J, editors. Modern Coronary Care. Little Brown and Co., 1995.
23. Zahger D, **Shah PK**, Ganz W: Streptokinase in Acute Myocardial Infarction In: Francis G and Alpert J, editors. Modern Coronary Care. Little Brown and Co., 1995.
24. Moreno PR, **Shah PK**, Falk E: Determinants of Rupture of Atherosclerotic Coronary Lesions. In: Willich SN and Muller JE, editors. Triggering of Acute Coronary Syndromes-Implications for Prevention. 1995.
25. Falk E, **Shah PK**, Fuster V: Pathogenesis of Plaque Rupture. In: Fuster V, Ross R and Topol E, editors. Atherosclerosis and coronary artery disease. 1995.
26. Ganz W, **Shah PK**, Forrester JS: Hemodynamic monitoring in acute myocardial infarction. In: Fuster V, Ross R and Topol E, editors. Atherosclerosis and coronary artery disease. 1995.
27. **Shah PK**: Pathophysiology of plaque rupture and the concept of plaque stabilization. In: Abrams J and Pasternak R, editors. Cardiology Clinic. 1995.
28. **Shah PK**: Management of Evolving Acute Myocardial Infarction. In: Conn's Textbook, 1997
29. Falk E, Fuster V, **Shah PK**: Interrelationship between Atherosclerosis and Thrombosis. In: Verstrate M, Fuster V, Topol E, editors. Thrombocardiology. 1997.
30. **Shah PK**. Pathogenesis of atherosclerosis. In: Rosendorf, C, editor. Essential Cardiology: Principles and Practice. W. B. Saunders Company, 2001.
31. Price M and **Shah PK**: Inflammation as a mechanism contributing to atherosclerosis. Harrison's TextBook of Medicine Online 2002

32. **Shah PK:** Pathophysiology of Chronic and Acute Myocardial Ischemia: In "Heart rate and coronary artery disease" 2002
33. **Shah PK:** pathophysiology of plaque rupture and the concept of plaque stabilization. *Cardiology Clinics* 2003; 21(3):303-314
34. **Shah PK** and Falk E: Pathophysiology of Myocardial Ischemia. In: Shah, PK, editor. *International Textbook of Cardiology*, 2003.
35. Cercek, B and **Shah PK:** Hemodynamic Complications of Acute Myocardial Infarction. In: Shah, PK, editor. *International Textbook of Cardiology*, 2003.
36. **Shah PK:** Cellular and molecular mechanisms of plaque rupture. In: *High Risk Atherosclerotic Plaques: Edited by Levon M. Khachighian. CRC Press* 2005.
37. Kar S, **Shah PK:** Impact of new percutaneous techniques of aortic valve replacement on cardiology/cardiac surgery practice. In: *Transcatheter Valve Repair. Edited by Ziyad M. Hijazi, Philipp Bonhoeffer, Ted Feldman, Carlos Ruiz. Taylor and Francis: 2006*
38. **Shah PK.** Pathogenesis of atherosclerosis. In: Rosendorf, C, editor. *Essential Cardiology: Principles and Practice. W. B. Saunders Company*, 2004
39. **Shah PK, Sharifi B:** Insights into Molecular mechanisms of plaque rupture and Thrombosis. In *Biochemistry of Atherosclerosis* edited by S.K. Cheema. Springer, NY, 2006
40. **Shah PK, Falk E, Fuster V:** Inflammation and plaque rupture. In: *Hurst's The Heart 12th edition. Edited by Fuster V. McGraw Hill* 2007
41. **Shah PK:** Inflammatory Mechanisms in Atherosclerosis. In: *Inflammation: Edited by Cornelia Weyand* 2008
42. Chyu KY, **Shah PK:** Management of Unstable Angina: Conn's Current diagnosis and treatment in cardiology. Edited by: Michael Crawford. Publisher: McGraw Hill 2008
43. Chyu KY and **Shah PK:** Immune system in acute coronary syndromes. Theroux: *Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease. Elsevier* 2010
44. Morteza Naghavi, Erling Falk, Khurram Nasir, Harvey S. Hecht, Matthew J. Budoff, Zahi A. Fayad, Daniel S. Berman, and **Prediman K. Shah.** Approach to Atherosclerosis as a Disease: Primary Prevention Based on the Detection and Treatment of Asymptomatic Atherosclerosis. In *Asymptomatic Atherosclerosis; Edited by Morteza Naghavi, MD; Springer* 2010

45. Morteza Naghavi, Erling Falk, Harvey S. Hecht, Michael J. Jamieson, Sanjay Kaul, Daniel S. Berman, Zahi Fayad, Matthew J. Budoff, John Rumberger, Tasneem Z. Naqvi, Leslee J. Shaw, Jay N. Cohn, Ole Faergeman, Raymond D. Bahr, Wolfgang Koenig, Jasenka Demirovic, Dan Arking, Victoria L.M. Herrera, Juan Jose Badimon, James A. Goldstein, Arturo G. Touchard, Yoram Rudy, K.E. Juhani Airaksinen, Robert S. Schwartz, Ward A. Riley, Robert A. Mendes, Pamela S. Douglas, and **Prediman K. Shah**. From Vulnerable Plaque to Vulnerable Patient – Part III; In Asymptomatic Atherosclerosis, Edited by: Morteza Naghavi, MD, Springer 2010.
46. **Prediman K. Shah**, Kuang-Yuh Chyu, Jan Nilsson, and Gunilla N. Fredrikson: Vaccine for Atherosclerosis: An Emerging New Paradigm: In Asymptomatic Atherosclerosis Edited by Morteza Naghavi, MD. Springer 2010
47. **Shah PK**: Pathogenesis of Atherothrombosis. Textbook of Cardiology edited by Kanu Chatterjee: In Press 2012
48. Chen S, **Shah PK**, Arditi Moshe: Innate Immunity and Atherosclerosis. In Clinical Immunology 4th Edition, Elsevier 2011. Edited by: Robert R. Rich, Thomas A. Fleischer, William T. Shearer, Harry W. Schroeder Jr., Anthony J. Frew, Cornelia M. Weyand (In Press 2012)

LETTERS TO THE EDITOR

1. **Shah PK**: Buccal nitroglycerin ointment in acute cardiac pulmonary edema. Ann Intern Med 103(1):153-154, 1985.
2. Furst SR, Fallon SP, Reznick GN, **Shah PK**: Myocardial infarction after inhalation of Methamphetamine. N Engl J Med 323(16):1147-1148, 1990.
3. Zahger D, **Shah PK**. Effect of smoking status on response to thrombolytic therapy. J Am Coll Cardiol, 28(1):283, 1996.
4. **Shah PK**: Right ventricular infarction. New Engl J of Med 329(14):1043, 1993.
5. **Shah PK**: Sildenafil in the treatment of erectile dysfunction. N Engl J Med 339(10):699, 1998.
6. **Shah PK**. J Am Coll Cardiol. 2010 Nov 23;56(22):1861-2. No abstract available.

REVIEWS

1. **Shah PK**: Ventricular unloading in the management of heart disease: role of vasodilators. Part I. Am Heart J 93(2):256-260, 1977.

2. **Shah PK:** Ventricular unloading in the management of heart disease: role of vasodilators. Part II. *Am Heart J* 93(3):403-406, 1977.
3. **Shah PK,** Hattori V, Berman DS, Maddahi J, Pichler M: Clinical implications of precordial ST depression in acute inferior myocardial infarction. *Primary Cardiology* 9(7):173-182, 1983.
4. **Shah PK:** Clinical applications of bedside hemodynamic monitoring using the Swan-Ganz catheter. *Physiologist* 26(1):43-45, 1983.
5. Swan HJC and **Shah PK:** Bedside hemodynamic monitoring in the critically ill. The rationale for bedside hemodynamic monitoring. *J Crit Illn (Part I)*. 1(4):24-28, 1986.
6. Amin DK, **Shah PK** and Swan HJC: Bedside hemodynamic monitoring in the critically ill. The Swan-Ganz catheter: Choosing and using the equipment. (Part II). *J Crit Illn* 1(4):34-37, 1986.
7. Amin DK, **Shah PK** and Swan HJC: Bedside hemodynamic monitoring in the critically ill. The Swan-Ganz catheter: Insertion technique. (Part III). *J Crit Illn* 1(4):38-45, 1986.
8. Amin DK, **Shah PK** and Swan HJC: Bedside hemodynamic monitoring in the critically ill. The Swan-Ganz catheter: Tips on interpreting results. (Part IV). *J Crit Illn* 1(5):40-48, 1986.
9. Amin DK, **Shah PK** and Swan HJC: Bedside hemodynamic monitoring in the critically ill. The Swan-Ganz catheter: Indications for insertion. (Part V). *J Crit Illn* 1(5):54-61, 1986.
10. Gonick HC, Weiler EWJ, Horn E, Khalil-Manesh F, **Shah PK,** Amin D: Urinary Na-K-ATPase inhibitors and digoxin-like immunoreactive substances in acute congestive heart failure. *Proceedings of the Seminar on Actual Problems of Cardiac Failure, Tbilisi, Georgia, USSR, October 23-26, 1989.*
11. **Shah PK:** Complication of acute myocardial infarction: Relative usefulness of non-invasive diagnostic techniques (Echocardiography versus radionuclide ventriculography) *Cardiovascular Imaging* 2(2), 1990.
12. Goodman JS and **Shah PK:** How and when to suspect post-MI mechanical complications. *J Crit Illn* 5(7):681-694, 1990.
13. **Shah PK.** Pathophysiology of unstable angina. *Cardiology Clinics*, 9(1):11-26, 1991.

14. **Shah PK:** New pathophysiologic insights into the mechanism of acute coronary syndromes. In: *Advances in Cardiology and Cardiac Surgery. An International Symposium. Il Ciocco, May 2-5, 1991.*
15. Cercek B, **Shah PK.** Complicated acute myocardial infarction. Heart failure, shock, mechanical complications. *Cardiology Clinics, 9(4):569-93, 1991.*
16. Ameli S, **Shah PK.** Cardiac tamponade. Pathophysiology, diagnosis, and management. *Cardiology Clinics, 9(4):665-74, 1991.*
17. Bingham SE, Berman DS, **Shah PK.** Nuclear imaging in acute cardiac care. *Cardiology Clinics, 9(4):733-59, 1991.*
18. **Shah PK,** Forrester JS: Pathophysiology of acute coronary syndromes. *Am J Cardiol 68(12):16C-23C, 1991.*
19. **Shah PK:** The role of thrombolytic therapy in patients with acute myocardial infarction presenting later than six hours after the onset of symptoms. *Am J Cardiol 68(12):72C-77C, 1991.*
20. **Shah PK:** Acute aortic dissection, Part 1: Clues that signal impending disaster. Acute aortic dissection, Part 2: Choosing among management options. *J Crit Illn 7(7):1075-1078, 1992.*
21. Zahger D, **Shah PK:** Anticoagulant therapy following myocardial infarction. *Cardiology in Review: 60 123-134, 1993.*
22. **Shah PK,** Pasternak R: The role of lipids in restenosis following angioplasty. *Current Opinions in Lipidology 4:310-313, 1993.*
23. Amin DK, **Shah PK,** Swan HJC: Deciding when hemodynamic monitoring is appropriate. *J Crit Illn 8(9) 1053, 1993.*
24. Amin DK, **Shah PK,** Swan HJC: The technique of inserting a Swan-Ganz catheter. *J Crit Illn 8(10)1147, 1993.*
25. Falk E, **Shah PK,** Fuster V: Coronary plaque disruption. *Circulation 92(3):657-671, 1995.*
26. **Shah PK:** New antithrombotic drugs for systemic and local delivery for coronary artery disease. *J Interv Cardiol 8(4): 427-437, 1995.*
27. **Shah PK:** Pathophysiology of plaque rupture and the concept of plaque stabilization. [Review] *Cardiol Clin 14(1):17-29, 1996.*

28. Forrester JS, **Shah PK**: Using serum cholesterol as a screening test for preventing coronary heart disease: the five fundamental flaws of the American College of Physicians Guidelines. *Am J Cardiol* 79(6):790-792, 1997.
29. **Shah PK**: Pathophysiology of Acute Coronary Syndromes. *Am J Cardiol*: 79(12B) 17-23, 1997.
30. **Shah PK**. Plaque disruption and coronary thrombosis: new insight into pathogenesis and prevention. *Clin Cardiol* 20(11 Suppl 2):II-38-44, 1997
31. **Shah PK**: Novel Anti-atherogenic strategies: from gene therapy to Nitric Oxide Donors. *Cardiology Today* 1:25-29, 1997.
32. **Shah PK**: New insights into the pathogenesis and prevention of acute coronary syndromes. *Am J Cardiol* 79(12B):17-23, 1997
33. **Shah PK**: Role of inflammation and metalloproteinases in plaque disruption and thrombosis. *Vasc Med* 3(3):199-206, 1998
34. **Shah PK**. Plaque disruption and thrombosis. Potential role of inflammation and infection. *Cardiol Clin.* 17(2):271-81, 1999.
35. **Shah PK**: Targeting the proteolytic arsenal of neutrophils: A promising approach to postpump syndrome and ARDS *Circulation* 100(4):333-334, 1999.
36. **Shah PK**, Dhar S: New and emerging risk factors for atherothrombotic coronary artery disease. *Indian Heart J*, 2000
37. **Shah PK**: Focus on HDL: A new treatment paradigm for athero-thrombotic vascular disease. *Expert Opinion on Investigational Drugs*, 2000
38. Chyu KY, **Shah PK**: Role of Inflammation in atherothrombosis. *Drug News & Perspectives, Drug News Perspect* 14(2): 101-109,2001
39. Kar S, **Shah PK**. Acute coronary syndrome caused by coronary artery dissection mimicking acute plaque rupture. *Rev Cardiovasc Med.* 2001 Fall;2(4):215-9.
40. Chyu KY, **Shah PK**: Role of inflammation in plaque disruption and thrombosis. *Reviews in Cardiovascular Medicine*, 2002
41. **Shah PK**: Chronic infection and atherothrombosis. *Current Atherosclerosis Reviews* 2002 (In press)

42. Price M, **Shah PK**: HDL and apolipoprotein A-1: the next frontier in atherosclerosis management. International Atherosclerosis Society Proceeding (Electronic Publication on the Web 2002)
43. Price MJ, **Shah PK**. New strategies in managing and preventing atherosclerosis: focus on HDL. Reviews in Cardiovasc Medicine. 2002; 3(3):129-37.
44. **Shah PK**: Emerging non-statin LDL-lowering Therapies for Dyslipidemia and Atherosclerosis: Reviews in Cardiovascular Medicine 2003; 4(3):136-141
45. **Shah PK**: Pathophysiology of plaque rupture and the concept of plaque stabilization. [Review] Cardiol Clin 2003; 21(3): 303-314
46. **Shah PK**, Chyu KY, Nilsson J: Immunotherapy for atherosclerosis: An emerging paradigm. Reviews in Cardiovascular Medicine. 2004

INVITED EDITORIALS

1. **Shah PK**, Berman DS: Implications of precordial ST segment depression in acute inferior myocardial infarction. Am J Cardiol 48(6):1167-1168, 1981.
2. **Shah PK**, Berman DS, Swan HJC: Precordial ST segment depression in acute inferior myocardial infarction: Innocent bystander or a high risk indicator? Int J Cardiol 4(1):75-80, 1983.
3. **Shah PK** and Helfant RH: Smoking and coronary artery disease. Chest 96(3):449-452, 1988.
4. **Shah PK**: Application of nuclear cardiology in the coronary care unit: Achievements and challenges. J Nuclear Cardiology, 1(3):304-6, 1994.
5. Forrester JS, **Shah PK**: Lipid lowering versus revascularization: An idea whose time for testing has come. Circulation 96(4):1360-1362, 1997.
6. **Shah PK**: Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation 96(7):2115-2117, 1997.
7. **Shah PK**: Plaque size, vessel size and plaque vulnerability: bigger may not be better. J Am Coll Cardiol, 32(3):663-4, 1998.
8. **Shah PK**: Targeting the Proteolytic Arsenal of Neutrophils: A promising approach to post-pump syndrome and ARDS. Circulation 100:333-334, 1999.

9. **Shah PK:** Circulating markers of inflammation for vascular risk prediction: are they ready for prime time. *Circulation* 101(15):1758-9, 2000.
10. **Shah PK:** Link Between Infection and Atherosclerosis: Who Are The Culprits: Viruses, Bacteria, Both, or Neither? *Circulation* 103(1):5-6, 2001.
11. **Shah PK,** Galis Zorina: MMP Hypothesis of Plaque Rupture: Players keep piling up but questions remain. *Circulation* 2001
12. **Shah PK:** LDL lowering and Progression of Atherosclerosis: Does More mean Less. *Circulation* 2002; 106:2039-2040.
13. **Shah PK:** As the leucocytes roll the arteries thicken. *Circulation* 2003; 107:2175-2177.
14. **Shah PK:** Preservation of extracellular matrix by passive myocardial restraint: A new paradigm for prevention of adverse remodeling and progressive heart failure. *Circulation* 2005 ;112(9):1245-1247.
15. Chyu KY, **Shah PK:** Choking off plaque neovascularity: a novel athero-protective strategy or a double edged sword. *Arteriosclerosis, Thrombosis and Vascular Biology* 2007;27(5): 993-995
16. **Shah PK:** Innate immune pathway links obesity to insulin resistance. *Circulation Research*, 2007 ;100(11):1531-1533

ABSTRACTS

1. Harris WS, Zanghellini WM, **Shah PK,** Swan HJC, Matloff JM: Loss of reflex vasodilative response to cardiac stretch in coronary artery disease. *Circulation* 55:(Suppl III):781, 1977.
2. Gray R, Shell WE, Conklin C, **Shah PK,** Miyamoto AT, Matloff JM, Swan HJC: Quantification of myocardial injury during coronary artery bypass graft. *Circulation* 58 (Suppl I):I-42, 1978.
3. Maddahi J, Berman DS, Silverberg R, Charuzi Y, Buchbinder N, Gray R, Waxman AD, **Shah PK,** Swan HJC, Forrester JS: Validation of a two-minute technique for multiple gated scintigraphic assessment of left ventricular ejection fraction and regional wall motion. *J Nucl Med* 19:669, 1978.
4. **Shah PK,** Maddahi J, Berman D, Pichler M, Peter T, Waxman A, Singh BN, Forrester J, Swan HJC: Scintigraphic correlates of precordial ST depression in acute inferior myocardial infarction: identification of a high risk subset. *Clin Res* 26(3):217A, 1978.

5. **Shah PK**, Maddahi J, Berman D, Pichler M, Peter T, Waxman A, Singh BN, Swan HJC, Forrester J: Relation between scintigraphic and hemodynamic parameters in early acute myocardial infarction. *Clin Res* 26(3):217A, 1978.
6. Maddahi J, Berman D, Silverberg R, Gray R, Waxman A, Charuzi Y, Vas R, Buchbinder N, **Shah PK**, Swan HJC, Forrester J: Two-minute gated scintigraphic assessment of left ventricular ejection fraction and regional wall motion: validation of the method. *Clin Res* 26(3):250A, 1978.
7. Maddahi J, Berman D, Silverberg R, Charuzi Y, Buchbinder N, Gray R, Waxman A, Vas R, **Shah PK**, Swan HJC, Forrester J: Validation of a two-minute technique for multiple gated ejection fraction and regional wall motion. *J Nucl Med* 19:669, 1978.
8. **Shah PK**, Berman D, Maddahi J, Pichler M, Peter T, Waxman A, Singh BN, Forrester J, Swan HJC: Scintigraphic identification of a high risk subset of acute inferior myocardial infarction. *J Nucl Med* 19:680, 1978. (Presented at the Annual Meeting of Society of Nuclear Medicine, Anaheim, June 1978.)
9. Charuzi Y, Davidson R, Barrett M, **Shah PK**, Berman D, Waxman A, Pichler M, Maddahi J, Corday E, Swan HJC: A quantitative comparison of cross-sectional echocardiography and radionuclide angiography in acute myocardial infarction. *Circulation* 58(Suppl II):52, 1978.
10. **Shah PK**, Pichler M, Berman D, Maddahi J, Urban M, Shellock F, Swan HJC: Nitroprusside induced improvement in global and segmental ventricular function in acute myocardial infarction. *Am J Cardiol* 43:394, 1979. (Presented at the American College of Cardiology Meeting, Miami Beach, March 1979.)
11. Maddahi J, **Shah PK**, Berman DS, Pichler M, Matsuoka DT, Forrester JS, Swan HJC: Assessment of right ventricular ejection fraction in early acute myocardial infarction by multiple gated equilibrium scintigraphy: hemodynamic correlates and prognostic significance. *Am J Cardiol* 43:371, 1979.
12. Pichler M, **Shah PK**, Diamond G, Berman D, Shell W, Swan HJC, Forrester JS: Correlation between creatine kinase-isoenzyme MB infarct size and left ventricular function in patients with first transmural myocardial infarction. *Clin Res* 29, February 1979.
13. Freeman M, Pichler M, Berman D, **Shah PK**, Maddahi J, Waxman A, Staniloff H, Elkayam U, Anderson A, Swan HJC, Forrester JS: Improved noninvasive assessment of segmental wall motion in acute myocardial infarction by an additional 70° LAO view in multiple gated equilibrium scintigraphy. *Clin Res* 29, February 1979.

14. Maddahi J, **Shah PK**, Berman D, Pichler M, Matsuoka D, Forrester JS, Swan HJC: Multiple gated equilibrium in assessment of right ventricular ejection fraction in early acute myocardial infarction: hemodynamic correlates and prognostic significance. Clin Res 29, February 1979.
15. Pichler M, **Shah PK**, Peter T, Berman D, Shell W, Forrester J, Swan HJC: Evidence for functional differences between anterior and inferior walls of left ventricle. Clin Res 29, February 1979.
16. **Shah PK**, Pichler M, Berman D, Stankus K, Peter T, Swan HJC: Early prediction of risk of mortality in acute myocardial infarction. Clin Res 29, February 1979.
17. Swan HJC, **Shah PK**, Pichler M, Berman D: Significance of sequential measurements of left ventricular ejection fraction in acute myocardial infarction - a preliminary report. (Presented at the Symposium on Hemodynamics and Ventricular Function During Exercise, European Society of Cardiology, Berlin [West Germany], September 13-15, 1979.)
18. **Shah PK**, Pichler M, Berman D, Freeman M, Waxman A, Swan HJC: Prognosis following acute myocardial infarction is related to initial left ventricular ejection fraction. Circulation 60:11-163, 1979. (Presented at the American Heart Association Annual Meeting, Anaheim, November 1979.)
19. Ganz W, Marcus HS, Buchbinder N, Mondkar A, Berezovsky L, Peter T, O'Connor L, Charuzi Y, **Shah PK**, Maddahi J, Berman D, Shell W, Beeder C: Rapid intracoronary thrombolysis in evolving myocardial infarction. Clin Res 28(2):172A, 1980.
20. **Shah PK**, Mickle D, Shell W, O'Connor L, Berman D, Swan HJC: Influence of right ventricular dysfunction and time of determination on relationship between left ventricular ejection fraction and enzymatic infarct size. Clin Res 28(2):210A, 1980.
21. **Shah PK**, Rubin S, Shellock F, Berman D, Swan HJC: Can noninvasive determination of left ventricular ejection fraction alone predict beneficial hemodynamic response to vasodilator therapy in severe chronic heart failure. Clin Res 28(2):211A, 1980.
22. **Shah PK**, Nemerovski M, Pichler M, Berman D, Swan HJC: Early sequential changes in global and regional left ventricular function following acute myocardial infarction and their relationship to short term prognosis. Clin Res 28(2):211A, 1980.
23. **Shah PK**, Shellock F, Berman D, Swan HJC: Sustained beneficial hemodynamic effects of peritrate in chronic heart failure. (Presented at the International Symposium on Oral Nitrates, Paris [France], January 1980.)

24. **Shah PK**, Pichler M, Berman D, Swan HJC: Effects of intra-aortic balloon pumping on global and regional ventricular function in acute myocardial infarction. (Presented at the European Congress of Cardiology, Paris [France], June 1980.)
25. **Shah PK**, Picher M, Berman D, Swan HJC: Vasodilator induced changes in global and regional ventricular function in acute myocardial infarction. (Presented at the International Symposium on Nitrates, Monte Carlo [Monaco], June 1980.)
26. **Shah PK**, Ellrodt AG, Berman D, Shellock F, Maddahi J, Pichler M, Waxman A, Swan HJC: High and low risk subsets among patients with no or mild post-infarction heart failure: early identification by radionuclide ventriculography. Clin Nucl Med, September 1980. (Presented at the Western Regional Meeting of the Society of Nuclear Medicine, Los Angeles, October 1980.)
27. **Shah PK**, Maddahi J, Berman D, Shellock F, Pichler M, Waxman A, Swan HJC: Acute myocardial infarction with predominant right ventricular dysfunction: frequency, clinical, hemodynamic and scintigraphic findings. Clin Nucl Med, September 1980 (Presented at the Western Regional Meeting of the Society of Nuclear Medicine, Los Angeles, October, 1980.)
28. Ganz W, Buchbinder N, Marcus H, Mondkar A, O'Connor L, Maddahi J, Charuzi Y, Peter T, Berman D, **Shah PK**, Swan HJC, Kass R: Intracoronary thrombolysis in evolving myocardial infarction in man. Circulation 62:II-162 (part II), 1980. (Presented at the American Heart Association Meeting, Miami Beach, November 1980.)
29. **Shah PK**, Maddahi J, Pichler M, Shellock F, Berman DS, Swan HJC: Relationship of left and right ventricular ejection fraction to preadmission cardiac arrest and in-hospital prognosis in acute myocardial infarction. Circulation 62:III-128 (part II), 1980. (Presented at the American Heart Association Annual Meeting, Miami Beach, November 1980.)
30. **Shah PK**, Shellock F, Berman D, Maddahi J, Pichler M, Swan HJC: Predominant right ventricular dysfunction in acute myocardial infarction: frequency, clinical, hemodynamic and scintigraphic findings. Circulation 62:III-313 (part II), 1980. (Presented at the American Heart Association Annual Meeting, Miami Beach, November 1980.)
31. Levy R, **Shah PK**, Pichler M, Shellock F, Berman D, Swan HJC: Inferior lead ST depression in transmural anterior infarction: an indicator of extensive global and regional ventricular dysfunction. J Nucl Med 22:80, 1981. (Presented at the Society of Nuclear Medicine 28th Annual Meeting, Las Vegas, June 1981.)

32. **Shah PK**, Ellrodt AG, Pichler M, Berman D, Shellock F, Swan HJC: Radionuclide ventriculography for early identification of high and low risk subsets among patients with no or mild post-infarction heart failure. *J Nucl Med* 22:54, 1981. (Presented at the Society of Nuclear Medicine 28th Annual Meeting, Las Vegas, June 1981.)
33. **Shah PK**, Ganz W, Maddahi J, Berman D, Shellock F, Swan HJC: Intracoronary thrombolysis in early acute myocardial infarction improves biventricular function compared to conventional therapy. *Circulation* 64-II, IV-194, 1981. (Presented at the American Heart Association 54th Scientific Sessions, Dallas, November 1981.)
34. Swan HJC, Ganz W, Maddahi J, **Shah PK**: Intracoronary thrombolysis in evolving myocardial infarction. (Presented at the Autumn Meeting of the British Cardiac Society, Wembly [England], December 7-8, 1981.)
35. Levy R, Rozanski A, Zwehl W, Childs W, Maurer G, Garcia E, Areeda J, Corday S, **Shah PK**, Shellock F, Berman D, Corday E: Comparison of computerized two-dimensional echocardiography and radionuclide ventriculography in the assessment of left ventricular function in patients with acute myocardial infarction. *J of Nuclear Med.* 1982.
36. Shellock FG, Rubin SA, Ellrodt G, Muchlinski A, **Shah PK**, Swan HJC: Unusual core temperature decrease in exercising heart failure patients. *Clinical Research* 30(2):220A, 1982.
37. Peter T, **Shah PK**, Shellock F, Maddahi J, Berman D, Swan HJC: Two view stress radionuclide ventriculography soon after transmural myocardial infarction: safety, reproducibility and advantages. *Clinical Research* 30(2):213A, 1982.
38. **Shah PK**, Levy R, Shellock F, Berman D, Swan HJC: Adverse functional and prognostic implications of inferior ST depression in first transmural anterior infarction. (Presented at the International Symposium on Ventricular Wall Motion, Lausanne [Switzerland], May 1982.)
39. **Shah PK**, Ganz W, Shellock F, Berman D, Swan HJC: Influence of early intracoronary thrombolysis and time from onset of infarction to reperfusion on ventricular function in acute myocardial infarction. (Presented at the International Symposium on Ventricular Wall Motion in Lausanne [Switzerland], May 1982.)
40. Ganz W, Mercier JC, **Shah PK**, Fishbein MC: Divergent effects of inotropic stimulation on the mechanical functions of the ischemic and the severely depressed reperfused myocardium. (Presented at the International Symposium on Ventricular Wall Motion, Lausanne [Switzerland], May 1982.)

41. **Shah PK**, Ganz W, Shellock F, Berman D, Maddahi J, Swan HJC: Effect of intracoronary thrombolysis and time from onset of infarction to reperfusion on ventricular function in acute myocardial infarction. *J of Nuclear Med* 33(5):4, 1982. (Presented at the Society of Nuclear Medicine 29th Annual Meeting, Miami Beach, June 1982.)
42. Reisman S, Shellock FG, **Shah PK**, Berman D, Swan HJC: Relationship between early electrocardiographic changes and left ventricular function in acute transmural anterior myocardial infarction. *Clin Res* 31(1):16A, 1983.
43. Reisman S, **Shah PK**, Shellock FG, Berman D, Swan HJC: Right bundle branch block in acute transmural anterior myocardial infarction: Relationship of prognosis to degree of ventricular dysfunction. *J Nuc Med* 24:P68, 1983.
44. Weiss AT, Maddahi J, Geft I, **Shah PK**, Swan HJC, Ganz W, Berman D: "Apparent worsening" in late post-streptokinase rest-redistribution T1-201 scans: a sign of reperfused viable myocardium. *Circulation* 68, III-245, 1983.
45. Geft IL, Rodriguez L, **Shah PK**, Charuzi Y, Sasaki H, Weiss a, Maddahi J, Berman DS, Swan HJC, Ganz W: Comparison of intravenous and intracoronary streptokinase in evolving myocardial infarction. *Circulation* 68, III-326, 1983.
46. Riedinger MS, Shellock FG, **Shah PK**, Weissfeld AS, Ellrodt AG: Sterility of thermodilution cardiac output injectate solutions: room vs, ice temperature. *Circulation* 68, III-222, 1983.
47. Amin D, **Shah PK**, Shellock FG, Hulse S, Brandon G, Spangenberg R, Swan HJC: Comparative hemodynamic effects of dobutamine and MDL 17,043 in congestive heart failure. *Circulation* 68, III-127, 1983.
48. Maddahi J, Weiss T, Geft I, **Shah PK**, Berman D, Swan HJC, Ganz W: Coronary thrombolysis with intravenous streptokinase salvages jeopardized myocardium in evolving myocardial infarction: Assessment by quantitative T1-201 imaging. *Circulation* 68, III-120, 1983.
49. Geft IL, Rodriguez L, **Shah PK**, Weiss A, Maddahi J, Berman D, Ganz W: Intracoronary thrombolysis: Long-term follow up. *Circulation* 68 III-412, 1983.
50. Amin DK, **Shah PK**, Shellock FG, Hulse S: Comparative hemodynamic effects of intravenous nitroprusside and MDL 17, 043 in severe congestive heart failure. *Clin Res* 32(2), 148A, 1984.
51. Amin DK, **Shah PK**, Shellock FG, Hulse S: Acute hemodynamic and myocardial metabolic effects of a new phosphodiesterase inhibitor, MDL 17,043 in severe heart failure. *Clin Res* 32(2), 147A, 1984.

52. Amin DK, **Shah PK**, Hulse S, Shellock FG, Rubin S, Swan HJC: Salutory hemodynamic effects of IV and oral MDL 17,043 in severe congestive heart failure. Clin Res 32(2), 148A, 1984.
53. Maurer G, Haendchen R, Amin DK, **Shah PK**: Quantitative 2D-Echo evaluation of a new inotropic drug, MDL-17,043, in congestive heart failure of patients. Clin Res 32(2) 188A, 1984.
54. Maurer G, Haendchen R, Amin DK, **Shah PK**: Quantitative 2D-Echo evaluation of a new inotropic drug, MDL-17,043, in congestive heart failure patients. (Presented at the IXth European Congress of Cardiology, Dusseldorf [West Germany], 1984.)
55. Shellock FG, Riedinger MS, Fishbein MC, **Shah PK**: Brown adipose tissue in cancer patients: Possible cause of cancer-induced cachexia. Clin Res 33(1):74A, 1985.
56. Lew AS, Laramée P, **Shah PK**, Rodriguez L, Ganz W: The effect of the rate of intravenous infusion of streptokinase on the time interval to reperfusion and on blood pressure. Clin Res 33(1), 1985.
57. Lew AS, Peter T, **Shah P**, Maddahi J, Berman D, Ganz W: Q waves predict larger infarction size and worse left ventricular function after early reperfusion. Clin Res 33(1), 1985.
58. Kimchi A, Ellrodt AG, **Shah PK**, Riedinger MS, Berman DS, Swan HJC, Murata GH: Salutory hemodynamic effects of nisoldipine (Bay K 5552), a new calcium channel blocker, in patients with severe chronic congestive heart failure. Clin Res 33(1), 1985.
59. Kimchi A, Ellrodt AG, **Shah PK**, Riedinger MS, Berman DS, Swan HJC, Murata GH. Salutory hemodynamic effects of nisoldipine (Bay K 5552) a new calcium channel blocker, in patients with severe chronic congestive heart failure. J Am Coll Cardiol 5(2) 420, 1985.
60. Lew AS, Laramée P, **Shah PK**, Rodriguez L, Ganz W: The effect of the rate of intravenous infusion of streptokinase on systolic blood pressure and on the time interval to reperfusion. J Am Coll Cardiol 5(2):421, 1985.
61. Lew AS, Geft I, Rodriguez L, **Shah PK**, Swan HJC, Ganz W: Short and long-term mortality following intracoronary of intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 5(2):496, 1985.
62. Amin D, **Shah PK**, Hulse S, Shellock FG: Superior acute hemodynamic effects of intravenous MDL-17,043 in comparison to nitroprusside and dobutamine in severe congestive heart failure. J Am Coll Cardiol 5(2):543, 1985. (Presented at

the 34th Annual Scientific Session of the American College of Cardiology, March 1985.)

63. Amin DK, **Shah PK**, Hulse S: Diagnosis of postero-lateral infarction: lack of accuracy of commonly used EKG criteria. Federation Proceedings 44:2312. (Presented at FASEB, April 1985.)
64. Amin DK, **Shah PK**, Shellock FG, Hulse S: Comparative hemodynamic and myocardial metabolic effects of intravenous dobutamine and MDL 17,043 in congestive heart failure. Federation Proceedings 44:716, 1985. (Presented at FASEB, April 1985.)
65. **Shah PK**, Amin DK, Hulse S (Sponsor: F. Shellock): Diagnosis of posterolateral infarction: Lack of accuracy of commonly used EKG criteria. Federation Proceedings 44:2312, 1985.
66. Cercek B, Lew AS, Laramée P, **Shah PK**, Ganz W, Peter T: Ventricular arrhythmias during the 24 hours following reperfusion and before discharge in patients with acute myocardial infarction. Clin Res 34(1):5A, 1986.
67. Lew AS, Berberian L, Laramée P, Cercek B, Lee S, Hod H, **Shah PK**, Ganz W: Elevated serum D dimer, a degradation product of crosslinked fibrin (XDP) following intravenous streptokinase during acute myocardial infarction. Clin Res 34(1):10A, 1986.
68. Lew AS, Peter T, Maddahi J, Laramée P, Cercek B, Hod H, **Shah PK**, Ganz W: Do pre-treatment pathological Q waves preclude myocardial salvage following early reperfusion? Clin Res 34(1):10A, 1986.
69. Weiler E, Khalil-Manesh F, Horn E, Amin D, **Shah PK**, Gonick HC: Circulating high molecular weight form of Na-K-ATPase inhibitor: Changes in disease. Clin Res 34(1):90A, 1986.
70. Weiler E, Khalil-Manesh F, Horn E, Amin D, **Shah PK**, Gonick HC: Circulation high molecular weight form of Na-K-ATPase inhibitor: changes in disease. Clin Res 34(1):90A, 1986.
71. Roberts R, Gibson RS and the Diltiazem Reinfarction Study (DRS) Group: Prophylactic therapy with diltiazem prevents early reinfarction: A multicenter randomized double-blind trial in patients recovering from non-Q-wave infarction. J Am Coll Cardiol 7(2), 68A, 1986.
72. Uretsky BF, Shaver JA, Liang C-S, Amin D, **Shah PK**, Levine TB, Walinsky P, LeJemtel T, Linnemeier TJ for the Lisinopril Study Group: Hemodynamics and renal function changes can be dose-titrated with the converting enzyme inhibitor lisinopril. (Presented at the American Heart Association Annual Meeting, 1986.)

73. Amin DK, Weiler E, **Shah PK**, Horn E, Hulse S, Khalil-Manesh F, Gonick HC: Urinary excretion of endogenous Quabain-like intermediate and low molecular weight Na-K-ATPase inhibitor in acute congestive heart failure. Clin Res 34(1):280A, 1986.
74. Stone CK, Uretsky BF, Linnemeier TJ, Amin DS, **Shah PK**: Snapinn SM, Wang CS: Persistent hemodynamic effects of lisinopril after chronic therapy in congestive heart failure J Am Coll Cardiol 9(2), 104A, 1987.
75. Mohsenifar A, Amin D, Jasper AC, **Shah PK**, Mickle E, Koerner SK: Dependency of oxygen consumption on oxygen delivery in patients with chronic congestive heart failure. Am Rev of Resp Dis 135 PA213, 198. (Presented at American Thoracic Society, 1987.)
76. Amin J, Antonescu A, **Shah PK**: Low HDL levels are associated with an increased restenosis rate following coronary angioplasty. Annual Scientific Session of the American Heart Association, 1990.
77. Ameli S, Fallon S, Sharifi B, **Shah PK**: Increased circulating Neutrophil specific elastase in acute ischemic syndromes: Evidence for enhanced neutrophil activity in coronary artery disease. Annual Scientific Session of American Heart Association, 1990.
78. Schmidt D and **Shah PK**: Simple bedside application of Valsalva maneuver accurately detects elevated left ventricular filling pressures in patients with normal or depressed ejection fraction. American College of Cardiology 40th Annual Scientific Session, 1991.
79. **Shah PK**, Lew AS, Cercek B, Ganz W: Temporal distribution of treatment to reperfusion times in patients with acute myocardial infarction receiving streptokinase or tissue plasminogen activator. American College of Cardiology 40th Annual Scientific Session, 1991.
80. Anderson JL, Sorensen SG, Kargounis L, Browne KF, **Shah PK**, Morris DC, Fintel DJ, Mueller HS, Ross AM: A double-blind randomized comparison and Anistreplase and Alteplase in acute myocardial infarction: Coronary patency results from the team-3 study. American College of Cardiology 40th Annual Scientific Session, 1991.
81. Baratz DM, Westbrook PR, **Shah PK**, Mohsenifar Z: The effect of nasal continuous positive airway pressure (CPAP) on hemodynamics and oxygen delivery in acute decompensation of congestive heart failure (CHF). American Thoracic Society - American Lung Association, 1991.

82. **Shah PK** and Ganz W: Diagnostic and therapeutic implications of Bezold-Jarisch reflex during thrombolytic therapy in acute myocardial infarction. American Federation of Clinical Research, 1991.
83. Sharifi BG, Fallon S, Ameli S, **Shah PK**: Vascular smooth muscle cells enhance survival and superoxide production by human neutrophils. American Federation of Clinical Research, 1991.
84. Sharifi BG, Chen DM, Forrester JS, **Shah PK**: Platelet derived growth factor-AA and transforming growth factor-beta regulate colony-stimulating-factor production in vascular smooth muscle cells. American Federation of Clinical Research, 1991.
85. Ameli S, Kaul S, Arora C, Mirea A, Castro L, Sharifi B, Antonescu A, **Shah PK**: Coronary angioplasty increases circulating endothelin levels. American Federation of Clinical Research, 1991.
86. Ameli S, Kaul S, Arora C, Mirea A, Czer L, **Shah PK**: Transient increase in circulating endothelin following cardiac transplantation: Relationship to cyclosporine and plasma catecholamines. 64th Scientific Session of the American Heart Association, 1991.
87. Ganz W, **Shah PK**: Reperfusion times in patients receiving streptokinase (SK or tissue-type plasminogen activator [t-PA]). 64th Scientific Session of the American Heart Association, 1991.
88. **Shah PK**, Ganz W, Lew A, Cercek B: Nonangiographic recognition of reperfusion (TIMI-3 flow) in acute myocardial infarction. 64th Scientific Session of the American Heart Association, 1991.
89. Kaul S, Ameli S, Arora Ch, Castro L, Mirea A, **Shah PK**: Does PTCA increase circulating endothelin level in man? 64th Scientific Session of the American Heart Association, 1991.
90. Vassolo M, Maurer G, Cercek B, Siegel R, Palmas W, **Shah PK**: Echo-Doppler characteristics of silent mitral regurgitation in patients with chronic congestive heart failure. *Circulation* 86, I-256, 1992.
91. **Shah PK**, Cercek B, Ganz W: Marked transient worsening of ST segment elevation during thrombolytic therapy: a marker of impending reperfusion. *Circulation* 86:I-268, 1992.
92. Haghani K, **Shah PK**, Cercek B: Unstable angina developing in patients on chronic aspirin therapy is associated with an increased risk of early adverse cardiac events. *J Amer Coll Cardiol* 21(2):137A, 1993.

93. Urman M, **Shah PK**: Is endogenous fibrinolysis impaired in acute coronary syndromes? *J Amer Coll Cardiol* 21(2):137A, 1993.
94. Zahger D, Cercek B, Davis V, Mirea M, Cannon CP, **Shah PK**, for the TIMI-4 investigators: Is the outcome of thrombolysis in smokers better than that of non-smokers? A TIMI-4 related study. *Circulation* 88:4(2):252, 1993.
95. Theroux P, Kleiman N, **Shah PK**, Williams M, Gill J, Rodriguez S, et al, for the MK-852 in unstable angina. *Circulation* 88:4(2):1075, 1993.
96. **Shah PK**, Falk E, Badimon JJ, Levy G, Ortiz AF, Fallon J, Fuster V: Human monocyte-derived macrophages express collagenase and induce collagen breakdown in atherosclerotic fibrous caps: Implications for plaque rupture. *Circulation* 88:4(2):1361, 1993.
97. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, **Shah PK**, et al, for the TIMI 4 Investigators. Clinical benefit of front-loaded t-PA over combination thrombolytic therapy or APSAC for acute MI: Results of the TIMI 4 Trial. *Circulation* 88:4(2):1556, 1993.
98. Ameli S, Hultgardh-Nilsson A, Yano J, Cercek B, **Shah PK**, Nilsson J: Recombinant human apolipoprotein A1-Milano reduces injury induced neointimal thickening in hypercholesterolemic rabbits. *J Am Col Cardiol* 23, 233A, 1994.
99. Zahger D, Karagounis LA, Cercek B, Anderson JL, Sorensen S, Moreno F, **Shah PK**: Incomplete recanalization rather "no reflow" is the main determinant of TIMI-2 flow after thrombolysis: Results from the TEAM studies. *Circulation* 90, I-220, 1994.
100. Kaul S, Naqvi TZ, Fishbein MC, Cercek B, Forrester JS, Molloy MD, Badimon JJ, Hutsell TC, **Shah PK**: Profound inhibition of arterial thrombosis by a novel oxide donor. *J Am Coll Cardiol*, 34A, 1995.
101. Stiko A, Regnstrom J, Cercek B, **Shah PK**, Nilsson J: Oxidized low density lipoprotein induced activation of smooth muscle cell DNA synthesis is mediated through active oxygen species and lysolecithin. *J Am Coll Cardiol*, 194A, 1995.
102. Naqvi TZ, Fishbein MC, Cercek B, Thomas AM, Molloy MD, Badimon L, **Shah PK**: Restoration of thromboresistance in injured aortic segments by a novel nitric oxide donor. *J Am Coll Cardiol*, 382A, 1995.
103. Kaul S, Naqvi TZ, Panicker S, Cercek B, Molloy MD, Forrester JS, Hutsell TC, **Shah PK**: Comparative effects of nitric oxide donors and aspirin on ex-vivo platelet-thrombus formation in normal and hypercholesterolemic rabbits. *Circulation* 92:(8):2982, 1995.

104. Naqvi TZ, Ivy P, Linn P, Israeli ML, Kaul S, **Shah PK**: Low dose heparin enhances and high dose heparin suppresses platelet P-selectin expression and platelet aggregation. *Circulation* 92:(8):3230, 1995.
105. Kaul S, Regnstrom J, Lake JP, Yano J, Yamashita M, Forrester JS, **Shah PK**, Hutsell TC, Cercek B: Marked antiproliferative effects of locally delivered nitric oxide donor. *Circulation* 92:(8):1103, 1995.
106. Kaul S, Naqvi TZ, Cercek B, Fishbein MC, Molloy MD, Badimon L, Hutsell TC, **Shah PK**: Profound inhibition of arterial-injury induced thrombosis in normal and hypercholesterolemic humans by nitric oxide donors: An ex-vivo study. *Circulation* 92;1-2011, 1995.
107. Naqvi TZ, **Shah PK**, Badimon JJ, Cercek B, Forrester JS, Molloy MD, Kaul S: Variable effect of lipids on arterial injury-induced thrombus formation. *Circulation* 92:(8):3334, 1995.
108. Yamashita M, Dimayuga P, Zhu J, Yano J, Forrester JS, **Shah PK**, Regnstrom J, Nilsson J, Cercek B: Octreotide inhibits arterial AP-1 and nuclear factor-kB activation after balloon injury and reduces smooth muscle cell proliferation. *Circulation* 92;1-:293, 1995.
109. Regnstrom J, Yamashita M, Dimayuga P, Lake, JP, **Shah PK**, Kaul S, Nilsson J, Cercek B: Arterial activation of nuclear factor-kB following balloon injury in rats. *Circulation* 92:(8):1094, 1995.
110. Xu X-P, Cercek B, **Shah PK**, Sharifi K, Radparvar K, Dimayuga P, Kaul S: Mechanical injury-induced DNA synthesis in cultured vascular smooth muscle cells is inhibited by a nitric oxide donor via modulation of nuclear factor-Kappa B. *Biochemistry and Molecular Biology of Nitric Oxide, an international conference*, 1996.
111. Xu X-P, Cercek B, Sharifi B, Dimayuga P, Radparvar K, **Shah PK**: Nitric oxide donor inhibits mechanical injury-induced activation and expression of nuclear factor-Kappa B in cultured vascular smooth muscle cells. *American Federation of Clinical Research*, 1996.
112. Calara F, Dimayuga P, **Shah PK**, Cercek B, Nilsson J, Regnstrom J: Local oxidation of LDL in the arterial wall is associated with NF-kB activation and endothelial expression of ICAM-1 in vivo. *Circulation* 1996.
113. Xu XP, Meisel SR, Cercek B, Ong JM, Sharifi B, Radparvar K, **Shah PK**: Differential effects of modified low density lipoprotein on matrix metalloproteinases and their tissue inhibitors in human monocyte derived macrophages. *Circulation* 1996.

114. Xu XP, Cercek B, Meisel S, Dimayuga P, Sharifi B, Ong J, Radparvar K, **Shah PK**, Kaul S: Nitric oxide donor suppresses vascular smooth muscle cell proliferation via inhibition of nuclear factor kB. *Circulation* 1996.
115. Yamashita M, Dimayuga P, Yano J, **Shah PK**, Nilsson J, Cercek B: Inhibition of protein phosphatases by Okadaic Acid enhances vascular Phos/Jun and NF kB activation in vivo. *Circulation* 1996.
116. White H, Cohen M, Sax FL, **Shah PK**, Snapinn S, van de Werf FJ: The effect of Tirofiban vs Heparin in patients presenting with non-Q-wave myocardial infarction. *Circulation*, 1997.
117. Oguchi S, Zhu J, Dimayuga P, Yano J, Kaul S, **Shah PK**, Cercek B: Increased intimal thickening after arterial injury in hypercholesterolemic Apolipoprotein E-deficient mice: finding a novel model. *Circulation*, 1997.
118. Ong J, Pan TH, Kaul S, Cercek B, Sharifi BG, Nilsson J, de la Llera Moya M, **Shah PK**: Is Apolipoprotein A-1 Milano more efficient in promoting cholesterol efflux than Wild type Apoprotein A-1? *Circulation*, 1997.
119. Shechter M, Merz NB, Rude RK, Paul-Labrador M, Meisel S, Malloy MD, Cercek B, **Shah PK**: Low intracellular magnesium levels promote platelet-thrombus formation in patients with coronary artery disease. *J Am Coll Cardiol*, 1997.
120. Meisel SR, Xu, XP, Cercek B, Kaul S, Radparvar S, Lee S, **Shah PK**: A long-acting nitric oxide donor suppresses basal and LPS-stimulated tissue factor procoagulant activity in human monocyte-derived macrophages. *J Am Coll Cardiol*, 1997.
121. Makkar R, Goff B, Eigler N, Fischell T, Barr L, D'Haem C, **Shah PK**, Effron MB, Litvack F: The effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study. Society for Cardiac Angiography & Interventions/ Transcatheter Cardiovascular Therapeutics Scientific Sessions, 1998.
122. Rajavashisth TB, Xu XP, Jovinge SM, **Shah PK**, Tripathi S: Macrophage Colony-Stimulating Factor Selectively Increases the Expression of Membrane Type-Matrix Metalloproteinase-3 in Cultured Human Monocyte Derived Macrophages. *Circulation*. 98(17S):809I, 1998.
123. Wallner K, **Shah PK**, Fishbein MC, Sharifi BG: Arterialization of human vein graft accompanies Tenascin-C expression. *Circulation*. 98(17S):809I, 1998.
124. Wallner, Kurt. Li, Chen. Pan, Theresa. Fishbein, Michael C. **Shah, Prediman K.** Sharifi, Behrooz G: Tenascin-X, a novel extracellular matrix protein, modulates adhesion of aortic smooth muscle cells. *Circulation*. 98(17S):801I, 1998.

125. Rajavashisth TB, Lagasse E, Jovinge SM, Xu X-P, Loussararian, AH, Tripathi S, **Shah PK**: Antiatherogenic Effects of Macrophage Colony-Stimulating Factor Deficiency are not Reversed by Rescue of Circulating Monocyte Number or Survival. *Circulation*. 98(17S):464I, 1998.
126. Makkar R, **Shah, PK**, Terhakopian A,. Cercek B, Kaul S: Intrapericardial Delivery of a Nitric Oxide Donor Inhibits In-Stent Stenosis in Porcine Coronary Arteries. *Circulation*. 98(17S):399I, 1998.
127. Rajavashisth TB, **Shah PK**, Qiao J-H, Tripathi S: Monoclonal antibody against murine macrophage colony-stimulating factor receptor inhibits atherogenesis in LDL receptor-deficient mice. *Circulation*. 98(17S):327I, 1998.
128. Kaul S, Terhakopian A, Cercek B, Yano J, Sinai N, **Shah PK**: Intrapericardial Apo A-I *Milano* reduces intimal and adventitial hyperplasia in porcine coronary overstretch model. *J Am Coll Cardiol* 33(2) 845-6,1999.
129. Kaul S, Makkar R, Terhakopian A, Sinai N, **Shah PK**: Pharmacokinetic profile of Intrapericardial Administration of NO donors critically modulates vascular response to injury. *J Am Coll Cardiol* 33(2) 1190-6,1999.
130. Dimayuga, P, Zhu J, Kaul S, **Shah PK**, Cercek B: Reduced phosphatase activity in the arterial wall following balloon injury. *J Am Coll Cardiol* 33(2) 1011-30,1999.
131. Xu HX, **Shah PK**, Faure E, Thomas L, Luthringer D, Xu XP, Yano J, Kaul S, Cercek B, Arditi M: Toll-like receptors-4 is expressed in human coronary atherosclerotic plaques and upregulated by oxidized low density lipoprotein in macrophages. *J. Am Coll Cardiol* 35 Suppl;313A, 2000
132. Xu XP, Xu H, Chyu KY, Collins J, Rajavashisth T, Kaul S, Cercek B, **Shah PK**: Estrogen and progesterone but not tamoxifen inhibits oxidized low density lipoprotein induced matrix metalloproteinase-9 in cultured human macrophages. *J Am Coll Cardiol* 35 Suppl; 368A, 2000.
133. Azarbal B, Miricha J, **Shah PK**, Cercek B, Kaul S; Adverse cardiovascular events associated with the use of viagra. *J am Coll Cardiol*, 35 suppl; 553A,2000
134. Rajavashisth R, Liu M, Shi J, Shukla AK, Kumar A, Chai N N, **Shah PK**: Macrophages in human atherosclerotic plaques express uPA and M-CSF induces u-PA gene expression in Macrophages: Potential implications for u-PA mediated activation of MMP-cascade and Plaque Rupture: *Circulation suppl*; 82:2000.

135. Chyu KY, Reyes O, Xu XH, Yano J, Kaul S, Cercek B, **Shah PK**: Immunization with homologous native LDL reduces atherosclerosis in hyperlipidemic apo E null mice receiving interleukin-12. *Circulation*, suppl, 100: 2000
136. Swissa M, Ohara T, Lee M, Kaul S, **Shah PK**, Chen PS, Karageuzian H: Sildenafil and Nitric Oxide Donor facilitate the induction of ventricular tachycardia and ventricular fibrillation in the isolated normal swine right ventricle. *Circulation*; suppl ;204: 2000
137. Sharifi BG, Wu KG, Wang L, Rajavashisth T, Kaul S, **Shah PK**: Adenoassociated virus mediated Apo A-I Milano gene therapy for Atherosclerosis and Restenosis. *J Am Coll Cardiol* 2001; 37,suppl-2, 270 A
138. Rukshin V, Azarbal B, Tsang V, **Shah PK**, Cercek B, Kaul S: Dethrombotic effects of glycoprotein lib/IIIa inhibitor Tirofiban in an ex-vivo canine stent thrombosis model. *J Am Coll Cardiol* 2001; 37; suppl-2,277A.
139. **Shah PK**, Yano J, Bisgaier C, Reyes O, Xu H, McMurty M, Drake S, Kaul S, Chyu KY, Cercek B: High-dose rApo A-I Milano mobilizes tissue cholesterol and reduces plaque-lipid and macrophages within 48 hours: implications for plaque stabilization. *J Am Coll Cardiol* 2001; 32; suppl-2, 242A
140. Wallner K, Sharifi BG, **Shah PK**, Noguchi S, DeLeon H, Wilcox JN: Adventitial remodeling after angioplasty is associated with expression of Tenascin mRNA by adventitial myofibroblasts. *J Am Coll Cardiol* 2001; 32; suppl-2,36A
141. Liu, M, Chai NN, Shukla A, Kaul S, **Shah PK**, Cercek B, Rajavashisth T: Absence of neointimal thickening following arterial injury in M-CSF deficient mice and its reversal by local delivery of M-CSF highlights the critical role of M-CSF in neointima formation. *J Am Coll Cardiol* 2001; 32-Suppl-2 49A
142. Remskar M, Li H, Xu H, **Shah PK**, Chyu KY, Cercek B: Absence of CD40 signaling is associated with increased intimal thickening following acute arterial injury. *J Am Coll Cardiol* 2001;32, suppl-2, 49A.
143. Li, H., Dimayuga, P., Anazawa, T., Yano, J., Nilsson, J., Chyu, K.Y., **Shah, P.K.**, Cercek, B.: T Cell Secreted Interferon-Gamma Mediates the Repair Response to Arterial Injury: Studies on Immune-Deficient Rag-1 KO Mice. Supplement to *Journal of the American College of Cardiology*, March 6, 2002, Vol. 39, Issue 5, Suppl. A.
144. Anazawa, T., Li, H., Zhao, X., Yano, J., Chyu, K.Y., Kaul, S., **Shah, P.K.**, Cercek, B.: Selective Inducible Nitric Oxide Synthase Inhibitor Mercaptoethylguanidine Attenuates Neointimal Formation in Injured Mice Exposed to Cigarette Smoke. Supplement to *Journal of the American College of Cardiology*, March 6, 2002, Vol. 39, Issue 5, Suppl. A.

145. Sharifi, B. G., Qin, M., Pan., T., **Shah, PK**: Selective Expression of Tenascin in the Coronary Artery and Its High Affinity Interaction with LDL May Account for Lipid Retention Capacity of Coronary Vessels and Their Susceptibility to Atherosclerosis. Supplement of the American College of Cardiology, March 6, 2002, Vol. 39, Issue 5, Suppl A.
146. Reyes, O. S., Chyu, K. Y., Yano, J., Zhao, X., Cercek, B., Kaul, S., Nilsson, J., **Shah, P.K**: Immunization with a Novel Human Apo B100 Related Peptide Reduces Atherosclerosis and Inflammation in Apo E Null Mice. Supplement to Journal of the American College of Cardiology, March 6, 2002, Vol. 39, Issue 5, Suppl. A.
147. Anazawa, T., Yano, J., Zhao, X., Kaul, S., Dimayuga, P., Chyu, K. Y., Cercek, B., **Shah, P.K.**: Cigarette Smoke Creates an Unstable Atherosclerotic Plaque Phenotype by Enhancing Vascular Oxidative Stress, Increasing Vascular Endothelial Growth Factor Expression and Producing Collagen Loss in apo E-/- Mice. Supplement to Journal of the American College of Cardiology, March 6, 2002, Vol. 39, Issue 5, Suppl. A.
148. Shukla, A.K., Uzui, H., Doherty, T.M., Tripathi, P.V., Asotra, K., Wilkin, D.J., **Shah, P.K.**, Rajavashisth, T. B.: HMG-COA Reductase Inhibition Down Regulates Tumor Necrosis Factor-A and Oxidized Low Density Liprotein-Induced Endothelial Cell Expression of Macrophage-Colony Stimulating Factor. Supplement to Circulation 2002.
149. Chyu, K.Y., Zhao, X., Dimayuga, P.C., Cercek, B., **Shah, P.K.**: Altered AP-1/Redox Pathway in iNOS Deficient Vascular Smooth Muscle Cells: A Novel Involvement of iNOS in Cellular Signaling. Supplement to Journal of the American College of Cardiology, March 19, 2003, Vol. 41, Issue 6, Suppl. A.
150. Li, H., de Silva, P., Chyu, K.Y., Anazawa, Y., Yano, J., **Shah, P.K.**, Cercek, B., Dimayuga, P.C.: Cellular and Humoral Immune-Modulation of Intimal Thickening After Injury in Mice. Supplement to Journal of the American College of Cardiology, March 19, 2003, Vol. 41, Issue 6, Suppl. A.
151. Li, X. J., Yano, J., Chyu, K.Y., Zhao, X., Dimayuga, P.C., Cercek, B., **Shah, P.K**: Early Expression of Toll-Like Receptor-4 in Vein Graft Atherosclerosis in ApoE (-/-) Mice Suggests a Potential Role for Activation of Innate Immunity in Accelerated Atherosclerosis. Supplement to Journal of the American College of Cardiology, March 19, 2003, Vol. 41, Issue 6, Suppl. A.
152. Babbidge, S.M., Zhao, X., Dandillaya, R., Yano, J., Dimayuga, P.C., Cercek, B., **Shah, P.K.**, Chyu, K.Y.: Green Tea Derived Polyphenol Antioxidant, EGCG, Differentially Modulates Developing Compared to Mature Atherosclerotic Lesions

- in Apo E $-/-$ Mice. Supplement to Journal of the American College of Cardiology, March 19, 2003, Vol. 41, Issue 6, Suppl. A.
153. Anazawa, T., Dimayuga, P.C., Li, H., de Silva, P., Yano, J., Chyu, K.Y., **Shah, P. K.**, Cercek, B.: iNOS Is a Mediator of Increased Arterial Intimal Thickening Induced by Passive Cigarette Smoke Exposure in Mice. Supplement to Journal of the American College of Cardiology, March 19, 2003, Vol. 41, Issue 6, Suppl. A.
 154. Rajavashisth, T.B., Liu, M., Tanaka, H., Tripathi, J., Tripathi, P., Loussararian, A., Libby, P., Uzui, H., Kumar, A., Doherty, T. M., Cercek, B., Kaul, S., **Shah, P.K.**: Obligate Role of Macrophage Colony-Stimulating Factor for the Development of Neointimal Thickening Following Arterial Injury. Supplement to Journal of the American College of Cardiology, March 19, 2003, Vol. 41, Issue 6, Suppl. A.
 155. rAAV Mediated Apolipoprotein A-1-Milano Gene Therapy for Atherosclerosis. Svapna Patel¹, Julie Yano², Behrooz Sharifi², **Prediman K. Shah**², K.K. Wong¹, Saswati Chatterjee¹ (6th Annual Meeting of the American Society of Gene Therapy, June 4-6, 2003, Washington, DC).
 156. Rajavashisth, T.B., Chai, N.N., Tripathy, P.V., Kumar, A., Tsang, V., **Shah, P.K.**, Kaul, S.: Local Adenoviral Delivery of Antisense c-fms Gene Inhibits In-Stent Stenosis in Porcine Coronary Arteries. Supplement to Circulation, October 28, 2003, Vol. 108, No 17, Suppl. IV.
 157. Michelsen, K.S., Wong, M.H., Zhang, W., Yano, J., Rajavashisth, T. B., **Shah, P.K.**, Arditi, M.: Genetic ablation of MyD88, an Adaptor Molecule Involved in TLR-Signaling and Innate Immunity, Reduces Atherosclerosis and Alters Plaque Phenotype in Apo E Null Mice without Changing Circulating Cholesterol Levels. Supplement to Circulation, October 28, 2003, Vol. 108, No 17, Suppl. IV.
 158. Dimayuga, P.C., De Silva, P., Li, H., Chyu, K.Y., **Shah, P.K.**, Cercek, B.: Absence of CD4+T Cells Markedly Inhibits Intimal Thickening After Arterial Injury in Mice. Supplement to Circulation, October 28, 2003, Vol. 108, No 17, Suppl. IV.
 159. Dimayuga, P.C., Anazawa, T., Li, H., Chyu, K.Y., Kaul, S., **Shah, P.K.**, Cercek, B. : Altered Innate and Adaptive Immune Response Following Exposure to Cigarette Smoke: Potential Role in Enhanced Intimal Thickening After Injury. Supplement to Circulation, October 28, 2003, Vol. 108, No 17, Suppl. IV.
 160. Rajavashisth, T.B., Kumar, A., Lee, G., Doherty, T., Uzui, H., Tripathi, P., Xu, J., Neyer, J., Chen, S., Espinoza, C., Zong, X.H., Dai, X.M., **Shah, P.K.**, Stanley, R: Transgenic Expression of the Cell Surface Isoform of CSF-1 Reverses Altheroprotective Effects of CSF-1 Deficiency in Apolipoprotein E Knockout Mice. Supplement of Circulation, October 28, 2003, Vol. 108, No 17, Suppl. IV

161. **Shah PK**, Hardy Sarah, Patel Swapna, Yano Juliana, Rajavashisth T, Wong KK, Chatterjee Saswati: A Single Intramuscular Injection of Recombinant Adeno Associated Virus Vector encoding Apo A-I milano Gene Inhibits Atherosclerosis in Apo E Null mice. *Circulation 2004 (suppl)(abstract)*.
162. **Shah PK**, Hardy Sarah, Patel Swapna, Yano Juliana, Rajavashisth T, Wong KK, Chatterjee Saswati: Transplantation of Bone Marrow Cells Transduced with Adeno Associated Virus Vectors Encoding the Apo A-1 Milano Gene inhibits Atherosclerosis in Apo E Null mice. *Circulation 2004 (suppl)(abstract)*.
163. Xiao-Jun Li, Kuang-Yuh Chyu, Paul Dimayuga, Juliana Yano, Carmel Ferreira, Ang Ji, Lai Wang, Bojan Cercek, Saswati Chatterjee*, **Prediman K. Shah**: One Single I.M. Injection of Recombinant Adeno-Associated Virus Encoding ApoA-_{Milano} Gene reduces aortic atherosclerosis and modulates the inflammatory phenotype of vein graft lesions in ApoE^(-/-) Mice. *Circulations 2005 (abst)*
164. Lai Wang, **Prediman K. Shah**, Behrooz G. Sharifi: Genetic ablation of of tenascin-c accelerates atherosclerosis in apo E null mice possibly through upregulation of VCAM-1 expression. *Circulation 2005 (abst)*.
165. Paul C Dimayuga, Hongyan Li, Kuang-Yuh Chyu, Michiaki Matsumoto, Juliana Yano, **Prediman K Shah**, Bojan Cercek: Dysregulation of Late Interferon-gamma Signaling Augments Intimal Thickening After Arterial Injury in Immune Deficient Mice. *Circulation 2005 (abstr)*
166. **Prediman K Shah**, Lai Wang, Theresa Pan, Ada Yukht, Behrooz G Sharifi: Comparative Anti-Atherogenic Effects of Macrophage Specific Expression of Apolipoprotein A-I Milano versus Apolipoprotein A-I Wild Type in Apo E /Apo A-I Double Knockout Mice. *Circulation 2005 (abst)*
167. Alexandru Schiopu, Bo Jansson, **Prediman K Shah**, Roland Carlsson, Jan Nilsson, Gunilla Nordin Fredrikson: Plaque Regression Induced by Human Recombinant Antibodies Against oxLDL Epitopes in LDLR^{-/-} Apobec Mice. *Circulation 2005, (abstract)*.
168. Zhao X, Chyu KY, Yano J, Dimayuga P, Ferreira C, Jovicic S, Cesena F, Fahr Y, Cercek B, Nilsson J, **Shah PK**: Vaccination for atherosclerosis in apo E (-/-) mice: Comparative efficacy of Native Versus MDA modified Apo B-100 Related Peptide Antigen and Subcutaneous Versus Intranasal Immunization. *Circulation 2006 (abstract)*.
169. Dimayuuga P, Cesena F, Amorn A, Chyu KY, Zhao X, **Shah PK**, Cercek B: B-cell Derived IgM and IgG Immunoglobulin Isotypes Modulate Intimal Thickening in Immune-deficient Mice. *Circulation 2006 (abstract)*.

170. Dimayuga P, Chyu KY, Yano J, Peter A, **Shah PK**, Cercek B: Selective and Specific Inhibitory Role of CD8+ T Cells in Intimal Thickening. *Circulation* 2006 (abstract).
171. Kaul S, Zadeh AA, Diamond GA, **Shah PK**: Does Homocysteine Lowering Impact Cardiovascular Outcomes? A Bayesian Analysis of NORVIT and HOPE-2 Trials. *Circulation* 2006 (abstract).
172. Eshaghian S, Amin S, **Shah PK**, Diamond GA, Kaul S: Does Clopidogrel Provide Clinically Important Benefit in Atherothrombotic Cardiovascular Disease? A Bayesian Perspective. *Circulation* 2006 (Abstract).
173. Kaul S, Tung RH, Diamond GA, **Shah PK**: Are Drug-Eluting Stents Really Worth the Money? Disconnect Between Clinical Trials and Clinical Practice. *Circulation* 2006 (abstract).
174. Cheng VY, Lepor NE, Madyoon H, Eshaghian S, Naraghi AL, **Shah PK**: Does Absence of Coronary Calcification Predict the Absence of Coronary Plaque or Significant Luminal Stenosis on 64-Slice Computed Tomographic Coronary Angiography? *Circulation* 2006 (abstract).
175. Kaul S, Das JR, **Shah PK**, Diamond GA, Joffe M: Does early invasive strategy provide a clinically important advantage over early conservative strategy in the management of acute coronary syndromes? *J Am Coll Cardiol*, March 6, 2007:49 (9)Suppl A
176. Eshaghian S, Amin S, **Shah PK**, Kaul S, Diamond GA: How likely are the therapeutic interventions recommended by 2002 ACC/AHA clinical guidelines for acute coronary syndromes to be clinically worthwhile? *J Am Coll Cardiol*, March 6, 2007:49 (9)Suppl A
177. Kedia G, Broukhim M, Chang G, **Shah PK**, Kupferwasser LI, Lee MS, Trento A, Mirocha J, Fontana GP, Makkar R: Outcomes of coronary artery bypass surgery compared to percutaneous coronary intervention with drug eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol*, March 6, 2007:49 (9)Suppl A
178. Eshaghian S, Kaul S, **Shah PK**, Amin S, Diamond GA: Should clinical guidelines emphasize statistical significance over clinical importance? A reappraisal of the 2004 ACC/AHA treatment guidelines for STEMI. *J Am Coll Cardiol*, March 6, 2007:49 (9)Suppl A
179. Song L, Wang L, **Shah PK**, Sharifi B: Tissue Engineered Graft Grown in the Mouse Peritoneal Cavity: the role of peritoneal-derived stem/progenitor cells. *Circulation* 2007.

180. Wang L, Song L, **Shah PK**, Sharifi BG: Tenascin-C Gene Deletion Induces Plaque Hemorrhage and Markedly Accelerates Atherosclerosis in Apo E Null Mice: Potential Role of Mast Cells and Eotaxin. *Circulation* 2007.
181. Li F, **Shah PK**, Sharifi BG: Pleiotrophin Is Expressed In Highly Vascularized Regions Of Human Atherosclerotic Plaques: Interferon-gamma Regulates Pleiotrophin Expression In Macrophages Through The Jak/stat Pathway. *Circulation* 2007.
182. Dimayuga P, Chyu KY, Yano J, Zhao X, Li X, **Shah PK**, Cercek B: Does Complement Contribute to Intimal Thickening of Injured Carotid Arteries? Insights from Immune Deficient Mice and Complement Depletion Strategy. *Circulation* 2007.
183. Das J, Diamond GA, Eshaghian S, Amin S, **Shah PK**, Kaul S: Predictors of benefit using an early invasive strategy in the management of unstable angina/Non-ST elevation myocardial infarction. *JACC* 2008;51(10):A194;1010-67.
184. Das J, Diamond GA, Eshaghian S, Amin S, **Shah PK**, Kaul S: Does an early invasive strategy in NSTEMI management result in long-term benefit? *JACC* 2008;51(10): A195;1010-71.
185. Das J, Diamond GA, Eshaghian S, Amin S, **Shah PK**, Kaul S: The impact of homocysteine lowering therapy on cardiovascular outcomes: An updated meta-analysis of 13 trials. *JACC* 2008;51(10): A248;1012-153
186. Mendoza F, Rafil F, **Shah PK**, Rafique A, Guerra M, Azmoon S, Lepor N, Berman D, Naqvi T: Do obesity and BMI differentially predict an abnormal C-IMT over coronary calcium? *JACC* 2008;51(10): A315;1021-174
187. Zhao X, Chyu KY, Yano J, Dimayuga P, Li X, Trinidad P, Jovicic S, Cercek B, Nilsson J, **Shah PK**: Athero-protective effects of a human apo B-100 related peptide vaccine in apo E^{-/-} mice are modulated by peptide dose and time of initiation of high fat diet. *JACC* 2008;51(10): A343;1028-207
188. Mendoza F, Berman D, Rafil F, Gransar H, Wong N, Guerra M, Azmoon S, Lepor N, **Shah PK**, Naqvi T: Does zero coronary or aortic calcium predict absence of plaque? *JACC* 2008;51(10): A152; 1907-255
189. Kaul S, Azarbal B, **Shah PK**, Diamond GA: Bivalirudin versus heparin alone in low risk PCI: indirect vs direct comparison *JACC* 2009 (abst)
190. Chakravarty T, White AJ, Forrester JS, Mirocha JM, Naik H, Luft U, Kar S, Czer L,, Fontana G, Trento A, **Shah PK**, Makkar R: Comparison of CABG and PCI for treatment of

- unprotected left main coronary artery stenosis: 3 year follow up analysis by propensity score adjustment. JACC 2009 (abstract)
191. Kaul S, Azarbal B, **Shah PK**, Diamond GA, Will Bivalirudin outperform heparin alone during primary PCI for STEMI: JACC 2009 (abstract)
 192. Tian F, Wang L, Yang M, Sharifi BG, **Shah PK**: Comparative antiatherogenic effects of a single intravenous injection of rAAV8 or rAAV2 encoding Apo A-I Milano gene. Circulation 2009 (abstract)
 193. Zhao X, Chyu KY, Dimayuga PC, Yano J, Li X, Trinidad P, Zhou J, Lio WM, Kirzner J, Chan LF, Cercek B, **Shah PK**: Athero-protective effects of immunization with apo B -100 related peptide vaccine is associated with enhanced CD 8 regulatory T-cell response. Circulation 2009 (abstract)
 194. Paul C. Dimayuga, Fernando H. Y. Cesena, Juliana Yano, Jonathan Kirzner, Xiaoning Zhao, Xiaojun Li, Portia Trinidad, Bojan Cercek, **Prediman K. Shah**, Kuang-Yuh Chyu Immune-modulation by Polyclonal IgM Treatment Reduced Atherosclerosis in Hypercholesterolemic apoE^{-/-} Mice. JACC 2010 (abstract)
 195. Kuang-Yuh Chyu, Juliana Yano, Xiao Jun Li, Jianchang Zhou, Wai Man Lio, Cheryl Chan, Paul C. Dimayuga, Bojan Cercek, Cory L. Nykiforuk, Yin Shen, Maurice M. Moloney, **Prediman K. Shah**: Safflower Seed-derived Des-1,2-apoA1milano Reduce Atherosclerosis in Hypercholesterolemic Apolipoprotein E (-/-) Mice. JACC 2010 (abstract)
 196. Heidi Gransar, MS, Jamal S. Rana, MD, PhD, Nathan D. Wong, PhD, Johanna Kim, MPH, Romalisa Miranda-Peats, MPH, **Prediman K. Shah, MD, PhD**, Alan Rozanski, MD, Sean Hayes MD, John Friedman, MD, Louise Thomson, MD, and Daniel S. Berman, M: Coronary Artery Calcification and Thoracic Aortic Wall Calcification are Associated With Increasing Categories of Blood Pressure. JACC 2010 (abstract)
 197. Das JR, Eshaghian S, Diamond GA, **Shah PK**, Kaul S: Aspirin therapy for primary versus secondary prevention of cardiovascular disease: An updated Meta analysis. JACC 2010 (abstract)
 198. Rana JS, Gransar H, Wong ND, **Shah PK**, Rozanski A, Friedman JD, Hayes S, Thompson L, Shaw LJ, Berman DS: Coronary calcium predicts mortality in low risk asymptomatic men. JACC 2010(abstract)
 199. Das JR, Eshaghian S, **Shah PK**, Diamond GA, Kaul S: Does contemporary trial evidence support the routine use of aspirin for primary prevention of cardiovascular disease? JACC 2010 (abstract)
 200. Madyoon H, Yee BE, Sadri L, Lepor N, Bretsky P, **Shah PK**: Does an abnormal carotid ultrasound test predict coronary atherosclerosis in asymptomatic subjects? JACC 2010

(abstract).

201. Tian F, Wang L, Yang M, Aria A, Sharifi B, **Shah PK**: Favorable Modulation of Atherosclerosis and Monocyte Phenotype by Intravenous AAV 8Mediated Apo A-I Milano Gene Transfer in Mice. Circulation 2010 Abstract.
202. Zhao X, Chyu KY, Dimayuga PC, Zhou J, Yano J, Lio WM, Chan LF, Li X, Kirzner J, Trinidad O, Cercek B, **Shah PK** Adoptive Cell Transfer Demonstrates that CD8+ T cells Mediate the Anti-atherogenic Effects of the ApoB-100 Peptide P210 Immunization in ApoE^{-/-} Mice. Circulation 2010 Abstract
203. Kuang-Yuh Chyu, Xiaoning Zhao, Lai Fan Chan, Paul C. Dimayuga, Juliana Yano, Jianchang Zhou, Wai Man Lio, Tomoyuki Honjo, Bojan Cercek, **Prediman K. Shah**. Apob-100 Peptide-Primed Dendritic Cells Confers Athero-Protective Effect in Hypercholesterolemic Apoe^{-/-} Mice. Circulation (abstract) 2011
204. Xiaoning Zhao, Kuang-Yuh Chyu, Paul C. Dimayuga, Jianchang Zhou, JulianaYano, Wai Man Lio, Tomoyuki Honjo, Portia Trinidad, Bojan Cercek, **Prediman K Shah**. Increased Cytolytic Activity by CD8+ T Cells From Apob-100 Related- Peptide Immunized Mice is Specific to Lipid-Associated Antigens. Circulation (abstract) 2011
205. Jianchang Zhou, Kuang-Yuh Chyu, Xiaoning Zhao, Paul C Dimayuga, Juliana Yano, Wai Man Lio, Lai Fan Chan, Portia Trinidad, Tomoyuki Honjo, Bojan Cercek, **Prediman K Shah**. Adoptive Transfer Experiments in ApoE^{-/-}Mice Define an Inhibitory Role for CD8+CD25+ T Cells in Atherosclerosis. Circulation (abstract) 2011
206. Tomoyuki Honjo, Paul C Dimayuga, Kuang-Yuh Chyu, Xiaoning Zhao, Jianchang Zhou, Juliana Yano, Wai Man Lio, Portia Trinidad, Bojan Cercek, **Prediman K Shah**. ApoB-100 Related Peptide Vaccine Reduces Hypertension and Mortality in a Model of Angiotensin II-Induced Aortic Aneurysm in Apo E (-/-) Mice: A Novel Therapeutic Paradigm. Circulation (abstract) 2011
207. Lei Song, Lai Wang, Ana Arias, Aurelio Chaux, **Prediman K Shah**, Behrooz G Sharifi. Tenascin-C Deficiency Promotes Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function in Chronic Pressure- Overload. Circulation (abstract) 2011
208. Jamal S Rana, Brigitte M Sondermeijer, Benoit J Arsenault, **Prediman K Shah**, Erik G Stroes, John J Kastelein, Nicholas J Wareham, Matthijs Boekholdt, Kay-Tee Khaw. Non-High-Density Lipoprotein Cholesterol Levels vs Apolipoprotein B or Apo B/Apo A 1 and risk of Coronary Heart Disease among Apparently Healthy Men and Women. Circulation (abstract) 2011.

209. Paul C Dimayuga, Kuang-Yuh Chyu, Xiaoning Zhao, Juliana Yano, Wai Man Lio, Jianchang Zhou, Tomoyuki Honjo, Portia Trinidad, **Prediman K Shah**, and Bojan Cercek: Increased Function of the CD28hi Phenotype Underlies the Reduction of Intimal Thickening by CD8+ T cells. *Circulation*. 2012;126:A16506
210. Xiaoning Zhao, Kuang-Yuh Chyu, Paul C Dimayuga, Juliana Yano, Jianchang Zhou, Wai Man Lio, Bojan Cercek, and **Prediman K Shah**: Dendritic Cells Primed with apoB-100-derived Peptide p210 Elicit a CD8+CD25+ T cell Response: *Circulation*. 2012;126:A16617
211. Mingjie Yang, Fuqiang Li, Lai Wang, Ada Yukht, Ana Arias, Fang Tian, Ian Williamson, **Prediman K Shah**, and Behrooz G Sharifi: GATA3 Regulates Macrophage Polarization and Phenotype: *Circulation*. 2012;126:A13424.

Signed: *Predimankshah*